"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_RIUNITIFOGGIA",2000,9,5.66666666666667,1.66666666666667,0.6,0.888888888888889,0.111111111111111,0.222222222222222,0,2,2,2,1,3,0.22,0.22,0.11,0.33,12.56,0.276975177120684,0,0.444444444444444,NA,0.382535688610455,0.107142857142857,0,0,"F BERERA;E. MINÓLA;O. FRACASSETTI;N. LORENZI;GIAMPAOLO QUINZAN;BRUNO MARIO CESANA;ANNA MARIA TORTORANO;ANNA GRANCINI;GAETANO SCOTTO;CLAUDIO FARINA;GIUSEPPE ROSSI;T. PARTZIGUIAN;DEL VECCHIO G;TERESA LEREDE;MAXINE CARTER;S MORANDI;L. CASTO;CARMINE ZOCCALI;VINCENZINA FAZIO;A. RABALLO","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARMINE ZOCCALI;BEATRICE LEUNG;F BERERA;E. MINÓLA;O. FRACASSETTI;N. LORENZI;GIAMPAOLO QUINZAN;GAETANO SCOTTO;VINCENZINA FAZIO;ANTONIO D'ADDUZIO;F CAMPANOZZI;BRUNO MARIO CESANA;T. PARTZIGUIAN;L. CASTO;B. CENSORI;FRANCESCA DUCA;FRANCESCA NORBIS;M. CAMERLINGO;MARCO MOIA;GUIDO FINAZZI","1;1;0.33;0.33;0.33;0.33;0.33;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","E. MINÓLA;GAETANO SCOTTO;CLAUDIO FARINA;T. PARTZIGUIAN;L. CASTO;CARMINE ZOCCALI;VINCENZINA FAZIO;B. CENSORI;FRANCESCA NORBIS;M. CAMERLINGO;GUIDO FINAZZI;MONICA GALLI;BEATRICE LEUNG;R BASSAN","2;1;1;1;1;1;1;1;1;1;1;1;1;1","CARMINE ZOCCALI;BEATRICE LEUNG;E. MINÓLA;GAETANO SCOTTO;VINCENZINA FAZIO;T. PARTZIGUIAN;L. CASTO;B. CENSORI;FRANCESCA NORBIS;M. CAMERLINGO;GUIDO FINAZZI;MONICA GALLI;CLAUDIO FARINA;R BASSAN","1;1;0.33;0.25;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.11;0.07","FRANCESCA DUCA;FRANCESCA NORBIS;GUIDO FINAZZI;MARCO MOIA;MONICA GALLI;BEATRICE LEUNG;A. Z. S. ROHATINER;ALESSANDRO RAMBALDI;ENRICO POGLIANI;EROS DI BONA;GIORGIO LAMBERTENGHI‐DELILIERS;GIUSEPPE ROSSI;MAXINE CARTER;PAOLO CASULA;PIETRO FABRIS;R BASSAN;S MORANDI;T. ANDREW LISTER;TERESA LEREDE;TIZIANO BARBUI","45;45;45;45;45;25;17;17;17;17;17;17;17;17;17;17;17;17;17;17","FRANCESCA NORBIS;GUIDO FINAZZI;MONICA GALLI;BEATRICE LEUNG;R BASSAN;GAETANO SCOTTO;VINCENZINA FAZIO;B. CENSORI;L. CASTO;M. CAMERLINGO;T. PARTZIGUIAN;E. MINÓLA;CARMINE ZOCCALI;CLAUDIO FARINA","45;45;45;25;17;11;11;5;5;5;5;4;3;3","E. MINÓLA;B. CENSORI;BEATRICE LEUNG;CARMINE ZOCCALI;CLAUDIO FARINA;FRANCESCA NORBIS;GAETANO SCOTTO;GUIDO FINAZZI;L. CASTO;M. CAMERLINGO;MONICA GALLI;R BASSAN;T. PARTZIGUIAN;VINCENZINA FAZIO","2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHILOSOPHY;POLITICAL SCIENCE","9;7;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;PEDIATRICS;VIROLOGY;ARTIFICIAL INTELLIGENCE;COMPUTATIONAL BIOLOGY;DATABASE;ECOLOGY;EMERGENCY MEDICINE;EPISTEMOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;LAW;MEDICAL PHYSICS;MICROBIOLOGY;ONCOLOGY;PSYCHIATRY;SURGERY","7;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;VIRUS;ANTIBODY;ALTERNATIVE MEDICINE;ASYMPTOMATIC;CANCER;CELL;CELL ADHESION MOLECULE;CIRRHOSIS;CLINICAL PRACTICE;CLINICAL TRIAL;EPIDEMIOLOGY;EPITHELIUM;HEPATITIS C;IDENTIFICATION (BIOLOGY);IMMUNOHISTOCHEMISTRY;INFLAMMATION;INTERFERON;INTERVENTIONAL RADIOLOGY;INTESTINAL MUCOSA;KNOWLEDGE BASE;LEUKEMIA;MEDICAL MICROBIOLOGY;MEDLINE;NEUROLOGY;NEUROSURGERY;NUCLEOSIDE;OBSERVATIONAL STUDY;QUALITY (PHILOSOPHY);RECEPTOR;RETROSPECTIVE COHORT STUDY;STROMAL CELL;THROMBOSIS;TUMOR NECROSIS FACTOR ALPHA","5;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEPATITIS B VIRUS;HEPATITIS C VIRUS;ALLELE;ANTIPHOSPHOLIPID SYNDROME;BREAKPOINT CLUSTER REGION;BREAST CANCER;CHROMOSOMAL TRANSLOCATION;CLINICAL EPIDEMIOLOGY;CYTARABINE;DOWNREGULATION AND UPREGULATION;FACTOR V;GENOTYPE;LYMPHOBLASTIC LEUKEMIA;MUTATION;NEURORADIOLOGY;NUCLEOSIDE ANALOGUE;PLACEBO;RNA;SYNDECAN 1;THROMBOPHILIA;VENOUS THROMBOSIS","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE LYMPHOCYTIC LEUKEMIA;ANTHRACYCLINE;FLAVIVIRIDAE;GENE MUTATION;HBSAG;IDARUBICIN;LAMIVUDINE;METHYLENETETRAHYDROFOLATE REDUCTASE;PHILADELPHIA CHROMOSOME","1;1;1;1;1;1;1;1;1","HUMANS;PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;CROHN DISEASE;INTESTINAL MUCOSA;;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;FUSION PROTEINS, BCR-ABL;ISCHEMIC ATTACK, TRANSIENT;MALE;MEMBRANE GLYCOPROTEINS;MIDDLE AGED;NEOPLASM PROTEINS;PROTEOGLYCANS;TUMOR NECROSIS FACTOR-ALPHA;AGED;ANTIBIOTICS, ANTINEOPLASTIC;ANTIBODIES, ANTICARDIOLIPIN;ANTIBODIES, MONOCLONAL","6;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;HEPATITIS E INFECTION AND TREATMENT;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;THROMBOSIS AND COAGULATION DISORDERS","1;1;1;1;1;1;1;1;1","ACUTE LYMPHOCYTIC LEUKEMIA;BREAKPOINT CLUSTER REGION;C-PEPTIDE LEVELS;CLINICAL EPIDEMIOLOGY;CLINICAL PRACTICE;CT DIAGNOSIS;FACTOR V;FACTOR V LEIDEN;GB VIRUS C;HBV INFECTION;HEALTH TECHNOLOGY ASSESSMENT;HEPATITIS C;IDARUBICIN;IDENTIFICATION (BIOLOGY);INTERVENTIONAL RADIOLOGY;INTESTINAL MUCOSA;MEDICAL MICROBIOLOGY;NEURORADIOLOGY;NUCLEOSIDE ANALOGUE;PHILADELPHIA CHROMOSOME","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACTIVE E-MINUS;ACUTE LYMPHOBLASTIC;ADULT ACUTE;ANTHRACYCLINE DOSE-INTENSITY;B-PRECURSOR ADULT;BRIDGING EFFORTS;CATHOLIC BRIDGING;CHROMOSOMEBCRABL REARRANGEMENTS;CHRONIC ACTIVE;CLINICAL DATABASES;CLINICAL YEASTS;CORRECTLY EVALUATED;E-MINUS VARIANT;FACTOR II;HCV INFECTION;INFECTION ACQUIRED;ISCHEMIC ATTACKS;LUPUS ANTICOAGULANTS;LYMPHOBLASTIC LEUKEMIA;METHYLENETETRAHYDROFOLATE REDUCTASE;NONRANDOMIZED OPEN-LABEL;OPEN-LABEL STUDY;PHILADELPHIA CHROMOSOMEBCRABL;REDUCTASE GENES;TRANSIENT ISCHEMIC;TRANSMITTED HGV;VARIANT HEPATITIS;VENOUS THROMBOSIS;VERTICALLY TRANSMITTED;VIRUS HCV","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2001,10,5.3,2.1,0.476190476190476,0.9,0.3,0,0.1,0,4,2,1,3,0.4,0.2,0.1,0.3,30.8,0.674072284165832,0.1,0.4,NA,0.23952559160359,0,0,0,"D. FALEO;GIOACCHINO LEANDRO;A SCISCO;C. POGGIANI;ENZO IERARDI;GIOVANNI TRIPEPI;CESARE HASSAN;BRUNO GRIDELLI;ALESSANDRA MANGIA;ADELE BORGHI;ANGELO ANDRIULLI;F. CENTINI;C. SGARRO;CLAUDIO ARICI;NACCHIERO MC;GIUSEPPE REMUZZI;VERONICA RAVASIO;FRANCESCA MALLAMACI;LAURA PAGLICCI REATTELLI;EMANUELA TURILLAZZI","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTONELLO GAVAZZI;MICHELE SENNI;C. POGGIANI;BRUNO GRIDELLI;ADELE BORGHI;GIUSEPPE REMUZZI;NORBERTO PERICO;GABRIELLA AGNOLETTI;D. FALEO;A SCISCO;GIOVANNI TRIPEPI;FRANCESCA MALLAMACI;FILIPPO BENEDETTO;DI CARLO FP;CARMINE ZOCCALI;DI PIETRO FP;A. MACCHIAROLA;F. CENTINI;LAURA PAGLICCI REATTELLI;EMANUELA TURILLAZZI","0.5;0.5;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.2;0.2;0.2","C. POGGIANI;CESARE HASSAN;BRUNO GRIDELLI;ADELE BORGHI;CLAUDIO ARICI;VERONICA RAVASIO;EMANUELA TURILLAZZI;MARCO RIZZI;MARINA CELA;F MAGGIOLO;CARMINE ZOCCALI;VITTORIO FINESCHI;MICHELE SENNI;ANGELO ZULLO;MARIA GRAZIA FINAZZI;NICOLA CRUCINIO;FREDY SUTER;GABRIELLA AGNOLETTI;DIEGO RIPAMONTI;VINCENZO DE FRANCESCO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MICHELE SENNI;C. POGGIANI;BRUNO GRIDELLI;ADELE BORGHI;GABRIELLA AGNOLETTI;CARMINE ZOCCALI;A. MACCHIAROLA;EMANUELA TURILLAZZI;VITTORIO FINESCHI;CESARE HASSAN;CLAUDIO ARICI;VERONICA RAVASIO;MARCO RIZZI;F MAGGIOLO;ANGELO ZULLO;MARIA GRAZIA FINAZZI;NICOLA CRUCINIO;FREDY SUTER;DIEGO RIPAMONTI;VINCENZO DE FRANCESCO","0.5;0.33;0.33;0.33;0.33;0.25;0.25;0.2;0.2;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14","CARMINE ZOCCALI;FILIPPO BENEDETTO;FRANCESCA MALLAMACI;GIOVANNI TRIPEPI;D. FALEO;ANGELO ZULLO;C. PAÑELLA;CESARE HASSAN;ENZO IERARDI;S. MORINI;VINCENZO DE FRANCESCO;EMANUELA TURILLAZZI;F. CENTINI;LAURA PAGLICCI REATTELLI;ROSSANA CECCHI;VITTORIO FINESCHI;A. GIANGASPERO;ALESSANDRA MANGIA;ANGELO ANDRIULLI;DONATO BACCA","80;80;80;80;66;65;65;65;65;65;65;56;56;56;56;56;30;30;30;30","CARMINE ZOCCALI;ANGELO ZULLO;CESARE HASSAN;VINCENZO DE FRANCESCO;EMANUELA TURILLAZZI;VITTORIO FINESCHI;MARINA CELA;ADELE BORGHI;C. POGGIANI;CLAUDIO ARICI;DIEGO RIPAMONTI;F MAGGIOLO;FREDY SUTER;GABRIELLA AGNOLETTI;MARCO RIZZI;MARIA GRAZIA FINAZZI;VERONICA RAVASIO;MICHELE SENNI;BRUNO GRIDELLI;A. MACCHIAROLA","80;65;65;65;56;56;30;28;28;28;28;28;28;28;28;28;28;16;3;1","A. MACCHIAROLA;ADELE BORGHI;ANGELO ZULLO;BRUNO GRIDELLI;C. POGGIANI;CARMINE ZOCCALI;CESARE HASSAN;CLAUDIO ARICI;DIEGO RIPAMONTI;EMANUELA TURILLAZZI;F MAGGIOLO;FREDY SUTER;GABRIELLA AGNOLETTI;MARCO RIZZI;MARIA GRAZIA FINAZZI;MARINA CELA;MICHELE SENNI;NICOLA CRUCINIO;VERONICA RAVASIO;VINCENZO DE FRANCESCO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHILOSOPHY;PHYSICS","10;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;EMERGENCY MEDICINE;FAMILY MEDICINE;GENETICS;LINGUISTICS;MEDICAL EMERGENCY;MICROBIOLOGY;OPTICS;PATHOLOGY;PHARMACOLOGY;RADIOLOGY","8;5;3;3;2;2;1;1;1;1;1;1;1;1;1;1","DOSE;REGIMEN;ABLATION;ANTIBIOTICS;ASTHMA;ASYMPTOMATIC;BALLOON;BIOPSY;BLOOD PRESSURE;CANCER;CARDIAC SURGERY;CELL CULTURE;CLINICAL TRIAL;COHORT;COMBINATION THERAPY;CONFIDENCE INTERVAL;DIALYSIS;DRUG;EXTERNAL FIXATOR;GOVERNMENT (LINGUISTICS);HEART FAILURE;HELICOBACTER PYLORI;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);INTERFERON;LIVER FUNCTION;LUMBAR;LUMBAR SPINE;MAST CELL;NOCTURNAL;OMEPRAZOLE;ORTHOPEDIC SURGERY;PERCUTANEOUS;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STENOSIS;TRANSPLANTATION;VIRUS","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALPHA INTERFERON;AMOXICILLIN;BALLOON DILATION;CHRONIC HEPATITIS;CLARITHROMYCIN;ECONOMIC SHORTAGE;EOSINOPHIL;GASTRITIS;HEPATITIS C VIRUS;HEROIN;LIVER TRANSPLANTATION;METRONIDAZOLE;NEUROBLASTOMA;ORTHOSTATIC VITAL SIGNS;PROSTATE CANCER;RADIOFREQUENCY ABLATION;TRYPTASE;VASCULAR SURGERY;VIRAL LOAD","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABLATION THERAPY;ANTIRETROVIRAL THERAPY;AUTONOMIC NEUROPATHY;EOSINOPHIL CATIONIC PROTEIN;PERCUTANEOUS ETHANOL INJECTION;PURE AUTONOMIC FAILURE;RAPID UREASE TEST;RF ABLATION;RIBAVIRIN;TINIDAZOLE","1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MALE;MIDDLE AGED;AGED;CAROTID STENOSIS;HEPATITIS C, CHRONIC;HEROIN;HIV INFECTIONS;KIDNEY FAILURE, CHRONIC;ACQUIRED IMMUNODEFICIENCY SYNDROME;ANTIVIRAL AGENTS;AORTIC VALVE STENOSIS;AUTONOMIC NERVOUS SYSTEM DISEASES;CAROTID ARTERIES;CATHETERIZATION;DRUG THERAPY, COMBINATION;HEART FAILURE;INTERFERONS","10;8;7;7;7;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3","ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND TREATMENT OF HEART FAILURE;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;SPINE SURGERY TECHNIQUES AND TECHNOLOGIES","1;1;1;1;1;1;1;1;1;1","DOSE;REGIMEN;TREATMENT;ABLATION THERAPY;ANTIRETROVIRAL THERAPY;AORTIC DISSECTION;AORTIC ROOT REPLACEMENT;AUTONOMIC DYSFUNCTION;AUTONOMIC NEUROPATHY;BALLOON DILATION;COMBINATION THERAPY;CORONARY ARTERY ANOMALIES;ECHOCARDIOGRAPHY;ECONOMIC SHORTAGE;HELICOBACTER PYLORI;HEPATOCELLULAR CARCINOMA;HIV;IMMUNE ACTIVATION;KIDNEY TRANSPLANTATION;LIVER FUNCTION","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACTIVE ANTIRETROVIRAL;ADVANCED HIV-;ANTIRETROVIRAL THERAPY;AORTIC BALLOON;AUTONOMIC NEUROPATHY;BALLOON VALVULOPLASTY;BLOOD DOSAGES;CAROTID ARTERY;CATIONIC PROTEIN;CHRONIC HEPATITIS;CLINICAL BENEFIT;CONCENTRIC HYPERTROPHY;CONTROLLED TRIAL;DIALYSIS PATIENTS;EOSINOPHIL CATIONIC;HEART FAILURE;HELICOBACTER PYLORI;HEPATOCELLULAR CARCINOMA;HEROIN-RELATED DEATHS;HIGHLY ACTIVE;HIV- INFECTION;IMMUNE RECONSTITUTION;IMMUNOHISTOCHEMICAL QUANTIFICATION;INFANCY MIDTERM;INTERNAL FIXATOR;LONG-TERM CLINICAL;MIDTERM FOLLOW-UP;NAIVE PATIENTS;NOCTURNAL HYPOXAEMIA;POST-MORTEM BLOOD","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NOCTURNAL HYPOXAEMIA;SLEEP APNOEA;ALTERED AUTONOMIC;APNOEA DAMPENS;AUTONOMIC CONTROL;AUTONOMIC DYSFUNCTION;AUTONOMIC REFLEXES;BACKGROUND AUTONOMIC;CHRONIC RENAL;DAMPENS AUTONOMIC;FREQUENT COMPLICATIONS;RENAL FAILURE;URAEMIC PATIENTS","2;2;1;1;1;1;1;1;1;1;1;1;1",2,0.2,3,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,25.5,25.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2002,14,8.57142857142857,1.5,0.666666666666667,0.571428571428571,0.142857142857143,0.0714285714285714,0.285714285714286,1,7,1,1,5,0.5,0.07,0.07,0.36,30.57,0.554144338071213,0.0714285714285714,0.571428571428571,NA,0.418047623434046,0.107142857142857,0.166666666666667,0,"GRUPPO DI STUDIO APULO-LUCANO SULLA NUTRIZIONE;DI IORIO B;TIZIANO BARBUI;STRIPPOLI GF;M QUERQUES;MICHELE GALLUCCI;MARIA COLOMBINO;VALENTINO CONTER;C MANNO;PIERA VIERO;GIOACCHINO LEANDRO;V. FESTAL;F MARINACCIO;RENATO BASSAN;ALFREDO ROSSI;CATHERINE S. MANNO;GIUSEPPE PALMIERI;SAVERIO LADOGANA;ANTONIO COSSU;CESARE HASSAN","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALESSANDRO RAMBALDI;PIER LUIGI LOPALCO;MARIO MASTROLONARDO;A DIAFERIO;GRUPPO DI STUDIO APULO-LUCANO SULLA NUTRIZIONE;DI IORIO B;STRIPPOLI GF;M QUERQUES;MICHELE GALLUCCI;F. CENTINI;EMANUELA TURILLAZZI;VITTORIO FINESCHI;FLORIANA MONCIOTTI;TIZIANO BARBUI;F MARINACCIO;FRANCO FABBRO;MARCO MARINACCIO;F. SUTER;CLAUDIO FARINA;DARIO FILIPUTTI","1;0.33;0.33;0.33;0.29;0.29;0.29;0.29;0.29;0.25;0.25;0.25;0.25;0.21;0.2;0.2;0.2;0.2;0.2;0.2","TIZIANO BARBUI;M QUERQUES;F MARINACCIO;RENATO BASSAN;ELENA OLDANI;EMANUELA TURILLAZZI;MARINA CELA;ANDREA ROSSI;D. FALEO;M. CASTRIOTA;SERGIO CORTELAZZO;ALESSANDRO RAMBALDI;VITTORIO FINESCHI;PIER LUIGI LOPALCO;MARGHERITA COMIS;GUIDO DE LUCA;VINCENZO DE FRANCESCO;LORENZA VORANO;TERESIO MOTTA;AMANDO GAMBA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALESSANDRO RAMBALDI;PIER LUIGI LOPALCO;M QUERQUES;EMANUELA TURILLAZZI;VITTORIO FINESCHI;TIZIANO BARBUI;F MARINACCIO;GUIDO DE LUCA;LORENZA VORANO;AMANDO GAMBA;RENATO BASSAN;D. FALEO;VINCENZO DE FRANCESCO;MARINA CELA;ELENA OLDANI;ANDREA ROSSI;M. CASTRIOTA;SERGIO CORTELAZZO;TERESIO MOTTA;MARGHERITA COMIS","1;0.33;0.29;0.25;0.25;0.21;0.2;0.2;0.2;0.2;0.14;0.12;0.12;0.08;0.07;0.07;0.07;0.07;0.07;0.04","ALESSANDRO RAMBALDI;EMANUELA TURILLAZZI;F. CENTINI;FLORIANA MONCIOTTI;VITTORIO FINESCHI;A MARGARI;ANNA CURCI;ANTONELLA MANCA;ANTONIO AVALLONE;ANTONIO COSSU;F TANDA;FRANCESCO SCINTU;G M BONOMO;G. COMELLA;GIUSEPPE PALMIERI;M. AMORUSO;M. CASTRIOTA;M.F. DEDOLA;MARIA COLOMBINO;MIRELLA GIORDANO","173;53;53;53;53;47;47;47;47;47;47;47;47;47;47;47;47;47;47;47","ALESSANDRO RAMBALDI;EMANUELA TURILLAZZI;VITTORIO FINESCHI;M. CASTRIOTA;D. FALEO;VINCENZO DE FRANCESCO;GUIDO DE LUCA;LORENZA VORANO;MARINA CELA;MARGHERITA COMIS;ANDREA ROSSI;ELENA OLDANI;SERGIO CORTELAZZO;TERESIO MOTTA;TIZIANO BARBUI;PIER LUIGI LOPALCO;F MARINACCIO;AMANDO GAMBA;M QUERQUES;RENATO BASSAN","173;53;53;47;43;43;30;30;26;21;18;18;18;18;18;13;2;1;1;0","M QUERQUES;ALESSANDRO RAMBALDI;AMANDO GAMBA;ANDREA ROSSI;D. FALEO;ELENA OLDANI;EMANUELA TURILLAZZI;F MARINACCIO;GUIDO DE LUCA;LORENZA VORANO;M. CASTRIOTA;MARGHERITA COMIS;MARINA CELA;PIER LUIGI LOPALCO;SERGIO CORTELAZZO;TERESIO MOTTA;TIZIANO BARBUI;VINCENZO DE FRANCESCO;VITTORIO FINESCHI;RENATO BASSAN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;0","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PHILOSOPHY;PSYCHOLOGY","14;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;ONCOLOGY;BIOCHEMISTRY;DERMATOLOGY;AUDIOLOGY;CARDIOLOGY;COGNITIVE PSYCHOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;LINGUISTICS;NEUROSCIENCE;NUCLEAR PHYSICS;OPTICS;PALEONTOLOGY;PATHOLOGY;PHARMACOLOGY;PHYSICAL MEDICINE AND REHABILITATION","12;7;4;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;LYMPHOMA;BODY MASS INDEX;CHEMOTHERAPY;DIALYSIS;DISEASE;GENE;HEMODIALYSIS;LEUKEMIA;STENOSIS;ABSCESS;ADENOMA;ALLERGY;ANASTOMOSIS;ANTIBODY;AORTIC VALVE;APHASIA;ATRESIA;BELLA;BODY SEGMENT;CARCINOMA;CREATININE;DIABETES MELLITUS;DIVERTICULAR DISEASE;DRUG;DYSPLASIA;ENDOCARDITIS;EPIDEMIOLOGY;ESOPHAGUS;FAILURE TO THRIVE;FISTULA;HEPATITIS C;HISTOLOGY;INCIDENCE (GEOMETRY);INFECTIVE ENDOCARDITIS;INTERFERON;MALNUTRITION;NATURAL HISTORY;OBESITY;ODDS RATIO;PATHOLOGICAL;POPULATION;PROPORTIONAL HAZARDS MODEL;RADIATION THERAPY;RECTUM;REGIMEN;REHABILITATION;RETROSPECTIVE COHORT STUDY;RISK FACTOR;SENSITIZATION;STAGE (STRATIGRAPHY);TREATMENT MODALITY;VIRUS","3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;ADJUVANT THERAPY;ALLELE;ALLERGIC CONTACT DERMATITIS;ALPHA INTERFERON;AORTIC VALVE REPLACEMENT;B CELL;B SYMPTOMS;CHOP;CHRONIC HEPATITIS;CONTACT DERMATITIS;CYTARABINE;DIALYSIS ADEQUACY;DIFFUSE LARGE B-CELL LYMPHOMA;FOLLICULAR LYMPHOMA;GENOTYPE;HEPATITIS C VIRUS;IMMUNOTHERAPY;LYMPHOBLASTIC LEUKEMIA;MINIMAL RESIDUAL DISEASE;RECREATIONAL DRUG;REFLUX;RITUXIMAB;SIGMOID COLON;TRACHEOESOPHAGEAL FISTULA;VALVE REPLACEMENT","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE LYMPHOCYTIC LEUKEMIA;COLONOSCOPY;IDARUBICIN;INTERFERON ALFA;INTERNATIONAL PROGNOSTIC INDEX;MARGINAL ZONE;MICROSATELLITE;RIBAVIRIN","1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MIDDLE AGED;UREMIA;ADULT;AGED;LYMPHOMA, B-CELL;LYMPHOMA, LARGE B-CELL, DIFFUSE;ITALY;ADENOCARCINOMA;DERMATITIS, ALLERGIC CONTACT;ENDOCARDITIS, BACTERIAL;LYMPHOMA, FOLLICULAR;PROTEIN-ENERGY MALNUTRITION;RECTAL NEOPLASMS;ADENOMA;ADOLESCENT;ALOPECIA","13;12;12;8;8;8;7;7;6;6;5;4;4;4;4;4;4;3;3;3","LYMPHOID NEOPLASMS;ATOPIC DERMATITIS AND SKIN MICROBIOME;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS;ESOPHAGEAL INTERVENTION TECHNIQUES;FORENSIC TOXICOLOGY METHODS AND ANALYSIS;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;HYPERGLYCEMIC CHOREA AND BASAL GANGLIA LESIONS;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;NEURAL MECHANISMS OF LANGUAGE PROCESSING;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS","2;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE LYMPHOBLASTIC LEUKEMIA;ACUTE LYMPHOCYTIC LEUKEMIA;ADJUVANT THERAPY;ADOLESCENT AND YOUNG ADULT ONCOLOGY;B SYMPTOMS;BELLA;BILINGUALISM;BODY SEGMENT;COLONIC DIVERTICULITIS;CONTACT ALLERGY;CUTANEOUS LYMPHOMAS;DESIGNER DRUGS;DIALYSIS ADEQUACY;DIVERTICULAR DISEASE;DIVERTICULITIS;ESOPHAGEAL ATRESIA;ESOPHAGEAL PERFORATION;FAILURE TO THRIVE;FOLLICULAR LYMPHOMA;HEART VALVE SURGERY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE LYMPHOBLASTIC;AORTIC VALVE;APHASIC PATIENT;BCELL HISTOLOGIES;BELLAS THERAPY;BODY STUFFER;CHILDHOOD HIGHRISK;CHRONIC HEPATITIS;COCAINE BODY;COLON ADENOMAS;CONTACT SENSITIZERS;CUTANEOUS LYMPHOMA;DELAYED HYPERSENSITIVITY;DI BELLAS;DIVERTICULAR DISEASE;ESOPHAGEAL ATRESIA;EXTRANODAL MARGINAL;FISTULA PERSONAL;FOLLICULAR LYMPHOMA;GENOTYPE CHRONIC;GIGANTIC CUTANEOUS;HCV GENOTYPE;HEMODIALYSIS PATIENTS;HEMODIALYSIS THERAPY;HIGHDOSE ARAC;HIGHRISK ACUTE;IDARUBICIN COMBINED;INFECTIVE ENDOCARDITIS;INTERNATIONAL PROGNOSTIC;INTESTINAL LYMPHOMA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RC PATIENTS;BONE MARROW;CLINICAL RESPONSE;COMPLETE REMISSION;DFSOS MONTHS;FOLLOW-UP WEEKS;INDUCTION THERAPY;INTENSIVE CONSOLIDATION;INTESTINAL LYMPHOMA;MEDIAN DFSOS;MOLECULAR FOLLOW-UP;PCR NEGATIVE;PCR-NEGATIVE STATUS;PRIMARY INTESTINAL;RECTAL CARCINOMA;RISK FACTOR;RITUXIMAB TREATMENT;SURVIVAL OS;ACCEPTABLE TOXICITY;ACHIEVED COMPLETE;ACHIEVING PCR-NEGATIVE;ACUTE LYMPHOBLASTIC;AD HOC;ADJUVANT CHEMOTHERAPY;ADJUVANT RADIOTHERAPY;ADJUVANT THERAPIES;ADMINISTERED TREATMENT;AIEOP ASSOCIAZIONE;ANALOGOUS POSITIVE;ANALYSIS PATIENTS","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1",1,0.07,12,2,0,1,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,21,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,6,6975,5,0,0,304,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","1;1","CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;NUTRITION","1;1;1;1;1","CARDIOVASCULAR","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2003,14,9.28571428571429,2.71428571428571,0.368421052631579,0.5,0.142857142857143,0.0714285714285714,0.285714285714286,1,8,2,0,4,0.57,0.14,0,0.29,48,0.906894066191833,0.142857142857143,0.785714285714286,NA,0.395492218202018,0.107142857142857,0.357142857142857,0,"ENZO IERARDI;VINCENZO DE FRANCESCO;CESARE HASSAN;ROSARIO CUOMO;C. PAÑELLA;ANGELO ZULLO;S. MORINI;MICAELA GENTILE;D. FALEO;NICOLA MUSCATIELLO;MARIA COLOMBINO;C NATALE;ANGELINA VASSILEVA;GIUSEPPE PALMIERI;CHIARA RICCI;FABIO FORNARI;MARIA ROSARIA D’AGNESSA;ANTONIO COSSU;P.B. BERLOCO;ALFREDO DI LEO","6;5;3;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1","PAOLO EMILIO BIANCHI;ENZO IERARDI;VINCENZO DE FRANCESCO;GIANCARLO LOGROSCINO;MARIO MASTROLONARDO;A DIAFERIO;C. PAÑELLA;CESARE HASSAN;ANGELO ZULLO;S. MORINI;ROSARIO CUOMO;VALENTINO TP;CLAUDIA MAZZARELLA;DI LAURO G;GIUSEPPE GIORDANO;PASQUALE CIANCI;ALBERTO FERSINI;VINCENZO NERI;MARIANGELA AMATUZIO;M. CASTRIOTA","1;0.58;0.48;0.33;0.33;0.33;0.3;0.29;0.29;0.29;0.29;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","ENZO IERARDI;VINCENZO DE FRANCESCO;C. PAÑELLA;MICAELA GENTILE;D. FALEO;NICOLA MUSCATIELLO;C NATALE;MARIA ROSARIA D’AGNESSA;VINCENZO DE FRANCESCO;PAOLO EMILIO BIANCHI;GIUSEPPE GIORDANO;VINCENZO NERI;CATERINA STELITANO;SEBASTIANO CUTRUPI;CARMINE ZOCCALI;P. COZZUPOLI;V. STOPPINO;ANTONIO STEFANO SALCUNI;CARLO CATALANO;C. MARTORANO","6;5;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PAOLO EMILIO BIANCHI;ENZO IERARDI;VINCENZO DE FRANCESCO;MARIO MASTROLONARDO;A DIAFERIO;C. PAÑELLA;GIUSEPPE GIORDANO;VINCENZO NERI;MICAELA GENTILE;NICOLA MUSCATIELLO;ORAZIO VALSECCHI;SEBASTIANO CUTRUPI;CARMINE ZOCCALI;P. COZZUPOLI;CARLO CATALANO;C. MARTORANO;PAOLO SCUDO;CARMEN MARINO;MAURIZIO POSTORINO;D. FALEO","1;0.58;0.48;0.33;0.33;0.3;0.2;0.2;0.18;0.18;0.14;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12","ENZO IERARDI;VINCENZO DE FRANCESCO;ANGELO ZULLO;CESARE HASSAN;S. MORINI;D. FALEO;A. SAVIOLI;ANDREA TAMPIERI;ANTONIO MERLA;CHIARA RICCI;CINZIA PAPADIA;D. VAIRA;FABIO FORNARI;FRANCESCO PERNA;FRANCESCO PERRI;G MARINONE;L. SANCHEZ METE;LUIGI GATTA;M MENEGATTI;M. MIGLIOLI","422;422;389;389;389;237;232;232;232;232;232;232;232;232;232;232;232;232;232;232","VINCENZO DE FRANCESCO;ENZO IERARDI;D. FALEO;C. MARTORANO;CARLO CATALANO;CARMEN MARINO;CARMINE ZOCCALI;MAURIZIO POSTORINO;P. COZZUPOLI;PAOLO SCUDO;SEBASTIANO CUTRUPI;A DIAFERIO;MARIO MASTROLONARDO;C. PAÑELLA;ORAZIO VALSECCHI;CATERINA STELITANO;VINCENZO NERI;MARIA ROSARIA D’AGNESSA;NICOLA MUSCATIELLO;M.C. NACCHIERO","422;391;237;70;70;70;70;70;70;70;70;58;58;54;51;32;20;19;7;5","VINCENZO DE FRANCESCO;ENZO IERARDI;C. PAÑELLA;D. FALEO;NICOLA MUSCATIELLO;A DIAFERIO;A. CONTILLO;ANTONIO STEFANO SALCUNI;C NATALE;C. MARTORANO;CARLO CATALANO;CARMEN MARINO;CARMINE ZOCCALI;CATERINA STELITANO;M.C. NACCHIERO;MARIA ROSARIA D’AGNESSA;MARIO MASTROLONARDO;MAURIZIO POSTORINO;MICAELA GENTILE;ORAZIO VALSECCHI","6;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS","14;6;1;1","INTERNAL MEDICINE;GASTROENTEROLOGY;SURGERY;MICROBIOLOGY;RADIOLOGY;PALEONTOLOGY;PATHOLOGY;ANATOMY;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;CANCER RESEARCH;CARDIOLOGY;DERMATOLOGY;ENDOCRINOLOGY;GENERAL SURGERY;GENETICS;ONCOLOGY;OPTICS;PSYCHIATRY","12;7;5;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","HELICOBACTER PYLORI;ANTIBIOTICS;GALLBLADDER;GENE;REGIMEN;ULTRASONOGRAPHY;ABDOMINAL MASS;ABDOMINAL WALL;AGENESIS;ANGIOPLASTY;ARTERY;ASYMPTOMATIC;ATROPHY;BILE DUCT;CANCER;CARDIAC CATHETERIZATION;CATHETER;CHEMOTHERAPY;CHOLECYSTECTOMY;CIRRHOSIS;COMPUTED TOMOGRAPHY;CONTEXT (ARCHAEOLOGY);DISEASE;ENDOSCOPIC ULTRASOUND;ENDOSCOPY;EPILEPSY;ETIOLOGY;FEMORAL ARTERY;GENITOURINARY SYSTEM;GOLD STANDARD (TEST);GROUP B;HEPATOLOGY;HYPOSPADIAS;INSULIN;KIDNEY;LACRIMAL GLAND;LANGUAGE MODEL;LAPAROSCOPIC CHOLECYSTECTOMY;LAPAROSCOPY;LASER;LYMPHOMA;METHOTREXATE;MYOCARDIAL INFARCTION;PANCREAS;PANCREATITIS;PEPTIC ULCER;PERCUTANEOUS;PHARMACOTHERAPY;PREDNISONE;RADIATION THERAPY;RESECTION;SALIVA;SALIVARY GLAND;SEBORRHEIC DERMATITIS;SEBORRHOEIC DERMATITIS;STAGE (STRATIGRAPHY);SURGICAL RESECTION;TOXICITY;ULTRASOUND;VITAMIN","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AMOXICILLIN;BREATH TEST;ABDOMINAL ULTRASONOGRAPHY;CLARITHROMYCIN;HELICOBACTER PYLORI INFECTION;LANSOPRAZOLE;RABEPRAZOLE;ACUTE CHOLECYSTITIS;ALLELE;BILIARY SLUDGE;BLEOMYCIN;CHOLECYSTITIS;COLORECTAL CANCER;CORONARY ANGIOGRAPHY;ENDOSCOPIC ULTRASONOGRAPHY;GASTRITIS;HELICOBACTER;HELICOBACTER INFECTIONS;HYPOGLYCEMIA;INSULIN RESISTANCE;INSULINOMA;LEVOFLOXACIN;METRONIDAZOLE;MUTATION;OPEN CHOLECYSTECTOMY;PARKINSONISM;PEPTIC;PERCUTANEOUS CORONARY INTERVENTION;PERPLEXITY;PULMONARY TOXICITY;RADIAL ARTERY;RENAL AGENESIS;RETINOL;SECOND-HARMONIC GENERATION;VINBLASTINE;VIRULENCE","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RAPID UREASE TEST;UREA BREATH TEST;CAGA;DNA MISMATCH REPAIR;GERMLINE MUTATION;HYPERINSULINEMIA;MICROSATELLITE;SECOND-HARMONIC IMAGING MICROSCOPY;TINIDAZOLE;VITAMIN A DEFICIENCY","2;2;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;HELICOBACTER INFECTIONS;MIDDLE AGED;AGED;ADULT;AMOXICILLIN;BENZIMIDAZOLES;TREATMENT OUTCOME;DRUG THERAPY, COMBINATION;HELICOBACTER PYLORI;OMEPRAZOLE;ANTI-ULCER AGENTS;CLARITHROMYCIN;TINIDAZOLE;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;DERMATITIS, SEBORRHEIC;DUODENAL ULCER","14;13;12;10;10;9;7;7;7;7;6;6;6;5;5;5;4;4;4;4","HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;LYMPHOID NEOPLASMS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;SARCOMA RESEARCH AND TREATMENT;UROTRAUMA AND GENITOURINARY DEVELOPMENT;VASCULAR ACCESS FOR CORONARY PROCEDURES AND TRAUMA MANAGEMENT","4;1;1;1;1;1;1;1;1;1;1","ABDOMINAL ULTRASONOGRAPHY;ENDOSCOPIC ULTRASOUND;ERADICATION THERAPY;HELICOBACTER PYLORI;LANSOPRAZOLE;RABEPRAZOLE;RAPID UREASE TEST;REGIMEN;UREA BREATH TEST;ABDOMINAL MASS;AGENESIS;BILIARY SLUDGE;CAGA;CARDIAC CATHETERIZATION;CHOLECYSTITIS;DNA MISMATCH REPAIR;EAR TUMORS;ENDOSCOPIC ULTRASONOGRAPHY;ETIOLOGY;EXTERNAL GENITAL DEVELOPMENT","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","IHELICOBACTER PYLORII;SEQUENTIAL TREATMENT;ABDOMINAL WALL;ACUTE MYOCARDIAL;ALTERATIONS ACCOUNTING;BILIARY SLUDGE;CARCINOMA DETECTION;CHOLECYSTECTOMIES VALIDITY;COLORECTAL CARCINOMA;COMPLETE AGENESIS;DERMATITIS INCREASED;DIFFICULT CHOLECYSTECTOMIES;DUODENAL ULCER;EARLYSTAGE FAVORABLE;ENDOSCOPIC ULTRASOUND;ERADICATION RATES;ERADICATION THERAPY;FAVORABLE HODGKIN;HARMONIC IMAGING;HELICOBACTER PYLORI;HISTOLOGICALLYRELATED LESIONS;HODGKIN LYMPHOMA;IDIOPATHIC PANCREATITIS;IMAGING IMPROVES;IMPOSSIBLE LINKS;IMPROVES TRANSABDOMINAL;INCREASED SEBUM;ITALIAN PATIENTS;LACRIMAL SECRETION;LAPAROSCOPIC APPROACH","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ERADICATION RATES;CRC FAMILIES;HODGKIN LYMPHOMA;RABEPRAZOLE MG;TRIPLE THERAPY;BLEOMYCIN DOSES;CLARITHROMYCIN MG;DAY SEQUENTIAL;EARLYSTAGE HODGKIN;ERADICATION RATE;HELICOBACTER PYLORI;LYMPHO-EPITHELIAL LESIONS;MG CLARITHROMYCIN;MICROSATELLITE ANALYSIS;NONULCER DYSPEPSIA;PEPTIC ULCER;REGIMEN COMPARED;SEQUENTIAL TREATMENT;THERAPEUTIC OUTCOME;TREATMENT REGIMEN;ULCER DISEASE;VBM SCHEDULE;ACKNOWLEDGED EFFECTIVENESS;ACTUAL INTENSIFICATION;AMERICAN CANCER;AMSTERDAM CRITERIA;BACKGROUND ERADICATION;BACTERIUM-INDUCED GASTRIC;BACTERIUM-RELATED LESIONS;BREATH TEST","5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1",3,0.21,3,1.5,0,0,0,0,0,0,1,1.5,0,0,1,0,2,1,0,0,0,0,0,42.5,42.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,11,0,3.7,0,0,143,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES","1;1;1;1","INFECTION","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2004,18,6.88888888888889,1.38888888888889,0.72,0.555555555555556,0.111111111111111,0,0.333333333333333,1,9,3,1,4,0.5,0.17,0.06,0.22,39.67,0.843010006935499,0.166666666666667,0.666666666666667,NA,0.345852624291463,0.0818181818181818,0.3,0,"ENZO IERARDI;C. PAÑELLA;LORETO GESUALDO;ALFREDO DI LEO;A. FRANCAVILLA;EMANUELA TURILLAZZI;A. AMORUSO;VITTORIO FINESCHI;V. STOPPINO;STEFANIA MARANGI;NETTI GS;GIANPAOLO QUINZAN;GIUSEPPE CARRIERI;ALESSIA D’INTRONO;EMILIO PALUMBO;MARIABEATRICE PRINCIPI;ALINA E. PERRONE;MARGHERITA NERI;MASSIMO DI MAÏO;P.B. BERLOCO","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MONICA GALLI;ENZO IERARDI;NICOLA FUIANO;CRISTOFORO INCORVAIA;CARMINE ZOCCALI;MAURIZIO POSTORINO;C. PAÑELLA;LORETO GESUALDO;EMANUELA TURILLAZZI;VITTORIO FINESCHI;NETTI GS;A. AMORUSO;C. PANELLA;M.C. NACCHIERO;NICOLA CRUCINIO;V. STOPPINO;MARTINO INTRONA;CORRADO CASLINI;ANDREA BIONDI;AMPARO SERNA","1;0.57;0.5;0.5;0.5;0.5;0.32;0.31;0.31;0.31;0.31;0.25;0.25;0.25;0.25;0.21;0.2;0.2;0.2;0.2","ENZO IERARDI;EMANUELA TURILLAZZI;VITTORIO FINESCHI;V. STOPPINO;GIUSEPPE CARRIERI;VINCENZO DE FRANCESCO;NICOLA FUIANO;GAETANO SCOTTO;CRISTOFORO POMARA;MARCO ALEX CAPUANO;MARTINO INTRONA;CARMINE ZOCCALI;GIANFRANCO COSTANTINO;CRISTIANO CAPURSO;M.F. MINENNA;NICOLA CRUCINIO;CARLA CESARANO;ANNAPAOLA CALLEGARO;VINCENZO DE FRANCESCO;MAURIZIO POSTORINO","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ENZO IERARDI;NICOLA FUIANO;CARMINE ZOCCALI;MAURIZIO POSTORINO;EMANUELA TURILLAZZI;VITTORIO FINESCHI;NICOLA CRUCINIO;V. STOPPINO;MARTINO INTRONA;GIUSEPPE CARRIERI;CARLA CESARANO;ANNAPAOLA CALLEGARO;VINCENZO DE FRANCESCO;GAETANO SCOTTO;CRISTOFORO POMARA;DI PALMA;NICOLA MUSCATIELLO;GIANFRANCO COSTANTINO;CRISTIANO CAPURSO;M.F. MINENNA","0.57;0.5;0.5;0.5;0.31;0.31;0.25;0.21;0.2;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.12;0.12;0.07","ENZO IERARDI;C. PAÑELLA;A. CERIBELLI;ALFREDO FALCONE;ANNA ILLIANO;CESARE GRIDELLI;CIRO GALLO;EMIDDIO BARLETTA;FRANCESCO PERRONE;FRANCO VITO PIANTEDOSI;GIOVANNI PALAZZOLO;L BRANCACCIO;L. ISA;MARCO ALEX CAPUANO;MASSIMO DI MAÏO;ORAZIO CAFFO;PAOLA MAZZANTI;PAOLO MAIONE;SANTI BARBERA;STEFANIA SALVAGNI","181;178;164;164;164;164;164;164;164;164;164;164;164;164;164;164;164;164;164;164","MARCO ALEX CAPUANO;V. STOPPINO;VINCENZO DE FRANCESCO;ANNAPAOLA CALLEGARO;M.F. MINENNA;CRISTOFORO POMARA;EMANUELA TURILLAZZI;VITTORIO FINESCHI;CRISTIANO CAPURSO;NICOLA MUSCATIELLO;MARTINO INTRONA;ENZO IERARDI;GIANFRANCO COSTANTINO;CARLA CESARANO;NICOLA FUIANO;NICOLA CRUCINIO;DI PALMA;GAETANO SCOTTO;GIUSEPPE CARRIERI;CARMINE ZOCCALI","164;149;149;125;112;61;61;61;37;37;35;29;26;22;8;3;2;1;1;0","V. STOPPINO;VINCENZO DE FRANCESCO;ANNAPAOLA CALLEGARO;CARLA CESARANO;CRISTIANO CAPURSO;CRISTOFORO POMARA;DI PALMA;EMANUELA TURILLAZZI;ENZO IERARDI;GAETANO SCOTTO;GIANFRANCO COSTANTINO;GIUSEPPE CARRIERI;M.F. MINENNA;MARCO ALEX CAPUANO;MARTINO INTRONA;NICOLA CRUCINIO;NICOLA FUIANO;NICOLA MUSCATIELLO;VITTORIO FINESCHI;CARMINE ZOCCALI","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;0","MEDICINE;BIOLOGY;PHYSICS","16;7;2","INTERNAL MEDICINE;GASTROENTEROLOGY;IMMUNOLOGY;SURGERY;GENETICS;MICROBIOLOGY;RADIOLOGY;BIOCHEMISTRY;DERMATOLOGY;PATHOLOGY;ANIMAL SCIENCE;BOTANY;CANCER RESEARCH;CARDIOLOGY;MECHANICS;MEDICAL EMERGENCY;NURSING;ONCOLOGY;OPHTHALMOLOGY;PEDIATRICS;QUANTUM MECHANICS;RISK ANALYSIS (ENGINEERING);THERMODYNAMICS;UROLOGY","15;7;7;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIBODY;DISEASE;GENE;ANTIBIOTICS;CONFIDENCE INTERVAL;HELICOBACTER PYLORI;HUMAN IMMUNODEFICIENCY VIRUS (HIV);KIDNEY;RESPIRATORY SYSTEM;ULTRASONOGRAPHY;ADVERSE EFFECT;ALLERGY;AORTA;APOPTOSIS;ARTIFICIAL KIDNEY;ASTHMA;ATOPIC DERMATITIS;BIOPSY;BREAKUP;CELL CULTURE;CELL GROWTH;CHEMOTHERAPY;COAGULATION;COST EFFECTIVENESS;CUTOFF;DISCONTINUATION;HAIR LOSS;HEART FAILURE;HEAT STRESS;HEMODIALYSIS;HEPATITIS C;IMMUNOHISTOCHEMISTRY;INCUBATOR;INFERIOR VENA CAVA;KIDNEY DISEASE;LESION;LEUKEMIA;LONGEVITY;LUNG;LUNG CANCER;MITE;MULTIPLE SCLEROSIS;NAUSEA;OBSERVATIONAL STUDY;ODDS RATIO;PEPTIC ULCER;PHARMACOTHERAPY;POISON CONTROL;PREGNANCY;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REGIMEN;RENAL CELL CARCINOMA;SENSITIZATION;SHOCK (CIRCULATORY);STROKE (ENGINE);SUDDEN CARDIAC DEATH;SUDDEN DEATH;SUPERIOR MESENTERIC ARTERY;THROMBOSIS;TOXICITY;TRANSPLANTATION;TUMOR NECROSIS FACTOR ALPHA;URETER;URINARY SYSTEM;VIRUS","3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AMOXICILLIN;CLARITHROMYCIN;METRONIDAZOLE;RABEPRAZOLE;VIRAL LOAD;ABDOMINAL AORTA;ABDOMINAL ULTRASONOGRAPHY;ADRENERGIC;ALLELE;ALLERGEN;ANTIPHOSPHOLIPID SYNDROME;APOLIPOPROTEIN E;ATOPY;CELL CYCLE;CHROMOSOME;CLINICAL ENDPOINT;COAGULATION TESTING;CROHN'S DISEASE;CRYOGLOBULINS;CYSTIC KIDNEY DISEASE;CYSTOSCOPY;DOCETAXEL;FETUS;GASTRITIS;GENE DUPLICATION;GENE EXPRESSION;GENE REARRANGEMENT;GENOTYPE;GLATIRAMER ACETATE;HAZARD RATIO;HEAT EXHAUSTION;HELICOBACTER PYLORI INFECTION;HEMORRHAGIC SHOCK;HEPATITIS C VIRUS;INFLIXIMAB;KIDNEY TRANSPLANTATION;LEFT RENAL VEIN;LEUKOPENIA;LUPUS ANTICOAGULANT;LUPUS NEPHRITIS;MONOCLONAL ANTIBODY;MUCOSITIS;MYOCARDIAL FIBROSIS;NEPHRECTOMY;NEUTROPENIA;PARTIAL THROMBOPLASTIN TIME;PATCH TEST;PEPTIC;PHENOTYPE;PROTEINURIA;RELAPSING REMITTING;RENAL BIOPSY;RENAL VEIN;SYSTEMIC LUPUS ERYTHEMATOSUS;VENOUS THROMBOSIS;VIREMIA;VIRULENCE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TINIDAZOLE;ANTIRETROVIRAL THERAPY;BILATERAL NEPHRECTOMY;BREAKPOINT;CAGA;COMPARATIVE GENOMIC HYBRIDIZATION;CRYOGLOBULINEMIA;CYTOGENETICS;FLUORESCENCE IN SITU HYBRIDIZATION;HOUSE DUST MITE;KARYOTYPE;MICROSCOPIC HEMATURIA;NUTCRACKER SYNDROME;PRENATAL DIAGNOSIS;PROMOTER;RAPID UREASE TEST;UREA BREATH TEST","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;DYSPEPSIA;HIV INFECTIONS;HELICOBACTER INFECTIONS;MIDDLE AGED;AMOXICILLIN;ANTI-ULCER AGENTS;ANTIBODIES, MONOCLONAL;BENZIMIDAZOLES;CLARITHROMYCIN;CROHN DISEASE;LUPUS NEPHRITIS;OMEPRAZOLE;PEPTIC ULCER;RNA, VIRAL;TINIDAZOLE;TREATMENT OUTCOME","15;11;10;8;7;7;6;6;4;4;4;4;4;4;4;4;4;4;4;4","HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;ADVANCEMENTS IN LUNG CANCER RESEARCH;ASTHMA;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;DIAGNOSIS AND MANAGEMENT OF DRY EYE DISEASE;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;MOLECULAR CHAPERONES IN PROTEIN FOLDING AND DISEASE;PULMONARY CALCIFICATION AND NODULAR TUMORS IN THE LUNG;VENOUS ANOMALIES AND SYNDROMES IN VASCULAR SYSTEM","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;RABEPRAZOLE;TINIDAZOLE;ABDOMINAL AORTA;ABDOMINAL ULTRASONOGRAPHY;ANTIPHOSPHOLIPID SYNDROME;ANTIRETROVIRAL THERAPY;APOLIPOPROTEIN E;ARTIFICIAL KIDNEY;ATOPY;BILATERAL NEPHRECTOMY;BREAKPOINT;CAGA;CARDIAC IMAGING;CHROMOSOMAL REARRANGEMENT;CLINICAL ENDPOINT;COAGULATION TESTING;COMPARATIVE GENOMIC HYBRIDIZATION;CRYOGLOBULIN;CRYOGLOBULINS","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SCPHELICOBACTER PYLORISCP;SEQUENTIAL TREATMENT;ADRENERGIC STRESS;ADVERSE REACTION;ALLERGY ANDOR;ALPHA MONOCLONAL;ANDOR ATOPIC;ANTIBODY INFLIXIMAB;ANTIPHOSPHOLIPID ANTIBODIES;ANTIRETROVIRAL THERAPY;ANTITUMOR NECROSIS;ARCHITECTURAL DISORGANIZATION;ATOPIC ECZEMADERMATITIS;ATOPY PATCH;BENIGN CYTOGENETIC;CELL CYCLE;CLINICAL TRIAL;CO-INFECTED PATIENTS;CONTRAST AGENT;CROHNS DISEASE;CYTOGENETIC VARIANT;DISEASE-MODIFYING AGENTS;DISORGANIZATION LINKED;DISTAL STUDY;DOCETAXEL REGIMENS;ECZEMADERMATITIS SYNDROME;FACTOR ALPHA;FUSION ONCOPROTEIN;FUTURE PERSPECTIVES;GC PROMOTER","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CD CELL;MG BD;CELL COUNT;COUNT CELLSL;RABEPRAZOLE MG;CLARITHROMYCIN DOSE;CLARITHROMYCIN MG;PYLORI ERADICATION;BREAKUP TIME;DRY EYE;ERADICATION RATE;LACRIMAL SECRETION;NADIR CD;NONULCER DYSPEPSIA;SEQUENTIAL THERAPY;TRIPLE THERAPY;WEEKLY SCHEDULE;ADVANCED NSCLC;ANTIHYPERTENSIVE DRUGS;CAGA GENE;CROSSREF PUBMED;DAY SEQUENTIAL;EXP RHEUMATOL;HAIR LOSS;HELICOBACTER PYLORI;PEPTIC ULCER;PREDICTING FACTORS;PUBMED GOOGLE;PUBMED SCOPUS;PYLORI INFECTION","12;11;8;5;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2",3,0.17,4.5,3,0,0,0,0,2,0,1,3,0,0,0,0,2.5,0,0,0,0,0,0,41,41,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,10,470,9.52,0,0,137,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1;1;1;1","CANCER;CHILDHOOD LEUKEMIA;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;HIV/AIDS;INFECTIOUS DISEASES;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;TRANSPLANTATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","1;1","6.1 PHARMACEUTICALS","1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA","1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2005,15,8,1.8,0.555555555555556,0.533333333333333,0.0666666666666667,0.266666666666667,0.533333333333333,1,7,2,1,4,0.47,0.13,0.07,0.27,102.6,1.93790657826119,0.266666666666667,0.866666666666667,NA,0.41468612147947,0.107142857142857,0,0,"ALESSANDRA MANGIA;ANGELO ANDRIULLI;ALBERTO FERSINI;VITO CARRETTA;MARCELLO PERSICO;VINCENZO NERI;MAURO ANNESE;DONATO BACCA;GIORGIO RICCI;CATALDO ABBATERUSSO;FERNANDO SOGARI;VERONICA BERNABUCCI;ALESSANDRA BERTOLA;MARIA NOBILI;MARGHERITA NERI;CHIARA RICCI;ENZO IERARDI;CESARE HASSAN;MARIELLA GRASSO;VALENTINO TP","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ELENA RANIERI;ALBERTO FERSINI;VINCENZO NERI;MARGHERITA NERI;EMANUELA TURILLAZZI;VITTORIO FINESCHI;MARIO MASTROLONARDO;ELIO CONTE;JOSEPH P. ZBILUT;VALENTINO TP;ALESSANDRO AMBROSI;MARIA NOBILI;RICCARDO IEVA;MARCO MARINACCIO;CINZIA GERMINARIO;MICHELE CORREALE;FEDERICO MARINACCIO;MAURO RINALDI;DANIELE MAGISTRO;ROSA PRATO","1;0.45;0.45;0.33;0.33;0.33;0.33;0.33;0.33;0.25;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","VINCENZO NERI;CATALDO ABBATERUSSO;ENZO IERARDI;SILVANA SAVOLDI;BRUNO CIANCIARUSO;MARIA VITTORIA ANDREUCCI;VINCENZO CALLEA;C. COMOTTI;CARMELO MANGANO;F. VINELLI;MASSIMO SABBATINI;MARINA CELA;FEDERICO MARINACCIO;MAURO RINALDI;ELENA RANIERI;ROSA PRATO;VITTORIO FINESCHI;ANTONIO PISANI;LETÌZIA SPINELLI;MARIO MASTROLONARDO","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ELENA RANIERI;VINCENZO NERI;VITTORIO FINESCHI;MARIO MASTROLONARDO;ELIO CONTE;FEDERICO MARINACCIO;MAURO RINALDI;ROSA PRATO;GIOVANNI RINALDI;CATALDO ABBATERUSSO;SILVANA SAVOLDI;BRUNO CIANCIARUSO;MARIA VITTORIA ANDREUCCI;VINCENZO CALLEA;C. COMOTTI;MASSIMO SABBATINI;ANTONIO PISANI;LETÌZIA SPINELLI;SONIA PASQUALI;DENI ALDO PROCACCINI","1;0.45;0.33;0.33;0.33;0.2;0.2;0.2;0.2;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1","ALESSANDRA MANGIA;ANGELO ANDRIULLI;DONATO BACCA;MARCELLO PERSICO;MAURO ANNESE;VITO CARRETTA;F ZECHINI;F. VINELLI;FERNANDO SOGARI;FULVIO SPIRITO;GAETANO SCOTTO;GIOVANNI RICCI;MARIO ROMANO;NICOLA MINERVA;ROSANNA SANTORO;ALFONSO MELE;ANDREA MARIANO;ANGELA AMANTE;CARMELO ANTONIO CASERTA;CARMELO MANGANO","905;905;905;905;905;905;854;854;854;854;854;854;854;854;854;178;178;178;178;178","F. VINELLI;CARMELO MANGANO;ENZO IERARDI;VINCENZO DE FRANCESCO;VITTORIO FINESCHI;VINCENZO CALLEA;ANTONIO PISANI;BRUNO CIANCIARUSO;C. COMOTTI;CATALDO ABBATERUSSO;DENI ALDO PROCACCINI;LETÌZIA SPINELLI;MARIA VITTORIA ANDREUCCI;MASSIMO SABBATINI;SILVANA SAVOLDI;SONIA PASQUALI;MARINA CELA;ELIO CONTE;MARIO MASTROLONARDO;ROSA PRATO","854;178;119;119;101;85;69;69;69;69;69;69;69;69;69;69;51;26;26;11","VINCENZO NERI;ANTONIO PISANI;BRUNO CIANCIARUSO;C. COMOTTI;CARMELO MANGANO;CATALDO ABBATERUSSO;DENI ALDO PROCACCINI;ELIO CONTE;ENZO IERARDI;F. VINELLI;FEDERICO MARINACCIO;GIOVANNI RINALDI;LETÌZIA SPINELLI;MARIA VITTORIA ANDREUCCI;MARINA CELA;MARIO MASTROLONARDO;MASSIMO SABBATINI;MAURO RINALDI;ROSA PRATO;SILVANA SAVOLDI","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;POLITICAL SCIENCE;SOCIOLOGY","13;4;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GENETICS;RADIOLOGY;ARTIFICIAL INTELLIGENCE;CANCER RESEARCH;DERMATOLOGY;GENERAL SURGERY;GEOMETRY;INTENSIVE CARE MEDICINE;LAW;MATHEMATICAL ANALYSIS;MICROBIOLOGY;NURSING;ONCOLOGY;OPTICS;PATHOLOGY;PHARMACOLOGY;STATISTICS;VIROLOGY","11;7;5;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DISEASE;VIRUS;CANCER;INCIDENCE (GEOMETRY);LAPAROSCOPY;ABDOMEN;ABDOMINAL PAIN;ACUTE ABDOMEN;ADJUVANT;ADVERSE EFFECT;AMANTADINE;ANASTOMOSIS;ANTIBIOTICS;ANTIGEN;CANDIDA ALBICANS;CARDIAC SURGERY;CATHETER;CHEMOTHERAPY;CIRRHOSIS;CONFIDENCE INTERVAL;CONVALESCENCE;DEHISCENCE;DIALYSIS;DYSPHAGIA;EMBRYO;ENDOCARDITIS;ENDOSCOPY;ESOPHAGUS;ETIOLOGY;FRACTAL;HELICOBACTER PYLORI;HEPATITIS;IMMUNE SYSTEM;INTERFERON;KRIGING;LAPAROTOMY;LEGISLATION;LITER;LIVER DISEASE;MEDICAL LAW;MEDICAL THERAPY;MELANOMA;MULTIPLE MYELOMA;MYCETOMA;MYOCARDIAL INFARCTION;OUTBREAK;PATTERN RECOGNITION (PSYCHOLOGY);POLITICS;POPULATION;PREDNISONE;PREGNANCY;PROMULGATION;PROTON-PUMP INHIBITOR;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;REGIMEN;RENAL REPLACEMENT THERAPY;REPRODUCTION;SPLEEN;TRANSPLANTATION;TRICUSPID VALVE;ULTRASONOGRAPHY","4;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEPATITIS C VIRUS;ACQUIRED IMMUNE SYSTEM;AMOXICILLIN;AUTOIMMUNITY;CENTRAL VENOUS CATHETER;CHRONIC LIVER DISEASE;CIPROFLOXACIN;CLARITHROMYCIN;COLOR DOPPLER;COLORECTAL CANCER;CRYOPRESERVATION;DENDRITIC CELL;ENZYME REPLACEMENT THERAPY;FABRY DISEASE;FATTY LIVER;FRACTAL DIMENSION;HELICOBACTER;HEPATITIS A;HEPATITIS A VIRUS;HEPATITIS B VIRUS;IMMUNITY;IMMUNOTHERAPY;INFARCTION;INFERTILITY;LEVOFLOXACIN;MELPHALAN;METRONIDAZOLE;PARLIAMENT;PROGRESSIVE DISEASE;REFLUX;SKIN CANCER;SPLENECTOMY;T CELL;THALIDOMIDE;VARIOGRAM","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RIBAVIRIN;ANTIGEN-PRESENTING CELL;ASSISTED REPRODUCTIVE TECHNOLOGY;COLECTOMY;EMBRYO CRYOPRESERVATION;FRACTAL ANALYSIS;HBSAG;HEPATITIS A VACCINE;NISSEN FUNDOPLICATION;NONALCOHOLIC FATTY LIVER DISEASE;OFLOXACIN;REFLUX ESOPHAGITIS;REPRODUCTIVE TECHNOLOGY;WANDERING SPLEEN","2;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;HEPATITIS C, CHRONIC;INTERFERON-ALPHA;RIBAVIRIN;ADULT;CANDIDIASIS;DRUG THERAPY, COMBINATION;FABRY DISEASE;HEPACIVIRUS;ITALY;MYCETOMA;PROSPECTIVE STUDIES;TREATMENT OUTCOME;HEART FAILURE;HIV INFECTIONS;HYPERTROPHY, LEFT VENTRICULAR","14;12;11;8;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4","HEPATITIS C INFECTION AND TREATMENT;ADVANCED TECHNIQUES IN BIOIMAGE ANALYSIS AND MICROSCOPY;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLOBAL TRENDS IN INFERTILITY AND REPRODUCTIVE TECHNOLOGIES;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS E INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;MANAGEMENT OF SPLEEN TRAUMA IN POLYTRAUMA PATIENTS","2;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;REGIMEN;ABDOMINAL WALL DEFECTS;ACUTE ABDOMEN;AMANTADINE;ANTIGEN PRESENTATION;ANTIRETROVIRAL THERAPY;ASSISTED REPRODUCTIVE TECHNOLOGY;BIOIMAGE ANALYSIS;CENTRAL VENOUS CATHETER;CHRONIC LIVER DISEASE;COLOR DOPPLER;CONVALESCENCE;DENDRITIC CELLS;DISCONTINUATION;ECHOCARDIOGRAPHY;EFAVIRENZ;EMBRYO CRYOPRESERVATION;ENZYME REPLACEMENT THERAPY;ESOPHAGEAL PERFORATION","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTERFERON IΑIA;ACUTE ABDOMEN;ALTERED LIVER;AMANTADINE IVSI;ANTIRETROVIRAL THERAPY;ASSISTED REPRODUCTION;CANCER VALIDITY;CHRONIC HEPATITIS;CONTROLLED TRIAL;DAY LEVOFLOXACINBASED;DIAGNOSED PATIENTS;DIALYSIS EFFECTS;DISEASE PATIENTS;ENZYME REPLACEMENT;ERADICATION COURSES;FABRY DISEASE;FIRST-LINE ANTIRETROVIRAL;FOOD HANDLERS;FRACTAL ANALYSIS;GASTROESOPHAGEAL REFLUX;HCV GENOTYPE;ITALIAN LAW;IVSI INTERFERON;IΑIA KD;LAPAROSCOPIC APPROACH;LAPAROSCOPIC TREATMENT;LEVOFLOXACINBASED TRIPLE;LIVER TESTS;MEDITERRANEAN TOWN;MELPHALAN PREDNISONE","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABNORMAL LTS;RH CI;CD RECOVERY;ASSISTED REPRODUCTION;BONE MARROW;CLINICAL PROGRESSION;COMPARING TIME;CR ACHIEVED;DAY LEVOFLOXACIN-BASED;EXAMINED COMPARING;LEVOFLOXACIN-BASED TRIPLE;LIVER DAMAGE;LIVER DISEASE;MARROW TRANSPLANTATION;MULTIPLE MYELOMA;PARTIAL RESPONSE;PATIENTS STARTING;TRIPLE THERAPY;VIROLOGICAL FAILURE;ABDOMINAL ECHOGRAPHY;ACCEPTABLE COSTBENEFIT;ACHIEVED IMMUNOFIXATIONNEGATIVE;ACHIEVED IMMUNOFIXATIONPOSITIVE;ACUTE ADVERSE;ADJUSTED HAZARDS;ADULT TREATMENT;ADVERSE EVENTS;ALCOHOL INTAKE;ALLOWING ERADICATION;ALT AST","7;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1",2,0.13,7,2.5,0,0,0,1,0,0,2,2.5,0,1,0,0,0,0,0,0,0,0,0,58,58,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,6,1865.5,8,0,0,89.5,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS","2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY;RARE DISEASES","2;2;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","LUNG CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2006,24,8.95833333333333,2.66666666666667,0.375,0.708333333333333,0.25,0.0416666666666667,0.333333333333333,0,10,5,3,5,0.42,0.21,0.12,0.21,58.42,1.14367104664264,0.166666666666667,0.833333333333333,NA,0.337286790746187,0.170040485829959,0.433333333333333,0,"ENZO IERARDI;OSVALDO BURATTINI;CESARE HASSAN;ALFREDO DI LEO;MARIO BOCCADORO;VINCENZO CALLEA;ANGELO ZULLO;S. MORINI;STEFANIA MARANGI;SARA GALIMBERTI;LORETO GESUALDO;RICHARD M. DAY;MARIABEATRICE PRINCIPI;U. CEA;L. PIETRINI;MARIA TERESA AMBROSINI;VINCENZO DE FRANCESCO;A. FRANCAVILLA;PAOLO TONTI;EMANUELA TURILLAZZI","7;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ENZO IERARDI;EMANUELA TURILLAZZI;LUIGI MARIA SPECCHIO;VINCENZO NERI;MARCO GUIDO;LORETO GESUALDO;OSVALDO BURATTINI;L. PIETRINI;PAOLO TONTI;NICOLA MUSCATIELLO;BARBARA INFANTE;GIOVANNI STALLONE;C. PANELLA;MARGHERITA NERI;VALENTINO TP;JOSEP TABERNERO;FERNANDO PANARESE;DI LAURO G;ALBERTO FERSINI;SABINA DI DONATO","0.72;0.5;0.5;0.5;0.5;0.44;0.38;0.34;0.34;0.34;0.33;0.33;0.27;0.25;0.25;0.25;0.25;0.25;0.25;0.25","ENZO IERARDI;OSVALDO BURATTINI;CESARE HASSAN;ALFREDO DI LEO;VINCENZO CALLEA;ANGELO ZULLO;S. MORINI;STEFANIA MARANGI;LORETO GESUALDO;MARIABEATRICE PRINCIPI;L. PIETRINI;VINCENZO DE FRANCESCO;PAOLO TONTI;EMANUELA TURILLAZZI;BENVENUTO GRISORIO;VINCENZO NERI;C. PANELLA;ROSA MONNO;VINCENZO DE FRANCESCO;NICOLA MUSCATIELLO","7;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","ENZO IERARDI;EMANUELA TURILLAZZI;VINCENZO NERI;MARCO GUIDO;LORETO GESUALDO;OSVALDO BURATTINI;L. PIETRINI;PAOLO TONTI;NICOLA MUSCATIELLO;GIOVANNI STALLONE;C. PANELLA;MARGHERITA NERI;SABINA DI DONATO;VITTORIO FINESCHI;ROBERTO LABIANCA;STEFANO ERRICO;ALFREDO DI LEO;STEFANIA MARANGI;CESARE HASSAN;ANGELO ZULLO","0.72;0.5;0.5;0.5;0.44;0.38;0.34;0.34;0.34;0.33;0.27;0.25;0.25;0.25;0.25;0.25;0.23;0.23;0.22;0.22","MARIO BOCCADORO;VINCENZO CALLEA;ANTONIO PALUMBO;CLOTILDE CANGIALOSI;ILARIA AVONTO;MARIA TERESA AMBROSINI;PATRIZIA FALCO;PELLEGRINO MUSTO;SARA GALIMBERTI;TOMMASO CARAVITA;ANNA MARINA LIBERATI;ELENA ZAMAGNI;EMANUELA MERLA;FAUSTO ROSSINI;GIOVANNINO CICCONE;LUCIO CATALANO;MANUELA CECCARELLI;MARIA TERESA PETRUCCI;MARIELLA GRASSO;MÓNICA GALLI","1027;1027;1007;1007;1007;1007;1007;1007;1007;1007;827;827;827;827;827;827;827;827;827;827","VINCENZO CALLEA;VINCENZO DE FRANCESCO;BEATRICE MESSINI;BENVENUTO GRISORIO;C. MASTRANGELO;CRISTINA MEAZZA;DILETTA GIOVENALE;GIULIANA CARDINALE;GIUSEPPE CITRO;M SPOSITO;MAURIZIO DELVECCHIO;SARA MAIO;DE FRANCESCO;ELENA RANIERI;SERGIO FERRARA;MARCO GUIDO;NICOLA MUSCATIELLO;PAOLO TONTI;EMANUELA TURILLAZZI;CATERINA STELITANO","1027;82;58;58;58;58;58;58;58;58;58;58;36;31;31;28;27;27;24;20","VINCENZO DE FRANCESCO;VINCENZO CALLEA;BENVENUTO GRISORIO;EMANUELA TURILLAZZI;ENZO IERARDI;MARIABEATRICE PRINCIPI;NICOLA MUSCATIELLO;PAOLO TONTI;VINCENZO NERI;ALFREDO DI LEO;ANGELO ZULLO;BEATRICE MESSINI;C. MASTRANGELO;C. PANELLA;C. RICCIARDELLI;CATERINA STELITANO;CESARE HASSAN;CRISTINA MEAZZA;DE FRANCESCO;DILETTA GIOVENALE","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;SOCIOLOGY;ART;CHEMISTRY;MATERIALS SCIENCE;PHYSICS","24;10;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;MICROBIOLOGY;BIOCHEMISTRY;PEDIATRICS;PHARMACOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PSYCHIATRY;ANATOMY;ANESTHESIA;ANIMAL SCIENCE;CANCER RESEARCH;CARDIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;GENDER STUDIES;GENERAL SURGERY;HUMANITIES;MEDICAL EMERGENCY;METALLURGY;OPTICS;VETERINARY MEDICINE;VIROLOGY","14;9;8;6;6;5;4;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;ADVERSE EFFECT;DISEASE;HELICOBACTER PYLORI;REGIMEN;ANTIBIOTICS;CANCER;CELL;CHEMOTHERAPY;COMPLICATION;CONFIDENCE INTERVAL;ENDOSCOPIC ULTRASOUND;ENDOSCOPY;EPITHELIUM;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;INTESTINAL MUCOSA;MULTIPLE MYELOMA;PANCREATITIS;POISON CONTROL;PREDNISONE;STROMAL CELL;TRANSPLANTATION;TUMOR NECROSIS FACTOR ALPHA","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CLARITHROMYCIN;GASTRITIS;POLYMERASE CHAIN REACTION;COLORECTAL CANCER;CROHN'S DISEASE;HAZARD RATIO;HIGH-POWER FIELD;MELPHALAN;SYNDECAN 1;THALIDOMIDE;VIRAL LOAD;ADRENERGIC;ADRENERGIC RECEPTOR;AMOXICILLIN;AZATHIOPRINE;BEVACIZUMAB;BORTEZOMIB;BREATH TEST;CALCINEURIN;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;DENDRITIC CELL;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;EPIDERMAL GROWTH FACTOR RECEPTOR;EPITOPE;FOLLICULAR LYMPHOMA;GENOTYPE;GRAM;GRAM STAINING;HEADACHE DISORDERS;HEART RATE;IMMUNOSUPPRESSIVE DRUG;IMMUNOTHERAPY;MECHANISM OF ACTION;METRONIDAZOLE;MULTICENTER STUDY;MUTATION;MYCOPHENOLATE;NASOPHARYNGEAL CARCINOMA;NEPHROTOXICITY;NEUROLOGICAL DISORDER;PANCREATIC DUCT;PANCREATIC PSEUDOCYST;PERFORATION;PROTEASE;RABEPRAZOLE;RECOMBINANT DNA;RITUXIMAB;SEROLOGY;SIGMOID COLON;SMOTHERING;STAIN;SUICIDE PREVENTION;SYMPATHETIC NERVOUS SYSTEM;T CELL;TACROLIMUS;TOLERABILITY;TOPIRAMATE;VIRULENCE","3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RAPID UREASE TEST;ANTIRETROVIRAL THERAPY;CAGA;CETUXIMAB;COLECTOMY;EGFR INHIBITORS;ERLOTINIB;FOLINIC ACID;GEFITINIB;HOMICIDE;IRINOTECAN;MULTICENTER TRIAL;OXALIPLATIN;POINT MUTATION;REVERSE TRANSCRIPTASE;TAQMAN;TINIDAZOLE;TOTAL BODY IRRADIATION","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;PREDNISONE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HELICOBACTER INFECTIONS;HELICOBACTER PYLORI;;ITALY;CELIAC DISEASE;INTESTINAL PERFORATION;MELPHALAN;MULTIPLE MYELOMA;THALIDOMIDE;ANTI-BACTERIAL AGENTS;CLARITHROMYCIN;DRUG RESISTANCE, BACTERIAL;NOSE NEOPLASMS","18;11;11;10;8;8;7;7;7;6;6;5;5;5;5;5;4;4;4;4","HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF GESTATIONAL TROPHOBLASTIC DISEASE;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;FACTORS AND RISKS IN RESTRAINT-RELATED DEATHS;IMMUNOBIOLOGY OF DENDRITIC CELLS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;LYMPHOID NEOPLASMS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;MICROBIAL IDENTIFICATION AND DIAGNOSIS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;RABIES VIRUS TRANSMISSION AND CONTROL;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIMICROBIAL RESISTANCE;ENDOSCOPIC ULTRASOUND;RAPID UREASE TEST;HIGH-POWER FIELD;INTERNATIONAL MYELOMA WORKING GROUP;INTESTINAL MUCOSA;MELPHALAN;MUCOSAL HEALING;REGIMEN;SYNDECAN 1;;ACUTE PANCREATITIS;ANTIRETROVIRAL THERAPY;ASPHYXIAL DEATHS;BILIARY DRAINAGE;BLOOD CULTURE;CAGA;CANCER THERAPY;CELIAC DISEASE;CELIAC PLEXUS","3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","COLONIC MUCOSA;CROHNS DISEASE;DIFFERENTIAL IMMUNOHISTOCHEMICAL;ENDOSCOPIC ULTRASOUND-GUIDED;FACTOR ALPHA;IHELICOBACTER PYLORII;IMMUNOHISTOCHEMICAL EXPRESSION;MULTIPLE MYELOMA;NECROSIS FACTOR;TUMOR NECROSIS;ADVANCED COLORECTAL;ADVANCED FOLLICULAR;ANTIGEN-DERIVED PEPTIDES;AUTOGRAFTING PROGRAM;BASILICATA CALABRIA;BORTEZOMIB MELPHALAN;CALABRIA PUGLIA;CANCER FOCUS;CANE CORSO;CARDIOVASCULAR REACTIVITY;CAROTID LESIONS;CASI DI;CD T-CELL;CELIAC DISEASE;CELIAC PLEXUS;CELLS LOADED;CHAIN REACTION;CHOLANGIOPANCREATOGRAPHY-ENDOSCOPIC SPHINCTEROTOMY;CLARITHROMYCIN RESISTANCE;CLARITHROMYCIN-RESISTANT GENOTYPES","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GRAM STAIN;PSORIATIC PATIENTS;BLOOD CULTURE;GLUTEN-FREE DIET;ABDOMINAL PAIN;BETA-ADRENERGIC RECEPTOR;BETA-ADRENERGIC RECEPTORS;CULTURE BROTH;ENDOSCOPIC ULTRASOUND;NASAL SCRAPING;PSORIATIC SKIN;RECEPTOR HYPORESPONSIVENESS;RESPONSE RATE;SHORT CHILDREN;ABSENT DEFINITION;ABUSE DEVELOPED;ACCESS ROUTE;ACUTE SEVERE;ADVERSE EVENTS;ADVISE CARRYING;ALCOHOL ABUSE;ANALGESIC DRUGS;ANALYSED RESULTS;ANESTHESIA EUS;ANTIBODIES EMA;ANTIENDOMYSIAL ANTIBODIES;ANTITISSUE TRANSGLUTAMINASE;ARTERIOLAR WALLS;AUTHORS ADVISE;BETA-ADRENERGIC FUNCTION","7;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",3,0.12,12,5.5,0,0,0,0,8,0,3,5.5,0,1,0,0,0,0,0,0,0,0,0,122,122,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2,407,2.33,0,0,54,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;KIDNEY DISEASE","1;1;1","BLOOD;RENAL AND UROGENITAL","1;1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2007,30,8.7,2.86666666666667,0.348837209302326,0.5,0.366666666666667,0.333333333333333,0.366666666666667,0,13,11,4,2,0.43,0.37,0.13,0.07,41.8,0.792026814760136,0.2,0.9,NA,0.413697977082446,0.199248120300752,0.22,0.25,"GIUSEPPE QUERQUES;ENZO IERARDI;GAETANO SCOTTO;ANGELO ANDRIULLI;RICCARDO IEVA;EMANUELA TURILLAZZI;MICHELE CORREALE;EMANUELE NICASTRO;VITO CARRETTA;ANTONINO NICOLÒ;RAFFAELE IORIO;LEONARDO MOTTOLA;G. STOPPINO;VITTORIO FINESCHI;FRANCESCA FOTI;DONATO BACCA;RAFFAELE COZZOLONGO;GIUSEPPINA TIMPANI;MATTEO DI BIASE;G. SOUBRANE","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GIUSEPPE QUERQUES;EMANUELA TURILLAZZI;VITTORIO FINESCHI;RICCARDO IEVA;MICHELE CORREALE;MATTEO DI BIASE;G. SOUBRANE;EMANUELE NICASTRO;ANTONINO NICOLÒ;RAFFAELE IORIO;FRANCESCA FOTI;GIUSEPPINA TIMPANI;ENZO IERARDI;GAETANO SCOTTO;ANNALISA FEDERICO;GIUSEPPE PELLICO;DARIO GALANTE;MARCO BALZANO;M.C. ANGULO BOCCO;ERIC H. SOUIED","0.7;0.7;0.7;0.58;0.58;0.58;0.5;0.31;0.31;0.31;0.31;0.31;0.29;0.27;0.25;0.25;0.25;0.25;0.25;0.25","GIUSEPPE QUERQUES;ENZO IERARDI;GAETANO SCOTTO;ANGELO ANDRIULLI;RICCARDO IEVA;EMANUELA TURILLAZZI;MICHELE CORREALE;ANTONINO NICOLÒ;LEONARDO MOTTOLA;G. STOPPINO;VITTORIO FINESCHI;FRANCESCA FOTI;RAFFAELE COZZOLONGO;GIUSEPPINA TIMPANI;MATTEO DI BIASE;LORETO GESUALDO;ANNALISA FEDERICO;U. CEA;MARGHERITA NERI;MARIA ROSARIA D’AGNESSA","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","GIUSEPPE QUERQUES;EMANUELA TURILLAZZI;VITTORIO FINESCHI;RICCARDO IEVA;MICHELE CORREALE;MATTEO DI BIASE;ANTONINO NICOLÒ;FRANCESCA FOTI;GIUSEPPINA TIMPANI;ENZO IERARDI;GAETANO SCOTTO;ANNALISA FEDERICO;GIUSEPPE PELLICO;DARIO GALANTE;M. DAMBROSIO;N. DELLE NOCI;G. STOPPINO;MARGHERITA NERI;FRANCESCO PRASCINA;VINCENZO NERI","0.7;0.7;0.7;0.58;0.58;0.58;0.31;0.31;0.31;0.29;0.27;0.25;0.25;0.25;0.25;0.25;0.22;0.2;0.2;0.2","GAETANO SCOTTO;ANGELO ANDRIULLI;DONATO BACCA;LEONARDO MOTTOLA;RAFFAELE COZZOLONGO;VITO CARRETTA;ALESSANDRA MANGIA;F. VINELLI;FULVIO SPIRITO;GIOVANNI RICCI;GIUSEPPE CRISTOFARO;GIUSEPPE MONTALTO;MARIO ROMANO;NICOLA MINERVA;ENZO IERARDI;ANTONELLA BLASI;ANTONIA LOVERRE;CARLO MANNO;CARMEN CAPOBIANCO;DILETTA DOMENICA TORRES","266;257;257;257;257;257;253;253;253;253;253;253;253;253;183;135;135;135;135;135","F. VINELLI;ENZO IERARDI;ELENA RANIERI;GIUSEPPE CASTELLANO;GIUSEPPE STEFANO NETTI;LORETO GESUALDO;ALDO SALVI;ALESSANDRO RAMBALDI;ANNA GRASSI;BARBARA PERUTA;CATERINA MICÒ;ELENA OLDANI;EMANUELE ANGELUCCI;G. LAMBERTENGHI‐DELILIERS;GIUSEPPE ROSSI;M. TOSI;M. ZANOTTI;ORIETTA SPINELLI;P FABRIS;R BASSAN","253;180;135;135;135;135;130;130;130;130;130;130;130;130;130;130;130;130;130;130","ANTONINO NICOLÒ;ENZO IERARDI;FRANCESCA FOTI;GAETANO SCOTTO;GIUSEPPE QUERQUES;GIUSEPPINA TIMPANI;MICHELE CORREALE;VINCENZO DE FRANCESCO;VITTORIO FINESCHI;A. CONTILLO;ALDO SALVI;ALESSANDRO RAMBALDI;ANGELO ANDRIULLI;ANNA GRASSI;ANNA MARIA DI PALMA;ANTONELLA PACE;ARTURO ROMONDIA;BARBARA PERUTA;CARMINE PANELLA;CATERINA MICÒ","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;ART;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","30;9;4;3;1;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;PEDIATRICS;ANESTHESIA;GENERAL SURGERY;OPHTHALMOLOGY;GYNECOLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;OPTICS;ARTIFICIAL INTELLIGENCE;ASTROBIOLOGY;AUDIOLOGY;BIOCHEMISTRY;BIOMEDICAL ENGINEERING;CANCER RESEARCH;CARDIOLOGY;CLINICAL PSYCHOLOGY;CRIMINOLOGY;CRYSTALLOGRAPHY;DERMATOLOGY;DEVELOPMENTAL PSYCHOLOGY;ECOLOGY;EMERGENCY MEDICINE;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GEOMETRY;LAW;LINGUISTICS;MACROECONOMICS;MEDICAL EMERGENCY;MEDICAL PHYSICS;NEUROSCIENCE;NURSING;OBSTETRICS;ONCOLOGY;OPTOMETRY;PATHOLOGY;PHYSICAL THERAPY;PROGRAMMING LANGUAGE;PSYCHIATRY;RADIOLOGY;UROLOGY;VISUAL ARTS","19;9;6;6;6;5;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DISEASE;TRANSPLANTATION;ANTIBIOTICS;ANTIBODY;EXCHANGE TRANSFUSION;FUNDUS (UTERUS);GENE;HEMOCHROMATOSIS;KIDNEY;MACULAR DEGENERATION;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;RETINAL;ABDOMINAL DISTENSION;ABSCESS;AMYLOIDOSIS;ANALGESIC;ANEMIA;ANESTHESIOLOGY;BARIUM MEAL;BONE AGE;CANCER;CAPSULE ENDOSCOPY;CATHETER;CENTER (CATEGORY THEORY);CENTRAL NERVOUS SYSTEM DISEASE;CHEMOTHERAPY;CHOLECYSTECTOMY;CLEARANCE;CLONIDINE;COAGULOPATHY;CONFIDENCE INTERVAL;CORRELATION;CYTOKINE;DIALYSIS;DISSECTION (MEDICAL);DRAINAGE;ENDOSCOPY;ENZYME;EPILEPSY;ETIOLOGY;FEMALE CIRCUMCISION;FLUORESCENCE;FULMINANT;GALLBLADDER;HELICOBACTER PYLORI;HEMODIALYSIS;HEMOGLOBIN;HEMOLYSIS;HEMOLYTIC ANEMIA;HEPATITIS C;HORMONE;HYSTERECTOMY;IMMUNE SYSTEM;INFERIOR VENA CAVA;INFUNDIBULUM;INTERVENTIONAL CARDIOLOGY;KIDNEY DISEASE;LAPAROSCOPIC CHOLECYSTECTOMY;LAPAROSCOPY;LEAKAGE (ECONOMICS);LEUKEMIA;LIVER DISEASE;MAGNETIC RESONANCE IMAGING;MELANOMA;MIGRAINE;MULTIPLE MYELOMA;MYELOID;NECROSIS;NEPHRITIS;NEUROLOGY;NEUROSURGERY;NURSING RESEARCH;OPERA;OPTICAL COHERENCE TOMOGRAPHY;PERCUTANEOUS;POPULATION;PREDNISOLONE;PSORIASIS;PSYCHOLOGICAL STRESS;QUALITY OF LIFE (HEALTHCARE);REFRACTORY (PLANETARY SCIENCE);RENAL FUNCTION;RENAL REPLACEMENT THERAPY;RETINA;RHEUMATOLOGY;SEPSIS;SEVOFLURANE;SEX ORGAN;SIBLING;SIDEROSIS;SOFTWARE;SPLEEN;SPONDYLODISCITIS;STEM CELL;STRESS (LINGUISTICS);UTERUS;VIRUS;VISUALIZATION","8;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FETUS;LIVER TRANSPLANTATION;ABDOMINAL HYSTERECTOMY;ACUTE LEUKEMIA;ALLELE;ALZHEIMER'S DISEASE;ANTIBIOTIC THERAPY;APOLIPOPROTEIN E;AURA;AUTOANTIBODY;AUTOIMMUNE HEMOLYTIC ANEMIA;AZATHIOPRINE;BEVACIZUMAB;CATHEPSIN D;CD20;CHOROIDAL NEOVASCULARIZATION;CLARITHROMYCIN;CUMULATIVE INCIDENCE;CYSTIC DUCT;DEGENERATIVE DISEASE;DENDRITIC CELL;ENDOSCOPIC ULTRASONOGRAPHY;ENTEROSCOPY;ENZYME REPLACEMENT THERAPY;EPOETIN ALFA;EXON;FABRY DISEASE;FAMILIAL MEDITERRANEAN FEVER;FLUORESCEIN;FLUORESCEIN ANGIOGRAPHY;FOVEAL;GENOTYPE;GESTATION;GLUTEN FREE;GROWTH HORMONE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS C VIRUS;IMMUNOGLOBULIN LIGHT CHAIN;INTERLEUKIN;INTERNATIONAL CLASSIFICATION OF HEADACHE DISORDERS;LAMOTRIGINE;LEVOBUPIVACAINE;LUPUS NEPHRITIS;LYMPHOBLASTIC LEUKEMIA;METASTASIS;MINIMAL RESIDUAL DISEASE;MUTATION;MYOMA;NEURORADIOLOGY;PAIN MEDICINE;PROTEINURIA;RETINAL PIGMENT EPITHELIUM;RITUXIMAB;SEPTIC SHOCK;SPLENECTOMY;STARGARDT DISEASE;UTERINE INVERSION;VIREMIA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AA AMYLOIDOSIS;ACUTE LYMPHOCYTIC LEUKEMIA;AL AMYLOIDOSIS;FULMINANT HEPATIC FAILURE;GROWTH HORMONE DEFICIENCY;GROWTH HORMONE TREATMENT;HYDROPS FETALIS;MIGRAINE WITH AURA;PLASMACYTOID DENDRITIC CELL;RANIBIZUMAB;RIBAVIRIN","1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;ITALY;AGED;KIDNEY FAILURE, CHRONIC;LEUKEMIA-LYMPHOMA, ADULT T-CELL;LIVER;PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;TREATMENT OUTCOME;CHOROIDAL NEOVASCULARIZATION;MELANOMA;;ADOLESCENT;AMYLOIDOSIS;ANEMIA;ANTI-BACTERIAL AGENTS","26;21;20;14;12;11;10;7;7;7;7;7;7;6;5;4;4;4;4;4","ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;AGE-RELATED MACULAR DEGENERATION RESEARCH;AMOEBIASIS: PATHOGENESIS AND CLINICAL MANAGEMENT;DETECTION AND MANAGEMENT OF RETINAL DISEASES;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS;DISEASES RELATED TO BLOOD GROUP VARIANTS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEALTH CONSEQUENCES OF FEMALE GENITAL MUTILATION/CUTTING;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS C INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MECHANISMS OF ALZHEIMER'S DISEASE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC IMAGING;EXCHANGE TRANSFUSION;FUNDUS (UTERUS);TRANSFUSION THERAPY;TREATMENT;AA AMYLOIDOSIS;ABDOMINAL DISTENSION;ABDOMINAL HYSTERECTOMY;ACUTE LYMPHOCYTIC LEUKEMIA;AL AMYLOIDOSIS;ANTIBIOTIC THERAPY;ANTIMICROBIAL RESISTANCE;APOLIPOPROTEIN E;BARIUM MEAL;CANCER TREATMENT;CARDIOVASCULAR RISK ASSESSMENT;CELIAC DISEASE;CENTER (CATEGORY THEORY);CHRONIC KIDNEY DISEASE;CLEARANCE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADULT PATIENTS;CLONIDINE MCGKG;CONTROLLED TRIAL;EXCHANGE TRANSFUSION;GROWTH HORMONE;RANDOMIZED CONTROLLED;ABDOMINAL ABSCESSES;ACUTE LYMPHOBLASTIC;ADMINISTERED ONCE-WEEKLY;AGALSIDASE THERAPY;ALFA IU;ALLOGENEIC STEM;ALZHEIMERS DISEASE;ANTEGRADE DISSECTION;ANTIBIOTIC THERAPY;AUTOIMMUNE HEMOLYTIC;BASILAR-TYPE MIGRAINE;CAPSULE ENDOSCOPY;CARDIOLOGIC CENTER;CAUDAL BLOCK;CELIAC DISEASE;CELL TRANSPLANTATION;CELLS INFILTRATE;CHOROIDAL NEOVASCULARIZATION;CLARITHROMYCIN RESISTANCE;CLINICAL OUTCOME;COHERENCE TOMOGRAPHY;COLLABORATIVE STUDY;COMBINED EFFECT;COMBINED FACTOR","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OPERA CHORISTERS;GASTROESOPHAGEAL REFLUX;POPULATION SAMPLE;REFLUX DISEASE;PUBMED SCOPUS;TALLEY NJ;CROSSREF PUBMED;MO MO;MO WK;SINGING ACTIVITY;WK DAYP;WK WK;PREVIOUS YEARP;PROFESSIONAL OPERA;REFLUX SYMPTOMS;Χ TEST;CHORISTERS REPORTED;EYETOOLKIT SOFTWARE;PUBMED GOOGLE;ALCOHOL CONSUMPTION;CLARITHROMYCIN RESISTANCE;INDIVIDUAL CHARACTERISTICS;LIFESTYLE HABITS;MASS INDEX;MISSING DATA;TABLE TABLE;BODY MASS;CHEST PAIN;CHORISTERSGENERAL POPULATION;DINNER LATE","38;17;14;13;12;11;9;9;9;9;9;9;8;8;8;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5",5,0.17,3,3,0,0,0,0,5.25,0,1,3,0,0,1,0,2,0,0,1,0,0,0,61,61,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,13,4000,1.39,0,0,31,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Switzerland","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","1;1;1","BIOMEDICAL IMAGING;CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;PREVENTION","1;1;1;1;1","CARDIOVASCULAR","1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2008,38,11.2105263157895,2.81578947368421,0.355140186915888,0.552631578947368,0.342105263157895,0.131578947368421,0.184210526315789,1,18,14,1,4,0.47,0.37,0.03,0.11,29.79,0.542891527311261,0.263157894736842,0.894736842105263,NA,0.379426457386969,0.288,0.213903743315508,0.36,"GIUSEPPE QUERQUES;CRISTIANA IACULLI;ENZO IERARDI;PELLEGRINO MUSTO;SILVANA CAPALBO;DENI ALDO PROCACCINI;SARA GALIMBERTI;LORETO GESUALDO;NICOLA LAFORGIA;G. VERDEROSA;ANGELO ANDRIULLI;GIUSEPPE PELLICO;MARIA KTENA;MARIO BOCCADORO;MASSIMO CONESE;VINCENZO CALLEA;ANTONIO CASO;ROSELLA MILILLO;VINCENZO NIRCHIO;ROSA PRATO","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MARIO MASTROLONARDO;GIUSEPPE QUERQUES;CRISTIANA IACULLI;MASSIMO CONESE;NICOLA DELLE NOCI;SANTE DI GIOIA;STEFANO CASTELLANI;JOANNA REJMAN;DONATELLA PIRO;ERIC H. SOUIED;N. DELLE NOCI;DENI ALDO PROCACCINI;GIUSEPPE PELLICO;ANTONIO CASO;ROSELLA MILILLO;DARIO GALANTE;ROSA PRATO;G. SOUBRANE;ENZO IERARDI;VINCENZO NIRCHIO","1;0.91;0.74;0.67;0.42;0.33;0.33;0.33;0.33;0.33;0.32;0.32;0.3;0.3;0.3;0.3;0.29;0.29;0.28;0.25","GIUSEPPE QUERQUES;CRISTIANA IACULLI;ENZO IERARDI;SILVANA CAPALBO;DENI ALDO PROCACCINI;LORETO GESUALDO;G. VERDEROSA;GIUSEPPE PELLICO;MASSIMO CONESE;VINCENZO CALLEA;ANTONIO CASO;ROSELLA MILILLO;VINCENZO NIRCHIO;ROSA PRATO;DARIO GALANTE;ANNA MARIA DI TARANTO;RAFFAELE ANTONETTI;ROSARIO MAGALDI;N. DELLE NOCI;NICOLA DELLE NOCI","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MARIO MASTROLONARDO;GIUSEPPE QUERQUES;CRISTIANA IACULLI;MASSIMO CONESE;NICOLA DELLE NOCI;SANTE DI GIOIA;STEFANO CASTELLANI;DONATELLA PIRO;N. DELLE NOCI;DENI ALDO PROCACCINI;GIUSEPPE PELLICO;ANTONIO CASO;ROSELLA MILILLO;DARIO GALANTE;ROSA PRATO;ENZO IERARDI;VINCENZO NIRCHIO;ANNA MARIA DI TARANTO;RAFFAELE ANTONETTI;VITO PRIMAVERA","1;0.91;0.74;0.67;0.42;0.33;0.33;0.33;0.32;0.32;0.3;0.3;0.3;0.3;0.29;0.28;0.25;0.25;0.25;0.25","PELLEGRINO MUSTO;ANTONIO PALUMBO;MARIO BOCCADORO;MICHÈLE CAVO;VINCENZO CALLEA;ANNA MARINA LIBERATI;ANTONIETTA FALCONE;ANTONIO CAPALDI;DANIELE DERUDAS;FEDERICA CAVALLO;FRANCESCA GAY;GIOVANNINO CICCONE;GIULIA BENEVOLO;MARCO MONTANARO;PATRIZIA FALCO;RENATO ZAMBELLO;ROBERTO RIA;SARA BRINGHEN;SYLVAIN DORÉ;TOMMASO CARAVITA","368;362;362;362;362;360;360;360;360;360;360;360;360;360;360;360;360;360;360;360","VINCENZO CALLEA;GIUSEPPE QUERQUES;D. COLOGNO;ENZO IERARDI;M. CASTRIOTA;NICOLA MUSCATIELLO;PAOLO TONTI;F. VINELLI;GAETANO SCOTTO;CRISTIANA IACULLI;ROSA PRATO;ANTONIO STEFANO SALCUNI;F. DI TERLIZZI;G. VERDEROSA;M.C. NACCHIERO;MAURO CIGNARELLI;NICOLA DELLA VALLE;V. D'AGNESSA;NICOLA DELLE NOCI;ANNA V. BUX","362;140;82;82;82;82;79;69;69;56;55;45;45;45;45;45;45;45;43;42","GIUSEPPE QUERQUES;CRISTIANA IACULLI;SILVANA CAPALBO;ANTONIO CASO;DARIO GALANTE;DENI ALDO PROCACCINI;ENZO IERARDI;M. CASTRIOTA;MASSIMO CONESE;N. DELLE NOCI;NICOLA DELLE NOCI;NICOLA MUSCATIELLO;ROSA PRATO;VINCENZO CALLEA;VINCENZO NIRCHIO;A. DE CAPRARIS;A. SALCUNI;ANNA MARIA DI TARANTO;ANNA V. BUX;ANNAMARIA MICCOLI","5;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;ENGINEERING;MATERIALS SCIENCE","37;13;5;3;3;2;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PATHOLOGY;OPHTHALMOLOGY;PEDIATRICS;VIROLOGY;BIOCHEMISTRY;OPTICS;RADIOLOGY;CARDIOLOGY;DERMATOLOGY;ENDOCRINOLOGY;GEOMETRY;GYNECOLOGY;INTENSIVE CARE MEDICINE;NURSING;OBSTETRICS;PSYCHIATRY","25;10;8;8;7;6;6;6;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;GENE;POPULATION;CHEMOTHERAPY;OPTICAL COHERENCE TOMOGRAPHY;RANDOMIZED CONTROLLED TRIAL;ALLERGY;DIALYSIS;DISEASE;FUNDUS (UTERUS);HORMONE;INCIDENCE (GEOMETRY);VIRUS;VISUAL ACUITY;ANEMIA;ANTIBODY;ASYMPTOMATIC;BIOPSY;CYSTIC FIBROSIS;ENDOSCOPIC ULTRASOUND;HEMODYNAMICS;HEMOLYSIS;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION;PANCREAS;PREGNANCY;QUALITY OF LIFE (HEALTHCARE);RETINAL;ULTRASOUND","6;6;6;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENOTYPE;ALLERGEN;BORTEZOMIB;CERVICAL CANCER;ENDOCRINE SYSTEM;GENETIC ENHANCEMENT;GESTATION;LEVOBUPIVACAINE;PANCREATIC CANCER;ACTINIC KERATOSES;ADRENOCORTICOTROPIC HORMONE;ALLELE;ANAPHYLAXIS;ATOPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BEVACIZUMAB;BIRTH WEIGHT;CELL THERAPY;CHRONIC HEPATITIS;COELIAC DISEASE;COLORECTAL CANCER;COMPLEMENT SYSTEM;CONTACT DERMATITIS;CORONARY ANGIOGRAPHY;CULPRIT;DIABETIC RETINOPATHY;DNA DAMAGE;EMBRYONIC STEM CELL;ERYTHROPOIESIS;EX VIVO;FETUS;FINE-NEEDLE ASPIRATION;GASTRITIS;GLOBIN;GLUCAGON;HAEMATOPOIESIS;HEMOGLOBINURIA;HEPATITIS C VIRUS;INTESTINAL METAPLASIA;INVOLUTION (ESOTERISM);LATEX ALLERGY;LEFT CORONARY ARTERY;LENALIDOMIDE;MACULAR EDEMA;MEDIAN FOLLOW-UP;MELPHALAN;MONOCLONAL ANTIBODY;NEONATAL SEPSIS;NEUROPEPTIDE;NEURORADIOLOGY;NEUTROPENIA;NON-HODGKIN'S LYMPHOMA;PAIN MEDICINE;PANCREATIC NEUROENDOCRINE TUMOR;PATCH TEST;PEPTIC;POLYMERASE CHAIN REACTION;PREVALENCE;PRIMARY HEADACHE;PROGRESSION-FREE SURVIVAL;RECOMBINANT DNA;REMIFENTANIL;RESTLESS LEGS SYNDROME;RETINAL PIGMENT EPITHELIUM;RIFAMYCIN;RITUXIMAB;STARGARDT DISEASE;STEM-CELL THERAPY;T CELL;THALIDOMIDE;TRYPTASE;UMBILICAL VEIN;UNIVARIATE;UNIVARIATE ANALYSIS;VITRECTOMY","4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HPV INFECTION;PANCREATIC TUMOR;ADULT STEM CELL;ANAPHYLACTIC SHOCK;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;CD59;CHRONIC GASTRITIS;COLPOSCOPY;COMPLEMENT COMPONENT 5;COMPLEMENT MEMBRANE ATTACK COMPLEX;CONTACT ALLERGY;DIABETIC MACULAR EDEMA;ECULIZUMAB;GENE DELIVERY;HAPLOTYPE;HOUSE DUST MITE;HUMAN PAPILLOMA VIRUS;INEFFECTIVE ERYTHROPOIESIS;MACULAR HOLE;MICROSATELLITE;MULTIPLEX POLYMERASE CHAIN REACTION;OXALIPLATIN;PANCREATIC POLYPEPTIDE;PAPILLOMAVIRIDAE;RADIOIMMUNOTHERAPY;RANIBIZUMAB;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RIBAVIRIN;RIGHT CORONARY ARTERY;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL FOR GESTATIONAL AGE;SPIRILLACEAE;THYMIC INVOLUTION;VASOACTIVE INTESTINAL PEPTIDE;VECTOR (MOLECULAR BIOLOGY);VIRAL VECTOR;XERODERMA PIGMENTOSUM","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;;ADULT;AGED;PANCREATIC NEOPLASMS;ITALY;MACULAR DEGENERATION;PAPILLOMAVIRUS INFECTIONS;ADOLESCENT;AGED, 80 AND OVER;CORONARY VESSEL ANOMALIES;PROSPECTIVE STUDIES;STROKE;TACHYCARDIA, VENTRICULAR;TREATMENT OUTCOME;VISUAL ACUITY;ADENOMA, ISLET CELL","25;21;16;16;13;12;11;7;6;6;6;5;5;5;5;5;5;5;5;4","AGE-RELATED MACULAR DEGENERATION RESEARCH;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HEPATITIS C INFECTION AND TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ATOPIC DERMATITIS AND SKIN MICROBIOME;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DETECTION AND MANAGEMENT OF RETINAL DISEASES;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DISEASES RELATED TO BLOOD GROUP VARIANTS;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EPIDEMIOLOGY AND MANAGEMENT OF STROKE","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","FUNDUS (UTERUS);ENDOSCOPIC ULTRASOUND;GASTROENTEROPANCREATIC NEOPLASMS;HPV VACCINATION;INTERNATIONAL MYELOMA WORKING GROUP;LEVOBUPIVACAINE;MACULAR DEGENERATION;NEUROENDOCRINE TUMORS;OCULAR HYPERTENSION;OPTICAL COHERENCE TOMOGRAPHY;OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY;PANCREATIC NEUROENDOCRINE TUMORS;PANCREATIC TUMOR;PRETERM INFANTS;TREATMENT;ACTINIC KERATOSES;ADULT CONGENITAL HEART DISEASE;ALLERGIC CONTACT DERMATITIS;ALPHA PARTICLE THERAPY;ANAPHYLACTIC SHOCK","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","COHERENCE TOMOGRAPHY;OPTICAL COHERENCE;COELIAC DISEASE;CYSTIC FIBROSIS;ENDOCRINE TUMOR;ENDOSCOPIC ULTRASOUND;ETHANOL INJECTION;FUNCTION IMPAIRMENT;HEMODYNAMIC EFFECTS;ITALIAN MULTICENTER;MACULAR DYSTROPHY;MULTICENTER STUDY;MULTIPLE MYELOMA;PANCREATIC ENDOCRINE;PEDIATRIC CAUDAL;STEM CELL;TRANSESOPHAGEAL DOPPLER;VISUAL FUNCTION;VITELLIFORM MACULAR;ACTINIC KERATOSES;ACUTE THROMBOCYTOPENIA;ADDITIONAL MECHANISM;ADULT-ONSET FOVEOMACULAR;AGE NEWBORN;ALTERNATIVE TREATMENT;ANAPHYLACTIC LATEX;ANESTHESIA EVALUATED;ANOMALOUS ORIGIN;ANTI-CANCER VACCINE;ANTIBIOTIC THERAPY","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","DIALYSIS PATIENTS;DC SUBSETS;INTRAVITREAL PEGAPTANIB;PR BAND;DENDRITIC CELLS;INVERSELY RELATED;LEFT VENTRICULAR;PEGAPTANIB SODIUM;PERIPHERAL BLOOD;PLATELETS COUNTS;TREATMENT DURATION;WALL THICKNESS;ASPIRATION FNA;BIOPSY FIG;BMI KGM;COLOR DOPPLER;DOPPLER HYPERVASCULAR;EOT RESPONSE;FNA BIOPSY;HYPERVASCULAR PATTERN;HYPOECHOIC LESIONS;ISLET TUMOR;LESIONS FIG;LESS-DEFINED PR;LYMPH NODES;NEUROENDOCRINE ISLET;NODULAR HYPOECHOIC;PATHOLOGY REPORT;PATTERN LOCATED;PEGIFN ALFA","5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",5,0.13,7,3,0,0,0,0,2.75,0,2,3,0,1,1,0,0,1,0,1,0,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,9,1760.5,2.33,0,0,52,0,0,0,0,1,0,1,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;CANCER;CARDIOVASCULAR;DIABETES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;PATIENT SAFETY;PREVENTION;RARE DISEASES","2;2;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;METABOLIC AND ENDOCRINE","1;1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2009,36,9.25,2.16666666666667,0.461538461538462,0.472222222222222,0.333333333333333,0.222222222222222,0.388888888888889,2,17,8,4,5,0.47,0.22,0.11,0.14,26.22,0.566878445407924,0.138888888888889,0.888888888888889,NA,0.381308520537465,0.198412698412698,0.228571428571429,0.238636363636364,"GIUSEPPE QUERQUES;DOMENICO MARTINELLI;VITTORIO FINESCHI;ANNA V. BUX;NICOLA DELLE NOCI;CRISTIANA IACULLI;SARA GALIMBERTI;BRUNELLO LECCE;GIOACCHINO ANGARANO;MARIO DE ROSAS;VINCENZO CALLEA;CRISTOFORO POMARA;CLAUDIO BABILONI;EMANUELA TURILLAZZI;FABRIZIO EUSEBI;ANNA VALENZANO;CLAUDIO DEL PERCIO;GIUSEPPE CIBELLI;CIRO MUNDI;NICOLA MARZANO","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ELENA RANIERI;DARIO GALANTE;GIUSEPPE QUERQUES;DOMENICO MARTINELLI;VITTORIO FINESCHI;ANNA V. BUX;CRISTIANA IACULLI;NICOLA DELLE NOCI;CRISTOFORO POMARA;EMANUELA TURILLAZZI;R MAGALDI;G MAFFEI;VINCENZO MANUPPELLI;F. URBANO;CARMELA FIORE;SABINA DI DONATO;F. PERFETTO;MARTA MASCHIO;B. JANDOLO;LOREDANA DINAPOLI","1;1;0.77;0.68;0.67;0.57;0.57;0.53;0.42;0.42;0.33;0.33;0.33;0.25;0.25;0.25;0.25;0.25;0.25;0.25","GIUSEPPE QUERQUES;DOMENICO MARTINELLI;VITTORIO FINESCHI;ANNA V. BUX;NICOLA DELLE NOCI;CRISTIANA IACULLI;BRUNELLO LECCE;GIOACCHINO ANGARANO;VINCENZO CALLEA;EMANUELA TURILLAZZI;CIRO MUNDI;ΑΝΤΏΝΙΟ ΒΑΡΌΝΕ;LORETO GESUALDO;MARIA GRAZIA FRANZESE;STEFANO ZOCCOLELLA;GIUSEPPINA SPINOSA;FRANCESCA SANGUEDOLCE;ENZO IERARDI;R MAGALDI;FILOMENA SPORTELLI","4;4;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","ELENA RANIERI;DARIO GALANTE;GIUSEPPE QUERQUES;DOMENICO MARTINELLI;VITTORIO FINESCHI;ANNA V. BUX;CRISTIANA IACULLI;NICOLA DELLE NOCI;EMANUELA TURILLAZZI;R MAGALDI;CARMELA FIORE;SABINA DI DONATO;F. PERFETTO;R. SILECCHIA;F. SAVERIANO;G. SCALZO;FRANCESCA SANGUEDOLCE;VINCENZO NERI;VITO CASAMASSIMA;TOMMASO LANGIALONGA","1;1;0.77;0.68;0.67;0.57;0.57;0.53;0.42;0.33;0.25;0.25;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2","GIOACCHINO ANGARANO;NICOLA DELLE NOCI;SARA GALIMBERTI;DOMENICO MARTINELLI;ANDREA DE LUCA;ANDRZÉJ HORBAN;ANGELOS HATZAKIS;ANNEMARIE M. J. WENSING;ANNE‐MIEKE VANDAMME;BIRGITTA ÅSJÖ;CARMEN DE MENDOZA;CHARLES A. BOUCHER;CLAUDIA BALOTTA;CLAUDIA KÜCHERER;CLAUS NIELSEN;CLIVE LOVEDAY;DANIEL STRUCK;DAVID VAN DE VIJVER;DIMITRIOS PARASKEVIS;DOMINIQUE COSTAGLIOLA","174;165;160;134;121;121;121;121;121;121;121;121;121;121;121;121;121;121;121;121","GIOACCHINO ANGARANO;NICOLA DELLE NOCI;VINCENZO CALLEA;ANDRÉA STELLA;EMANUELE CONTE;FRANCESCO PRASCINA;VINCENZO RUSSO;ΑΝΤΏΝΙΟ ΒΑΡΌΝΕ;GIUSEPPE QUERQUES;ENZO IERARDI;ANNA V. BUX;CRISTIANA IACULLI;STEFANO ZOCCOLELLA;GAETANO SCOTTO;ROCCO DI TULLIO;VINCENZINA FAZIO;BRUNELLO LECCE;CIRO MUNDI;G. SCALZO;DOMENICO MARTINELLI","174;165;120;106;106;106;106;106;84;79;69;69;66;53;53;53;51;51;51;39","GIUSEPPE QUERQUES;ANNA V. BUX;CRISTIANA IACULLI;NICOLA DELLE NOCI;BRUNELLO LECCE;CIRO MUNDI;DOMENICO MARTINELLI;GIOACCHINO ANGARANO;STEFANO ZOCCOLELLA;VINCENZO CALLEA;ANDRÉA STELLA;BRUNO MARTINO;CARMELA FIORE;CARMINE ZOCCALI;CATERINA STELITANO;CLELIA SCARANO;CRISTIANO CAPURSO;DARIO GALANTE;EMANUELA TURILLAZZI;EMANUELE CONTE","4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;CHEMISTRY;COMPUTER SCIENCE;GEOGRAPHY;PHILOSOPHY;SOCIOLOGY","32;16;4;3;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;GASTROENTEROLOGY;OPHTHALMOLOGY;PATHOLOGY;RADIOLOGY;IMMUNOLOGY;PEDIATRICS;VIROLOGY;ANATOMY;ANESTHESIA;ENDOCRINOLOGY;NEUROSCIENCE;ONCOLOGY;AUDIOLOGY;CARDIOLOGY;CLINICAL PSYCHOLOGY;COGNITIVE PSYCHOLOGY;CRIMINOLOGY;ENVIRONMENTAL HEALTH;GEOMETRY;LAW;MICROBIOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY;QUANTUM MECHANICS","19;10;9;6;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","GENE;CHEMOTHERAPY;AUTOPSY;DIABETES MELLITUS;DISEASE;RETINAL;VISUAL ACUITY;ANTIBIOTICS;CANCER;COGNITION;EATING DISORDERS;ELECTROENCEPHALOGRAPHY;LEUKEMIA;OPTICAL COHERENCE TOMOGRAPHY;PERCUTANEOUS;POPULATION;PREGNANCY;RETROSPECTIVE COHORT STUDY;SCALP;STIMULUS (PSYCHOLOGY);TOXICITY;VIRUS","8;6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BEVACIZUMAB;GENOTYPE;MACULAR EDEMA;ALLELE;ANTIBIOTIC RESISTANCE;DIABETIC RETINOPATHY;EVENT-RELATED POTENTIAL;FETUS;POLYMERASE CHAIN REACTION;AMIKACIN;AMNIOTIC FLUID EMBOLISM;ANCHOVY;ANISAKIS;ANISAKIS SIMPLEX;ATTACK RATE;BENIGNITY;BIOLOGICAL DISPERSAL;BLEOMYCIN;BORTEZOMIB;BREAST CANCER;CARBAMAZEPINE;CARDIOGENIC SHOCK;CHICKENPOX;CHOROIDAL NEOVASCULARIZATION;CHRONIC LYMPHOCYTIC LEUKEMIA;CIPROFLOXACIN;CLOBAZAM;CYCLOPHOSPHAMIDE;DACARBAZINE;DEMENTIA;EPIGASTRIC PAIN;ESCHERICHIA COLI;ESOPHAGOGASTRODUODENOSCOPY;FABRY DISEASE;FOLLICULAR LYMPHOMA;FORENSIC PATHOLOGY;GASTRITIS;GENOME;GESTATIONAL AGE;GLOBIN;HEMOGLOBINOPATHY;HEPATITIS B VIRUS;HEREDITARY HEMOCHROMATOSIS;HYPERHOMOCYSTEINEMIA;IMATINIB;IMMUNIZATION;INJURY PREVENTION;LOCUS (GENETICS);MITOCHONDRIAL DNA;MONOCLONAL ANTIBODY;MULTISLICE COMPUTED TOMOGRAPHY;MUTATION;NEUROCOGNITIVE;NON-HODGKIN'S LYMPHOMA;NUCLEIC ACID SEQUENCE;OBSTETRICS AND GYNAECOLOGY;OXYGENATION INDEX;PARKINSON'S DISEASE;PERCUTANEOUS CORONARY INTERVENTION;PERFORMANCE STATUS;PERSISTENT PULMONARY HYPERTENSION;PHYLOGENETICS;PLASMODIUM (LIFE CYCLE);PLASMODIUM FALCIPARUM;PREROGATIVE;PROGRESSIVE DISEASE;PROSTATE;PSEUDOMONAS AERUGINOSA;RADIOFREQUENCY ABLATION;RETINAL VEIN;RETINOPATHY;RITUXIMAB;RNA;THYROID NODULES;TOPIRAMATE;VINBLASTINE;VIRAL LOAD","4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RANIBIZUMAB;DIABETIC MACULAR EDEMA;HAPLOTYPE;HETEROZYGOTE ADVANTAGE;IMIPENEM;ODDBALL PARADIGM;AMNIOTIC FLUID;ANTIRETROVIRAL THERAPY;BRANCH RETINAL VEIN OCCLUSION;BREAST DISEASE;CLADE;COMPOUND HETEROZYGOSITY;CONGENITAL CYSTIC ADENOMATOID MALFORMATION;ENGRAULIS;EXTERNAL OPHTHALMOPLEGIA;GAMETOCYTE;HELICASE;HOMICIDE;IMATINIB MESYLATE;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;LEVODOPA;LOSS OF HETEROZYGOSITY;MAMMOGRAPHY;MITOCHONDRIAL DISEASE;MITOCHONDRIAL MYOPATHY;NASBA;NESTED POLYMERASE CHAIN REACTION;OXCARBAZEPINE;PERCUTANEOUS ETHANOL INJECTION;PHYLOGEOGRAPHY;PIPERACILLIN;PLASMODIUM VIVAX;PRIMARY ANGIOPLASTY;RADIOIMMUNOTHERAPY;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;REVERSE TRANSCRIPTASE;SINGLE-NUCLEOTIDE POLYMORPHISM;TANDEM REPEAT;TRANSURETHRAL RESECTION OF THE PROSTATE;VARIABLE NUMBER TANDEM REPEAT;VARICELLA VACCINE;VINCRISTINE;ZONISAMIDE","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;MACULAR EDEMA;ADULT;AGED;ITALY;DIABETIC RETINOPATHY;ADOLESCENT;KIDNEY DISEASES;OBESITY;VASCULAR ENDOTHELIAL GROWTH FACTOR A;YOUNG ADULT;;ANISAKIS;ANTIBODIES, MONOCLONAL;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BETA-THALASSEMIA;MACULA LUTEA","31;23;21;15;13;12;11;10;7;6;6;6;6;6;5;5;5;5;5;5","AGE-RELATED MACULAR DEGENERATION RESEARCH;LYMPHOID NEOPLASMS;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EATING DISORDERS AND BODY IMAGE CONCERNS;ECOLOGICAL INTERACTIONS OF PARASITES IN ECOSYSTEMS;EFFICACY AND RESISTANCE IN CML TREATMENT;FACTORS AND RISKS IN RESTRAINT-RELATED DEATHS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEPATITIS B INFECTION AND TREATMENT;HERPESVIRUSES: EPIDEMIOLOGY, PATHOGENESIS, AND MANAGEMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMMUNOGENICITY OF BIOSIMILAR THERAPEUTICS IN DRUG DEVELOPMENT;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE","5;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTRAVITREAL INJECTION;MACULAR DEGENERATION;AUTOPSY VALIDATION;DIABETIC MACULAR EDEMA;DIABETIC RETINOPATHY;HETEROZYGOTE ADVANTAGE;ODDBALL PARADIGM;PEGAPTANIB;POST-MORTEM IMAGING;STIMULUS (PSYCHOLOGY);ABVD;ACUTE PANCREATITIS;ADEFOVIR;AMIKACIN;AMNIOTIC FLUID EMBOLISM;ANISAKIS;ANISAKIS SIMPLEX;ANTIVIRAL THERAPY;ATTACK RATE;ATTENTIONAL NETWORKS","5;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","DIABETIC MACULAR;MACULAR EDEMA;PEGAPTANIB SODIUM;ELECTROENCEPHALOGRAPHIC STUDY;MACULAR LASER;Δ-GLOBIN GENE;ACID SEQUENCE;ACUTE BILIARY;ACUTE INTRAHEPATIC;ACUTE MYOCARDIAL;ADEFOVIR DIPIVOXIL;ADENOMATOID MALFORMATION;ADJUNCTIVE DIAGNOSTIC;ADVANCED HODGKIN;AFRICAN MIGRANTS;ALZHEIMERS DISEASE;AMNIOTIC FLUID;ANDERSON-FABRY DISEASE;ANTIMICROBIAL SUSCEPTIBILITY;ASYMPTOMATIC AFRICAN;ATTENTIONAL CORTICAL;ATTENTIONAL RESPONSES;AUTOPSIA DIGITALE;AUTOPSIA VIRTUOSA;AUTOSOMAL DOMINANT;BASED AMPLIFICATION;BENIGN THYROID;BEVACIZUMAB COMPARED;BILIARY PANCREATITIS;BODY FAT","3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTRAVITREAL PEGAPTANIB;LASER PHOTOCOAGULATION;MACULAR LASER;PEGAPTANIB SODIUM;ADV RESISTANCE;ADV MONOTHERAPY;MOLECULAR RESPONSE;ANTIBODY ACTIVITY;CHRONIC LYMPHOCYTIC;FOLLOW-UP VISIT;INVASIVE THYMOMA;MM PATIENTS;PR BAND;PROGNOSTIC INDEX;RETROSPECTIVE ANALYSIS;RISK FACTORS;STABLE MMOLR;STATISTICALLY SIGNIFICANT;VIROLOGICAL BREAKTHROUGH;VISUAL ACUITY;ACUITY BCVA;BEST-CORRECTED VISUAL;BINET STAGE;CCGR PATIENTS;CENTRAL MACULAR;CHRONIC MYELOID;CLINICAL MANIFESTATIONS;CNV TREATED;COMBINED TREATMENT;COMPLETE RESPONSE","11;6;6;6;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2",6,0.17,5.25,1.75,1,1,0,0,2,0,1,1.75,0,0,0,2,0,0,0,0,0,0,0,101,101,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,5,129,1.64,1,1,37,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;HEMATOLOGY;PEDIATRIC;PREVENTION;RARE DISEASES","1;1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2010,28,7.21428571428571,1.75,0.571428571428571,0.5,0.25,0.5,0.357142857142857,2,10,5,1,9,0.36,0.18,0.04,0.32,27.14,0.600630683656404,0.178571428571429,0.785714285714286,NA,0.439125178202486,0.212962962962963,0.158730158730159,0.201298701298701,"GAETANO SCOTTO;STEFANO ZOCCOLELLA;MARGHERITA NERI;CRISTOFORO POMARA;MARGHERITA GIGANTE;EMANUELA TURILLAZZI;ALBERTO FERSINI;VINCENZO NERI;GIANCARLO LOGROSCINO;ELENA RANIERI;CARMINE ZOCCALI;VITTORIO FINESCHI;IRENE RIEZZO;NICOLA TARTAGLIA;ANTONIO AMBROSI;DOMENICO MARTINELLI;GIUSEPPE CARRIERI;GIANCARLO MESSALLI;DOMENICO CIAVARELLA;MASSIMILIANO CHETTA","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","GAETANO SCOTTO;MARGHERITA GIGANTE;ELENA RANIERI;DARIO GALANTE;CARMINE ZOCCALI;GIOVANNA PARLONGO;ALBERTO FERSINI;VINCENZO NERI;NICOLA TARTAGLIA;ANTONIO AMBROSI;DOMENICO MARTINELLI;STEFANO ZOCCOLELLA;GIANCARLO LOGROSCINO;MARGHERITA NERI;CRISTOFORO POMARA;EMANUELA TURILLAZZI;VITTORIO FINESCHI;IRENE RIEZZO;GIUSEPPE CARRIERI;GIUSEPPE BOVE","1.31;1;1;1;0.62;0.5;0.45;0.45;0.45;0.45;0.42;0.34;0.34;0.26;0.26;0.26;0.26;0.26;0.25;0.25","GAETANO SCOTTO;STEFANO ZOCCOLELLA;MARGHERITA NERI;CRISTOFORO POMARA;MARGHERITA GIGANTE;EMANUELA TURILLAZZI;VINCENZO NERI;CARMINE ZOCCALI;VITTORIO FINESCHI;IRENE RIEZZO;DOMENICO MARTINELLI;GIUSEPPE CARRIERI;GIUSEPPINA SPINOSA;ROSA ROSANIA;VINCENZO DE FRANCESCO;NICOLA DELLA VALLE;GIUSEPPE BOVE;CARMELA FIORE;GIOVANNA PARLONGO;STEFANIA C. BELLO","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","GAETANO SCOTTO;MARGHERITA GIGANTE;DARIO GALANTE;CARMINE ZOCCALI;GIOVANNA PARLONGO;VINCENZO NERI;DOMENICO MARTINELLI;STEFANO ZOCCOLELLA;MARGHERITA NERI;CRISTOFORO POMARA;EMANUELA TURILLAZZI;VITTORIO FINESCHI;IRENE RIEZZO;GIUSEPPE CARRIERI;GIUSEPPE BOVE;BENVENUTO GRISORIO;VINCENZINA FAZIO;RITA MARCHESE;PANTALEO BUFO;SERGIO FERRARA","1.31;1;1;0.62;0.5;0.45;0.42;0.34;0.26;0.26;0.26;0.26;0.26;0.25;0.25;0.25;0.25;0.25;0.25;0.25","CARMINE ZOCCALI;EUGENIO PICAÑO;FILIPPO BENEDETTO;FRANCESCA MALLAMACI;GIOVANNI TRIPEPI;PIETRO CASTELLINO;ROCCO TRIPEPI;STEFANIA RASTELLI;ALDO DENI PROCACCINI;ANTONELLO PANI;BRUNO VOGT;CLAUDIO POZZI;FRANCESCO LOCATELLI;GIAMBATTISTA FOGAZZI;LANDINO ALLEGRI;LINO CIRAMI;LUCIA DEL VECCHIO;PATRIZIA SCAINI;SIMEONE ANDRULLI;V. DE CRISTOFARO","276;274;274;274;274;274;274;274;130;130;130;130;130;130;130;130;130;130;130;130","CARMINE ZOCCALI;FRANCESCA MALLAMACI;ALDO DENI PROCACCINI;STEFANO ZOCCOLELLA;ANDREA IGOREN GUARICCI;MARINA CELA;GIUSEPPINA SPINOSA;SILVANA CAPALBO;CLELIA SCARANO;DOMENICO MARTINELLI;ROSA PRATO;GIUSEPPINA PUSTORINO;VINCENZINA FAZIO;M. DAMBROSIO;C. PANELLA;FLORIANA GIORGIO;GIUSEPPE BOVE;GIUSEPPE CARRIERI;MARIANGELA ZOTTI;NICOLA DELLA VALLE","274;274;130;96;43;26;25;25;20;20;20;19;18;13;12;12;12;12;12;12","STEFANO ZOCCOLELLA;MARGHERITA GIGANTE;VINCENZO NERI;ALDO DENI PROCACCINI;ANDREA IGOREN GUARICCI;ANNA MARIA DI PALMA;C. PANELLA;CARMELA FIORE;CARMINE ZOCCALI;CLELIA SCARANO;CRISTOFORO POMARA;DOMENICO MARTINELLI;EMANUELA TURILLAZZI;FLORIANA GIORGIO;FRANCESCA MALLAMACI;GAETANO SCOTTO;GIOVANNA PARLONGO;GIUSEPPE BOVE;GIUSEPPE CARRIERI;GIUSEPPINA PUSTORINO","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;PHYSICS;BUSINESS;COMPUTER SCIENCE;GEOGRAPHY;SOCIOLOGY","25;11;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;SURGERY;GASTROENTEROLOGY;RADIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;LAW;PATHOLOGY;PSYCHIATRY;ANESTHESIA;BIOCHEMISTRY;CANCER RESEARCH;CARDIOLOGY;INTENSIVE CARE MEDICINE;NURSING;UROLOGY;VIROLOGY;ACCOUNTING;ACOUSTICS;ANATOMY;ARCHAEOLOGY;BOTANY;CELL BIOLOGY;DEMOGRAPHY;DENTISTRY;DEVELOPMENT ECONOMICS;ECONOMIC GROWTH;FAMILY MEDICINE;FORENSIC ENGINEERING;GENERAL SURGERY;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;MULTIMEDIA;ONCOLOGY;OPTICS;ORTHODONTICS;PALEONTOLOGY;PEDIATRICS","17;9;7;7;6;5;4;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;DISEASE;KIDNEY;POPULATION;ACUTE PANCREATITIS;AUTOPSY;CHEMOTHERAPY;CHOLECYSTECTOMY;CHOLESTASIS;DIABETES MELLITUS;DIALYSIS;EPIDEMIOLOGY;IMMUNE SYSTEM;INTUBATION;KIDNEY DISEASE;NEUROLOGY;PANCREATITIS;POLITICS;RENAL FUNCTION;VIRUS","7;6;4;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENOTYPE;PHENOTYPE;PROTEINURIA;ADJUVANT RADIOTHERAPY;ALPHA INTERFERON;AMYOTROPHIC LATERAL SCLEROSIS;AZATHIOPRINE;BREAST CANCER;CHROMOSOMAL TRANSLOCATION;CHROMOSOME;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;CORONARY ARTERIES;CORONARY ATHEROSCLEROSIS;CYCLOPHOSPHAMIDE;DUPLEX (BUILDING);EUROPEAN POPULATION;HEALTH PROFESSIONALS;HEMOGLOBINOPATHY;HEPATITIS B VIRUS;HEPATITIS C VIRUS;HEPATOCYTE;HYPERURICEMIA;IMMUNE TOLERANCE;IMMUNIZATION;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INNATE IMMUNE SYSTEM;INTRACEREBRAL HEMORRHAGE;LIFE EXPECTANCY;LIVER REGENERATION;LOCUS (GENETICS);MEPIVACAINE;METABOLIC SYNDROME;MILK FAT;MUTATION;NEPHRECTOMY;NEPHROPATHY;NEURORADIOLOGY;OSSEOINTEGRATION;POPULATION BASED STUDY;PROMOTION (CHESS);RECOMBINANT DNA;REFLUX;RENAL BIOPSY;RITUXIMAB;T CELL;TELOMERASE;TRACHEAL INTUBATION;UNIVARIATE ANALYSIS;X CHROMOSOME","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABDOMINAL OBESITY;ADJUVANT CHEMOTHERAPY;BREAKPOINT;CANCER IMMUNOTHERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);FLUDARABINE;GENOTYPING;GLOBULES OF FAT;HBSAG;IL-2 RECEPTOR;KARYOTYPE;LARYNGOSCOPES;LIMB-GIRDLE MUSCULAR DYSTROPHY;RIBAVIRIN;TOLL-LIKE RECEPTOR;VECTOR (MOLECULAR BIOLOGY);VESICOURETERAL REFLUX;VIDEO LARYNGOSCOPE;VINCRISTINE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;ADULT;KIDNEY FAILURE, CHRONIC;PANCREATITIS;;AGED, 80 AND OVER;ITALY;MALARIA;FOLLOW-UP STUDIES;KIDNEY DISEASES;YOUNG ADULT;CHOLELITHIASIS;DELTA-THALASSEMIA;HEPACIVIRUS;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;OBESITY","21;18;17;12;12;11;8;8;7;6;6;6;5;5;5;4;4;4;4;4","PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CALCINEURIN-NFAT SIGNALING IN TRANSCRIPTIONAL REGULATION;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DEVELOPMENT OF PROTEIN PHOSPHATASE INHIBITORS AS ANTICANCER AGENTS;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DISASTER RESPONSE AND PUBLIC HEALTH PREPAREDNESS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;INNATE IMMUNE RECOGNITION AND SIGNALING PATHWAYS;MALARIA;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE PANCREATITIS;PANCREATICOBILIARY MALJUNCTION;ABDOMINAL OBESITY;ADAPTIVE IMMUNITY REGULATION;ADJUVANT CHEMOTHERAPY;ADJUVANT RADIOTHERAPY;ANOSMIA;APOPTOSIS;APOPTOSIS INDUCTION;BILIRUBIN MEASUREMENT;BREAKPOINT;CANCER EPIGENETICS;CANCER IMMUNOTHERAPY;CARDIAC IMAGING;CARDIAC MYXOMAS;CARDIAC ULTRASOUND;CARDIOVASCULAR MRI;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL ENDPOINT;CORONARY ARTERIES","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE BILIARY;BILIARY PANCREATITIS;SOUTHERN ITALY;ACUTE POSTOPERATIVE;ADJUVANT RADIOTHERAPY;AMPUTATION DUE;AMYOTROPHIC LATERAL;ANESTHETIC MANAGEMENT;ARRAY CGH;ARTERY DISEASE;ASUBSUBVARIANTS OBSERVATION;AUGMENTED SITES;AUTOSOMAL-DOMINANT LIMB-GIRDLE;BENEFIT PATIENTS;CALCIFIED CORONARY;CARCINOMA MOLECULAR;CAROTID ATHEROSCLEROSIS;CELL APOPTOSIS;CHEST ULTRASOUND;CHRONIC KIDNEY;CHRONIC LIVER;CHRONIC LYMPHOCYTIC;CLINICAL FEATURES;CLINICALLY DEMONSTRATED;COLLAPSED BUILDING;COMMUNICATION SKILLS;COMPUTED TOMOGRAPHY;CONSEQUENCES CHARACTERIZATION;CORONARY ARTERY;CORONARY PLAQUE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OBSTRUCTIVE CAD;PULMONARY CONGESTION;CHRONIC HEPATITIS;INCIDENCE RATES;LUNG WATER;EJECTION FRACTION;LEFT VENTRICULAR;SINUS AUGMENTATION;VENTRICULAR EJECTION;ADDITIONAL BENEFIT;ADVERSE EVENTS;ASSOCIATION FUNCTIONAL;ATRIAL VOLUME;CHROMOSOME ARMS;CORONARY PLAQUE;DIALYSIS PATIENTS;DYSPLASTIC HEPATOCYTES;END-STAGE RENAL;FUNCTIONAL CLASS;HEART ASSOCIATION;HEART FAILURE;INTRAORAL WELDING;LEFT ATRIAL;MODERATESEVERE CHRONIC;MUSCLE WEAKNESS;PATIENTS CHEST;PRIMARY ENDPOINT;PROVIDE ADDITIONAL;PULMONARY PRESSURE;RENAL DISEASE","5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",6,0.21,4.12,4.5,0,1,0,0,0,0,1,4.5,0,1,2.5,0,4,0,1,4,0,0,0,70.75,70.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,4,172,2.5,1,1,61,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CONGENITAL STRUCTURAL ANOMALIES;KIDNEY DISEASE;PEDIATRIC;POLYCYSTIC KIDNEY DISEASE","1;1;1;1;1;1","RENAL AND UROGENITAL","1","6.1 PHARMACEUTICALS","1","KIDNEY CANCER","1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2011,43,9.55813953488372,2.3953488372093,0.41747572815534,0.395348837209302,0.325581395348837,0.116279069767442,0.186046511627907,1,12,16,7,5,0.28,0.37,0.16,0.12,17.91,0.421000985706251,0.13953488372093,0.86046511627907,NA,0.382045743678073,0.288770053475936,0.242857142857143,0.228571428571429,"FEDELE LEMBO;CLAUDIO BABILONI;ANTONIO IVANO TRIGGIANI;AURELIO PORTINCASA;DOMENICO PARISI;CIRO MUNDI;NICOLA MARZANO;CRISTINA LIMATOLA;NICOLA LAFORGIA;BRUNELLO LECCE;MAURO STRONATI;ANDREA SORICELLI;MATTEO RINALDI;ILARIA STOLFI;ANTONELLO BELLOMO;MAURIZIO MARGAGLIONE;ANNA VALENZANO;CLAUDIO DEL PERCIO;PAOLO MANZONI;SILVIA CATTANI","5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI;GAETANO SCOTTO;NICOLETTA URBANO;MARCO COLUCCI;SERGIO MODONI;N. RINALDI;P. MATRELLA;DARIO GALANTE;MASSIMO LAMBO;S. MEOLA;FLAVIA FABIANI;MARIELLA BANA;PIERFRANCESCO DE DOMENICO;PEDRO LUCAS AURÉLIO;ANGELO GARGANTINI;NICOLA MARZANO;MAURIZIO MARGAGLIONE;CLAUDIO BABILONI","1.42;1.08;1.08;1;0.5;0.5;0.5;0.4;0.4;0.4;0.4;0.4;0.33;0.33;0.33;0.33;0.33;0.32;0.31;0.27","FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI;CIRO MUNDI;BRUNELLO LECCE;MAURO STRONATI;MATTEO RINALDI;MAURIZIO MARGAGLIONE;ENZO IERARDI;N. RINALDI;GABRIELLA MARSALA;MARCO COLUCCI;P. MATRELLA;DARIO GALANTE;RAFFAELE ANTONETTI;MASSIMO LAMBO;VINCENZO DE FRANCESCO;ROSARIO MAGALDI;D. COLOGNO;S. ROMITO","5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI;GAETANO SCOTTO;NICOLETTA URBANO;MARCO COLUCCI;SERGIO MODONI;N. RINALDI;P. MATRELLA;DARIO GALANTE;MASSIMO LAMBO;S. MEOLA;FLAVIA FABIANI;MARIELLA BANA;PIERFRANCESCO DE DOMENICO;PEDRO LUCAS AURÉLIO;MAURIZIO MARGAGLIONE;CIRO MUNDI;GRAZIELLA CARIDI;SIMONETTA SPADA","1.42;1.08;1.08;1;0.5;0.5;0.5;0.4;0.4;0.4;0.4;0.4;0.33;0.33;0.33;0.33;0.31;0.27;0.25;0.25","ANGELA LA MANNA;ANITA AMMENTI;ANTONELLA TOFFOLO;FELICE SICA;GIOVANNI MONTINI;GIUSEPPINA MARRA;LORENA PISANELLO;LUIGI CATALDI;MARCO MATERASSI;MARCO PENNESI;PAOLO PECILE;ROBERTO CHIMENZ;VASSILIOS FANOS;ROSARIO MAGALDI;HUBERT MESSNER;ILARIA STOLFI;MATTEO RINALDI;MAURO STRONATI;NICOLA LAFORGIA;PAOLO MANZONI","165;165;165;165;165;165;165;165;165;165;165;165;165;156;154;154;154;154;154;154","FELICE SICA;ROSARIO MAGALDI;MATTEO RINALDI;MAURO STRONATI;CIRO MUNDI;MAURIZIO MARGAGLIONE;MARIA IOLE NATALICCHIO;BRUNELLO LECCE;GIANPAOLO GRILLI;VINCENZO DE FRANCESCO;D. COLOGNO;GABRIELLA MARSALA;ANDREA IGOREN GUARICCI;VALERIA BAFUNNO;MICHELE SCHIAVONE;ROSSANA SANTACROCE;RAFFAELE ANTONETTI;S. ROMITO;CATERINA STELITANO;FLAVIA FABIANI","165;156;154;151;89;61;52;47;47;38;34;34;33;33;31;28;17;15;14;12","FEDELE LEMBO;CIRO MUNDI;MATTEO RINALDI;BRUNELLO LECCE;D. COLOGNO;DARIO GALANTE;GABRIELLA MARSALA;GIANPAOLO GRILLI;MASSIMO LAMBO;MAURIZIO MARGAGLIONE;N. RINALDI;P. MATRELLA;ROSARIO MAGALDI;S. MEOLA;VINCENZO DE FRANCESCO;ANDREA IGOREN GUARICCI;ANNA NUNZIA POLITO;CARLO CATALANO;CATERINA STELITANO;CELESTINO FERRANDINA","5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PSYCHOLOGY;PHYSICS;ENGINEERING;GEOLOGY;POLITICAL SCIENCE;BUSINESS;ECONOMICS;GEOGRAPHY;MATERIALS SCIENCE;SOCIOLOGY","39;12;6;6;4;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;PEDIATRICS;RADIOLOGY;NEUROSCIENCE;PSYCHIATRY;AUDIOLOGY;MICROBIOLOGY;ONCOLOGY;ANESTHESIA;CARDIOLOGY;DEVELOPMENTAL PSYCHOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;OPTICS;PALEONTOLOGY;VIROLOGY;AEROSPACE ENGINEERING;ANATOMY;ANTHROPOLOGY;ARCHAEOLOGY;ASTROBIOLOGY;BIOCHEMISTRY;BIOINFORMATICS;CANCER RESEARCH;CLINICAL PSYCHOLOGY;COGNITIVE PSYCHOLOGY;COMPUTATIONAL BIOLOGY;COMPUTER SECURITY;DENTISTRY;DEVELOPMENT ECONOMICS;ECONOMIC GROWTH;ENDOCRINOLOGY;ENGINEERING DRAWING;FAMILY MEDICINE;FINANCE;IMMUNOLOGY;LAW;MARKET ECONOMY;METALLURGY;NUCLEAR MEDICINE;OBSTETRICS;OPHTHALMOLOGY;ORTHODONTICS;PHARMACOLOGY;PHYSICAL THERAPY;PROGRAMMING LANGUAGE;QUANTUM MECHANICS","26;13;10;7;6;6;5;5;4;4;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ELECTROENCEPHALOGRAPHY;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;DISEASE;ANTIBIOTICS;GENE;LACTOFERRIN;NEUROLOGY;OBESITY;CENTRAL NERVOUS SYSTEM DISEASE;CHEMOTHERAPY;CONTEXT (ARCHAEOLOGY);CORONARY ARTERY DISEASE;LUNG CANCER;MIGRAINE;NEUROSURGERY;OBSERVATIONAL STUDY;PREGNANCY;PSYCHOMETRICS;RESTING STATE FMRI","5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CONSTRUCT VALIDITY;BIRTH WEIGHT;CLINICAL ENDPOINT;LOW BIRTH WEIGHT;OVERWEIGHT;PLACEBO;RESTLESS LEGS SYNDROME;ALZHEIMER'S DISEASE;ANTIBIOTIC RESISTANCE;AURA;BACK PAIN;BEVACIZUMAB;BLEOMYCIN;CEFTRIAXONE;CEPHALOSPORIN;CHEMOTHERAPY REGIMEN;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;CLARITHROMYCIN;CLUSTER HEADACHE;COLORECTAL CANCER;COMMON HEPATIC DUCT;CONGENITAL MUSCULAR DYSTROPHY;CORONARY ANGIOGRAPHY;CORONARY ARTERIES;CYCLOPHOSPHAMIDE;DACARBAZINE;DEGENERATIVE DISC DISEASE;DEGENERATIVE DISEASE;DEGENERATIVE DISORDER;DIASTOLE;DOPAMINERGIC;ENOPHTHALMOS;EPIDERMAL GROWTH FACTOR RECEPTOR;ETEST;EVENT-RELATED POTENTIAL;EXHALED BREATH CONDENSATE;EXON;FACTOR V;GENOTYPE;HYPERINTENSITY;HYPOKALEMIC PERIODIC PARALYSIS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFLIXIMAB;LACTOBACILLUS;LORDOSIS;LOW BACK PAIN;MAINTENANCE THERAPY;MINIMUM INHIBITORY CONCENTRATION;NERVE SHEATH;NEUROLOGICAL DISORDER;NEURORADIOLOGY;OSTEOARTHRITIS;PACLITAXEL;PERIODIC PARALYSIS;PHENOTYPE;POLIOVIRUS;QUALITY ASSURANCE;RARE DISEASE;RETINITIS PIGMENTOSA;SKIN BIOPSY;SORAFENIB;SPINAL DISEASE;SUMMARY OF PRODUCT CHARACTERISTICS;SUNITINIB;THROMBOPHILIA;THYROTOXIC PERIODIC PARALYSIS;UNSTABLE ANGINA;VENOUS THROMBOSIS;VINBLASTINE;WEIGHT LOSS;WHITE MATTER","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALPHA (FINANCE);UNDERWEIGHT;AGAR DILUTION;BARDET–BIEDL SYNDROME;CARBOPLATIN;CEFIXIME;CEFPODOXIME;CETUXIMAB;COMPOUND HETEROZYGOSITY;DIETING;DOPPLER IMAGING;ERLOTINIB;FACTOR V LEIDEN;LACTOBACILLUS RHAMNOSUS;MIGRAINE WITH AURA;MISSENSE MUTATION;ODDBALL PARADIGM;OSWESTRY DISABILITY INDEX;PEMETREXED;PULSED-FIELD GEL ELECTROPHORESIS;VINCRISTINE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;ADULT;AGED;MIDDLE AGED;YOUNG ADULT;CEREBRAL CORTEX;ADOLESCENT;ANTI-BACTERIAL AGENTS;ELECTROENCEPHALOGRAPHY;ABDOMINAL PAIN;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;LUNG NEOPLASMS;NEISSERIA GONORRHOEAE;RESTLESS LEGS SYNDROME;TREATMENT OUTCOME;URINARY TRACT INFECTIONS","29;22;19;13;13;13;13;8;7;6;6;6;5;5;5;5;5;5;5;5","COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;EPIDEMIOLOGY AND MANAGEMENT OF MAXILLOFACIAL TRAUMA;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;MICROSURGICAL RECONSTRUCTION TECHNIQUES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;CHOLANGIOCARCINOMA;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;ECONOMIC BURDEN OF CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND PATHOGENESIS OF BACTERIAL MENINGITIS;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;IMMUNOTOXIN THERAPY FOR CANCER TREATMENT;IMPACT OF NIGHTTIME LIGHT DATA ON VARIOUS FIELDS","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALPHA (FINANCE);LACTOFERRIN;CLINICAL ENDPOINT;EEG ANALYSIS;EPIDURAL ANALGESIA;FACE PERCEPTION;FREE FLAP;MACULAR DEGENERATION;MANDIBULAR RECONSTRUCTION;MICROSURGICAL RECONSTRUCTION;NEUROIMAGING DATA ANALYSIS;ORBITAL IMPLANTS;PERFORATOR FLAP;REGIONAL ANESTHESIA;RESTING-STATE FMRI;RESTLESS LEGS SYNDROME;UNDERWEIGHT;ABVD;AGAR DILUTION;ALZHEIMER'S DISEASE","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","BOVINE LACTOFERRIN;CLARITHROMYCIN RESISTANCE;CORTICAL ELECTROENCEPHALOGRAPHIC;ELECTROENCEPHALOGRAPHIC RHYTHMS;ELECTROENCEPHALOGRAPHIC STUDY;FLOOR RECONSTRUCTION;FUNGAL INFECTIONS;INVASIVE FUNGAL;LACTOFERRIN SUPPLEMENTATION;LEGS SYNDROME;LUNG CANCER;ORBITAL FLOOR;PREVENTS INVASIVE;RECONSTRUCTION PDS;RESTLESS LEGS;TITANIUM MESH;ABDOMINIS PLANE;ABNORMAL BODY;ACCEPTANCE TESTING;ADMINISTERED DIFFERENCES;ADVANCED HODGKIN;ADVANCED NON-SQUAMOUS;ALTERED OSTEOBLASTIC;ALZHEIMERS DISEASE;AMBLYOPIC CHILDREN;ANALYSIS CONDUCTED;ANDIHOMO SAPIENSI;ANTI-CANCER DRUGS;ARM FLAP;ARTERY DISEASES","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LUNG CANCER;EGFR MLMIN;MKKS GENE;NEUTROPHILS LYMPHOCYTES;PERIPHERAL BLOOD;SERUM CREATININE;AUTOSOMAL RECESSIVE;BLOOD CELLS;BRONCHIAL BRUSHING;CANCER PATIENTS;CONTROLS HPV;COUNT NEUTROPHILS;CREATININE LEVEL;HEMATOCHEMICAL EXAMINATION;HEMOGLOBIN LEVEL;HPV INFECTION;INVERTED DIFFERENTIAL;LEUKOCYTOSIS CELLSL;LMOLL EGFR;LUNG TISSUE;NEOPLASTIC LUNG;PLATELET COUNT;POR ALLELE;PROTEIN LEVEL;RA THERAPY;RECESSIVE PATTERN;RED BLOOD;A--GLOBULIN LEVEL;AC NA;ACTIVATED PARTIAL","7;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1",9,0.21,3.5,3,0,1,0,0,0,0,2.5,3,0,0,6,0,1.75,0,0,6,0,0,0,91,91,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7.6,577.4,6.94,1,0.2,64.6,0,0,1,0,1,0,0,3,0,2,3,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Italy","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","4;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;HEMATOLOGY;PATIENT SAFETY;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;CANCER;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETICS;HEALTH SERVICES;HEART DISEASE;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE","5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","2;1;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2012,32,10.21875,3.40625,0.293577981651376,0.5,0.4375,0.40625,0.34375,0,18,4,6,1,0.56,0.12,0.19,0.03,14.75,0.353138329819571,0.15625,0.8125,4.96753246753247,0.279082566378523,0.138655462184874,0.276315789473684,0.226190476190476,"SILVANA CAPALBO;LUCA MACARINI;NICOLA CASCAVILLA;GIORGINA SPECCHIA;RAFFAELE ANTONETTI;GIOVANNI QUARTA;ESTHER NATALIE OLÍVA;GIUSEPPE MINCOLELLI;ANTONELLA CAMPANALE;NICOLA DI RENZO;LAURA MUMOLI;MICHELE MARIO GRECO;FLORA DONADEI;ALDO QUATTRONE;EMILIO IANNITTO;GIUSEPPE PELLICO;ANGELO MICHELE CARELLA;LUCA PIO STOPPINO;FORTUNATO MORABITO;FILIPPO CADEMARTIRI","6;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LUCA MACARINI;SILVANA CAPALBO;LUCA PIO STOPPINO;DEODATA MONTRONE;MATTEO DI BIASE;ANTONELLA CAMPANALE;LUIGI ANNACONTINI;ARIANNA MAIORELLA;FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI;RAFFAELE ANTONETTI;A. BERARDI;LAURA MUMOLI;ALDO QUATTRONE;RICCARDO IEVA;G. RIZZI;UMBERTO AGUGLIA;MICHELE CORREALE;ANTONIO GAMBARDELLA","0.48;0.37;0.34;0.34;0.34;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25","SILVANA CAPALBO;LUCA MACARINI;RAFFAELE ANTONETTI;ANTONELLA CAMPANALE;LUCA PIO STOPPINO;UMBERTO AGUGLIA;LUIGI ANNACONTINI;ARIANNA MAIORELLA;FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI;DARIO GALANTE;EDOARDO FERLAZZO;DEODATA MONTRONE;MASSIMO LAMBO;ANDREA IGOREN GUARICCI;MATTEO DI BIASE;CARLO TEDESCHI;SALVATORE MEOLA;SANTE DI GIOIA","6;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","LUCA MACARINI;SILVANA CAPALBO;LUCA PIO STOPPINO;DEODATA MONTRONE;MATTEO DI BIASE;ANTONELLA CAMPANALE;LUIGI ANNACONTINI;ARIANNA MAIORELLA;FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI;RAFFAELE ANTONETTI;A. BERARDI;RICCARDO IEVA;G. RIZZI;UMBERTO AGUGLIA;MICHELE CORREALE;G. MERLICCO;EDOARDO FERLAZZO;V. BOZZINI","0.48;0.37;0.34;0.34;0.34;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25","ANDREA IGOREN GUARICCI;CARLO TEDESCHI;ERICA MAFFEI;FILIPPO CADEMARTIRI;ALEXIA ROSSI;CHIARA MARTINI;GIANCARLO MESSALLI;KOEN NIEMAN;NICO R. MOLLET;ONOFRIO A. CATALANO;SARA SEITUN;LUCA MACARINI;C. MARCANTONI;CARMINE ZOCCALI;CLAUDIA TORINO;G. ENIA;G. GIORDANO;GIUSEPPE BATTAGLIA;LORENA INFANTONE;M LUPIA","176;176;176;176;138;138;138;138;138;138;138;84;74;74;74;74;74;74;74;74","ANDREA IGOREN GUARICCI;CARMINE ZOCCALI;G. ENIA;VINCENZO PANUCCIO;LUCA MACARINI;RAFFAELE ANTONETTI;ANNALUCIA CARBONE;MASSIMO CONESE;SANTE DI GIOIA;STEFANO CASTELLANI;MARIA IOLE NATALICCHIO;DEODATA MONTRONE;MATTEO DI BIASE;CARLO TEDESCHI;LUIGI DI BIASE;NATALE DANIELE BRUNETTI;EDOARDO FERLAZZO;SILVANA CAPALBO;UMBERTO AGUGLIA;DONATO MELCHIONDA","176;74;74;74;60;50;48;48;48;48;46;39;39;38;38;38;30;30;30;24","SILVANA CAPALBO;LUCA MACARINI;RAFFAELE ANTONETTI;ANDREA IGOREN GUARICCI;ANTONELLA CAMPANALE;ARIANNA MAIORELLA;AURELIO PORTINCASA;DARIO GALANTE;DEODATA MONTRONE;DOMENICO PARISI;EDOARDO FERLAZZO;FEDELE LEMBO;LUIGI ANNACONTINI;MASSIMO LAMBO;MATTEO DI BIASE;SALVATORE MEOLA;UMBERTO AGUGLIA;ADOLFO V. P CELLA;AMANDA CALI;ANNA NUNZIA POLITO","6;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;GEOGRAPHY;HISTORY","29;14;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;RADIOLOGY;PATHOLOGY;IMMUNOLOGY;PEDIATRICS;PSYCHIATRY;BIOCHEMISTRY;ONCOLOGY;ANESTHESIA;CARDIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;ARCHAEOLOGY;CANCER RESEARCH;DERMATOLOGY;NEUROSCIENCE;OPTICS;ORGANIC CHEMISTRY;VIROLOGY","18;12;7;7;6;5;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2","DISEASE;GENE;TRANSPLANTATION;BONE MARROW;HEART FAILURE;HEMODIALYSIS;LUMBAR;POPULATION;ASYMPTOMATIC;CANCER;CHEMOTHERAPY;CONTEXT (ARCHAEOLOGY);COPPER;DECOMPRESSION;EPIDEMIOLOGY;EPILEPSY;INCIDENCE (GEOMETRY);LOCAL ANAESTHETIC;LUMBOSACRAL JOINT;MAGNETIC RESONANCE IMAGING;MULTIPLE MYELOMA;NEUROLOGY;REGIMEN;STEM CELL;STENOSIS;ULTRASOUND;VIRUS","7;7;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EJECTION FRACTION;BORTEZOMIB;CHROMOSOME;COPPER METABOLISM;CYTOPENIA;GENOTYPE;MINIMAL RESIDUAL DISEASE;MYELODYSPLASTIC SYNDROMES;SKIN CANCER;SPINAL STENOSIS;TEMPORAL LOBE;ABLATIVE CASE;AGE OF ONSET;ALLELE;ANTIBIOTIC RESISTANCE;APACHE II;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BASILIC VEIN;BETA BLOCKER;BIOELECTRICAL IMPEDANCE ANALYSIS;CELLULAR DIFFERENTIATION;CEREBELLAR ATAXIA;CHOREA;CIPROFLOXACIN;CORONARY ANGIOGRAPHY;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;DEGENERATIVE DISC DISEASE;DEMENTIA;DOXORUBICIN;FETUS;FLUCONAZOLE;FUNGEMIA;GALACTOMANNAN;GENETIC PREDISPOSITION;GENETIC VARIATION;GESTATIONAL AGE;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEMOFILTRATION;INFLUENZA A VIRUS;LENALIDOMIDE;LEUKODYSTROPHY;LEUKOENCEPHALOPATHY;LIVER TRANSPLANTATION;LOW BACK PAIN;LUMBAR SPINAL STENOSIS;LUNG ULTRASOUND;MAPK/ERK PATHWAY;MELPHALAN;MERKEL CELL CARCINOMA;MICRORNA;MOVEMENT DISORDERS;MULTIPLE ORGAN DYSFUNCTION SYNDROME;NEISSERIACEAE;NEUROENDOCRINE CARCINOMA;NEURORADIOLOGY;NEUTROPENIA;OZONE THERAPY;PARKINSON'S DISEASE;PENICILLIN;POLIOVIRUS;POLYMERASE CHAIN REACTION;PORTAL VEIN THROMBOSIS;RADICULAR PAIN;RESPIRATORY EPITHELIUM;RESPIRATORY TRACT;RESPIRATORY TRACT INFECTIONS;RHINOVIRUS;SPINAL CANAL;STEADY-STATE FREE PRECESSION IMAGING;SUNITINIB;SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;THYROID CARCINOMA;TISSUE TRANSGLUTAMINASE;UNIVARIATE ANALYSIS;VASCULAR ACCESS;WHITE MATTER","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CYTOGENETICS;FLUORESCENCE IN SITU HYBRIDIZATION;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MENKES DISEASE;ADULT STEM CELL;DONEPEZIL;HUMAN METAPNEUMOVIRUS;IVABRADINE;MERKEL CELL;MERKEL CELL POLYOMAVIRUS;MULTIPLEX POLYMERASE CHAIN REACTION;OSWESTRY DISABILITY INDEX;POLYMORPHISM (COMPUTER SCIENCE);SPINAL CANAL STENOSIS;STROKE VOLUME","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;CORONARY ARTERY DISEASE;EPILEPSY, TEMPORAL LOBE;MYCOSES;ADENOCARCINOMA, FOLLICULAR;ARTERIOVENOUS SHUNT, SURGICAL;BLOOD VESSEL PROSTHESIS IMPLANTATION;CARCINOMA, PAPILLARY;NEISSERIA GONORRHOEAE;THYROID NEOPLASMS;TOMOGRAPHY, X-RAY COMPUTED;YOUNG ADULT;AGED, 80 AND OVER","18;13;9;8;8;7;7;7;6;5;5;4;4;4;4;4;4;4;4;3","ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;PATHOPHYSIOLOGY OF LUMBAR DISC DEGENERATION AND TREATMENT;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EPIDEMIOLOGY AND PATHOGENESIS OF BACTERIAL MENINGITIS;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;EPILEPSY AND SEIZURES;ERRORS AND COMMUNICATION IN RADIOLOGY IMAGING;FUNCTIONS AND REGULATION OF RNA EDITING BY ADARS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;IMPACT OF RESTING HEART RATE ON CARDIOVASCULAR HEALTH;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BONE MARROW BIOPSY;CARDIAC IMAGING;CARDIAC ULTRASOUND;CARDIOVASCULAR RISK ASSESSMENT;CYTOPENIA;DEGENERATIVE DISC DISEASE;ECHOCARDIOGRAPHY;LOCAL ANAESTHETIC;LUMBAR DISC DEGENERATION;LUMBOSACRAL JOINT;LUNG ULTRASOUND;MENKES DISEASE;MINIMAL RESIDUAL DISEASE;REGIMEN;TRISOMY 8;ABLATIVE CASE;ACADEMIC YEAR;ACUTE PANCREATITIS;AMNIOTIC EPITHELIAL CELLS;AMNIOTIC STEM CELLS","2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","ABDOMINIS PLANE;BILATERAL ULTRASOUND;CELL TRANSPLANTATION;CYTOGENETIC ANALYSIS;DEGENERATIVE DISK;DIAGNOSED MYELODYSPLASTIC;DISK DISEASE;FLOW CYTOMETRY;IN-SPACE DEVICES;INTERSPINOUS STABILIZATIONDECOMPRESSION;LOBE EPILEPSY;LUMBOSACRAL LEVEL;MENKES DISEASE;MULTIPLE MYELOMA;MYELODYSPLASTIC SYNDROMES;NEWLY DIAGNOSED;PATIENT AFFECTED;PLANE BLOCK;SOUTHERN ITALY;SPINAL STENOSIS;STEM CELL;TEMPORAL LOBE;TRANSVERSUS ABDOMINIS;ULTRASOUND TRANSVERSUS;ACCESS CONSENSUS;ACUTE LEUKEMIA;ACUTE PANCREATITIS;AFFECTS AGE;AIRWAY EPITHELIAL;ALLOGENEIC STEM","2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","TAP BLOCK;GROWTH FACTOR;DOUBLE LEVEL;LOCAL ANAESTHETIC;MENKES DISEASE;ULTRASOUND TAP;CFTR EXPRESSION;EPITHELIAL CELLS;LUNG CONGESTION;MOULD INFECTION;MOULD INFECTIONS;NYHA CLASS;ODI INDEX;PROSTHESIS DEVICE;RETPTC REARRANGEMENT;SEVERE LUNG;STRESS ECHOCARDIOGRAPHY;VAS SCALE;ABDOMINIS PLANE;ANAESTHETIC SAFELY;ANAESTHETIC TECHNIQUE;ANAESTHETIC TECHNIQUES;BRAF GENES;CANAL DIAMETERS;CARCINOMA CELLS;CARDIAC CT;CAREFUL ASSESSMENT;CAREFUL PREPARATION;CHILDHOOD DISEASE;CONSTITUTIVE ACTIVATION","6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",6,0.19,2.5,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,2,0,0,56.25,56.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,5.2,203,5.95,3,0.6,58.2,0,0,3,0,1,0,0,1,0,4,1,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","5;3;1;1;1;1","CLINICAL RESEARCH;CANCER;HEMATOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PEDIATRIC;RARE DISEASES;CHILDHOOD LEUKEMIA;PEDIATRIC CANCER;PREVENTION;TRANSPLANTATION;AGING;DIABETES;INFECTIOUS DISEASES;KIDNEY DISEASE;PEDIATRIC RESEARCH INITIATIVE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","5;4;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;METABOLIC AND ENDOCRINE","1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.2 CELLULAR AND GENE THERAPIES","4;2;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA","3;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2013,29,12.8275862068966,1.89655172413793,0.527272727272727,0.137931034482759,0.137931034482759,0.103448275862069,0.448275862068966,1,11,13,3,1,0.38,0.45,0.1,0.03,29.24,0.838040412613542,0.172413793103448,0.931034482758621,4.32972972972973,0.355206881465114,0.15,0.15,0.166666666666667,"CIRO MUNDI;HUBERT MESSNER;FABIO MOSCA;ROSARIO MAGALDI;SIMONE PRATESI;GIANLUCA LISTA;CAMILLA GIZZI;GIOVANNI AUGUSTO CARLESIMO;CARLO CALTAGIRONE;PAOLO BIBAN;DIEGO GAZZOLO;CARLO DANI;FABRIZIO SANDRI;LUIGI MARIA SPECCHIO;SALVATORE DE ROSA;SILVIA ZABBERONI;GIOVANNI VENTO;DANIELE TREVISANUTO;ERIOLA BAGOJ;DARIO GALANTE","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DARIO GALANTE;CIRO MUNDI;GIOVANNI AUGUSTO CARLESIMO;CARLO CALTAGIRONE;SALVATORE DE ROSA;SILVIA ZABBERONI;ERIOLA BAGOJ;ALBERTO COSTA;MARCO DI MONACO;FABIO BULLA;GAETANO SCOTTO;ALESSANDRA TARTAGLIA;VINCENZINA FAZIO;FRANCESCA CAMPANALE;FRANCESCO PAOLO CANTATORE;A. MARUCCI;ADDOLORATA CORRADO;ANNAMARIA GAUDIO;ANNA NEVE;A. MACCHIAROLA","1.1;0.41;0.24;0.24;0.24;0.24;0.24;0.24;0.24;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17","CIRO MUNDI;ROSARIO MAGALDI;LUIGI MARIA SPECCHIO;SALVATORE DE ROSA;ERIOLA BAGOJ;DARIO GALANTE;TERESA SANTANTONIO;ROMANO BUCCI;BRUNELLO LECCE;ANNA MARIA PAPANTONIO;ENZO IERARDI;CESARE HASSAN;MATTEO RINALDI;FRANCESCO PAOLO CANTATORE;GAETANO SCOTTO;DANIELA COLOGNO;UMBERTO AGUGLIA;EGIDIO GUERRA;MATTEO MELCHIONDA;MARIA GRAZIA PASCARELLA","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","DARIO GALANTE;CIRO MUNDI;SALVATORE DE ROSA;ERIOLA BAGOJ;GAETANO SCOTTO;FRANCESCO PAOLO CANTATORE;A. MARUCCI;ANNAMARIA GAUDIO;ANNA NEVE;A. MACCHIAROLA;TERESA SANTANTONIO;ROMANO BUCCI;ENZO IERARDI;DANIELA COLOGNO;UMBERTO AGUGLIA;O. CASTRIOTA;EDOARDO FERLAZZO;ROSARIO MAGALDI;EGIDIO GUERRA;ROBERTO LEONE","1.1;0.41;0.24;0.24;0.2;0.17;0.17;0.17;0.17;0.17;0.16;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.12;0.12","PIERO PORTINCASA;ANTONIO SPADACCINI;ANTONIO TURSI;ERMINIO CAPEZZUTO;F. POLIMENI;FABIO AIELLO;G PIANESE;G. STOPPINO;GIACOMO FORTI;GIAN MARCO GIORGETTI;GIOVANNI BRANDIMARTE;MARCELLO PICCHIO;N POLIMENI;N. SACCÀ;ROBERTO LATTANZIO;SERAFINA FIORELLA;SILVIO DANESE;STEFANO RODINÒ;TERESA D'AMICO;V. STOPPINO","222;138;138;138;138;138;138;138;138;138;138;138;138;138;138;138;138;138;138;138","G. STOPPINO;V. STOPPINO;CIRO MUNDI;ERIOLA BAGOJ;SALVATORE DE ROSA;ANNA MARIA PAPANTONIO;ROSARIO MAGALDI;MATTEO RINALDI;CESARE HASSAN;LUCY VANNELLA;VINCENZO DE FRANCESCO;FABIO BRUSAFERRI;A. MACCHIAROLA;A. MARUCCI;ANNA NEVE;ANNAMARIA GAUDIO;FRANCESCO PAOLO CANTATORE;ENZO IERARDI;TERESA SANTANTONIO;MACCHIAROLA","138;138;135;122;122;114;109;89;84;84;84;65;52;52;52;52;52;47;44;39","CIRO MUNDI;ROSARIO MAGALDI;DARIO GALANTE;ERIOLA BAGOJ;SALVATORE DE ROSA;A. MACCHIAROLA;A. MARUCCI;ANDREA IGOREN GUARICCI;ANNA MARIA PAPANTONIO;ANNA NEVE;ANNAMARIA GAUDIO;BRUNELLO LECCE;CESARE HASSAN;DANIELA COLOGNO;EDOARDO FERLAZZO;EGIDIO GUERRA;ELENA CARAPELLE;ENZO IERARDI;FABIO BRUSAFERRI;FRANCESCA PACILLO","4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PSYCHOLOGY;ECONOMICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;CHEMISTRY;COMPUTER SCIENCE;HISTORY","28;11;4;2;2;2;2;1;1;1","INTERNAL MEDICINE;GENETICS;PSYCHIATRY;SURGERY;ANESTHESIA;PEDIATRICS;PHYSICAL THERAPY;GASTROENTEROLOGY;DEVELOPMENTAL PSYCHOLOGY;IMMUNOLOGY;NEUROSCIENCE;AUDIOLOGY;CARDIOLOGY;CLINICAL PSYCHOLOGY;ENVIRONMENTAL HEALTH;EPISTEMOLOGY;FOOD SCIENCE;LAW;MACROECONOMICS;MICROBIOLOGY;NURSING;ONCOLOGY;PALEONTOLOGY;PATHOLOGY;VIROLOGY","21;8;6;6;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DISEASE;GENE;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;ANESTHETIC;ANTIBIOTICS;ANXIETY;BACTERIA;CANCER;CLINICAL PRACTICE;COGNITION;COHORT;CONCOMITANT;DEPRESSION (ECONOMICS);EPILEPSY;MECHANICAL VENTILATION;MYOCARDIAL INFARCTION;NEUROLOGY;NORMATIVE;OBSERVATIONAL STUDY;POPULATION;QUALITY OF LIFE (HEALTHCARE);RHEUMATOID ARTHRITIS;TEST (BIOLOGY);VIRUS","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ALLELE;GENOTYPE;GESTATIONAL AGE;NEUROPSYCHOLOGY;ACTIVATOR (GENETICS);ADALIMUMAB;ALPHA RHYTHM;ANTIBIOTIC THERAPY;AURA;BONE MINERAL;CHROMOSOME;CHRONIC HEPATITIS;CHRONIC LIVER DISEASE;CLINICAL ENDPOINT;CODING REGION;COGNITIVE IMPAIRMENT;COLORECTAL CANCER;CONSTRUCT VALIDITY;CONTINUOUS POSITIVE AIRWAY PRESSURE;ETANERCEPT;EYES OPEN;FINGOLIMOD;GESTATION;HOSPITAL ANXIETY AND DEPRESSION SCALE;INFLAMMATORY BOWEL DISEASE;INFLAMMATORY MYOPATHY;INFLIXIMAB;INTERIM ANALYSIS;INTRACEREBRAL HEMORRHAGE;ISCHEMIC STROKE;LACTOBACILLUS CASEI;LAMOTRIGINE;LEVOBUPIVACAINE;LUNG DISEASE;MINIMAL RESIDUAL DISEASE;NATALIZUMAB;NEONATAL SEPSIS;NEURORADIOLOGY;OPIOID;OVERWEIGHT;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;PLACEBO;POLYARTHRITIS;POLYMERASE CHAIN REACTION;PROBIOTIC;PSORIATIC ARTHRITIS;RAW SCORE;RELAPSING REMITTING;SLEEP DISORDER;SLEEP QUALITY;STAPHYLOCOCCUS AUREUS;SUPERINFECTION;TEMPORAL LOBE;THROMBOLYSIS;TLR4;TOCILIZUMAB;UNIVARIATE ANALYSIS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NEUROPSYCHOLOGICAL TEST;ALLELE FREQUENCY;ALPHA (FINANCE);BRONCHOPULMONARY DYSPLASIA;DOUBLE BLIND;GENE POLYMORPHISM;HAPLOINSUFFICIENCY;HAPLOTYPE;HEPATITIS E;HEPATITIS E VIRUS;LAMIVUDINE;MESALAZINE;MINI–MENTAL STATE EXAMINATION;MODIFIED RANKIN SCALE;NEUROPSYCHOLOGICAL ASSESSMENT;NORMAL WEIGHT;OSTEOPOROTIC FRACTURE;PITTSBURGH SLEEP QUALITY INDEX;POLYMORPHISM (COMPUTER SCIENCE);PRETERM DELIVERY;RANKL;RETINOPATHY OF PREMATURITY;TAQMAN;UNDERWEIGHT;VANCOMYCIN;VERBAL FLUENCY TEST","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;;AGED;ANTI-BACTERIAL AGENTS;AGED, 80 AND OVER;HEPATITIS E;ITALY;LEUKEMIA, MYELOID, ACUTE;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;PROBIOTICS;RESPIRATORY DISTRESS SYNDROME, NEWBORN;TREATMENT OUTCOME;YOUNG ADULT;BLIND LOOP SYNDROME;BRONCHOPULMONARY DYSPLASIA;NEOPLASM, RESIDUAL","20;16;16;12;11;9;8;8;5;5;5;5;5;5;5;5;5;4;4;4","NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;NEUROTOXIC EFFECTS OF ANESTHETIC AGENTS ON BRAIN DEVELOPMENT;RHEUMATOID ARTHRITIS;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANALYSIS OF GENE INTERACTION NETWORKS;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS;DIAGNOSIS AND TREATMENT OF PROSTHETIC JOINT INFECTIONS;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;EPIDEMIOLOGY AND PATHOGENESIS OF BACTERIAL MENINGITIS;EPIDEMIOLOGY, CLASSIFICATION, AND CLINICAL FEATURES OF INFLAMMATORY MYOPATHIES;EPILEPSY AND SEIZURES;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS B INFECTION AND TREATMENT","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL PRACTICE;CONCOMITANT;DEPRESSION (ECONOMICS);EPILEPSY;FETAL LUNG DEVELOPMENT;NEUROPSYCHOLOGICAL TEST;PRETERM INFANTS;TREATMENT;ALPHA (FINANCE);ANTIBIOTIC THERAPY;BACTERIAL OVERGROWTH;BRONCHOPULMONARY DYSPLASIA;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;CHRONIC LIVER DISEASE;CLINICAL ENDPOINT;CODING REGION;COMBINATION THERAPY;COMPLICATIONS;COMPUTED TOMOGRAPHY","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL PRACTICE;LUNG INFLATION;NORMATIVE DATA;PRETERM INFANTS;SLI STUDY;SUSTAINED LUNG;AB ANTI-TNFA;ABDOMINIS PLANE;ACUTE LEUKEMIA;ACUTE POSTOPERATIVE;ALLOGENEIC STEM;ALPHA RHYTHMS;ALTERNATE FLUENCY;ANDOR PROBIOTICS;ANGIOGRAPHY PROGNOSTIC;ANTI-TNFA THERAPY;ANTIBIOTIC THERAPY;ARTERY DISEASE;BACTERIAL OVERGROWTH;BASILAR-TYPE MIGRAINE;BILATERAL OPERCULAR;BRAIN DISEASE;CARCINOMA PRECEDED;CELL TRANSPLANT;CHIMERISM STATUS;CHIMERISM VERSUS;CHROMOSOME HAPLOTYPE;CHRONIC HEPATITIS;CILIARY DYSKINESIA;CLEFT COMPLICATIONS","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SLEEP DISTURBANCES;CASEI SUBSP;LACTOBACILLUS CASEI;SUBSP DG;NEUROLOGIC IMPROVEMENT;ACUTE PHASE;HIP FRACTURE;MAINTAINING REMISSION;TLR GENE;ACTIVE LACTOBACILLUS;ACTIVE MESALAZINE;ANESTHETIC RISKS;BM PATIENTS;CANCER PATIENTS;CELL POPULATION;CELL PROLIFERATION;DG BILLIONDAY;DG PLACEBO;DIVERTICULAR DISEASE;DKK- DKK-;DKK- EXPRESSION;ELDERLY PATIENTS;FRACTURE PATIENTS;FUNCTIONAL OUTCOME;IV THROMBOLYSIS;MAJOR NEUROLOGIC;MESALAZINE PLACEBO;NEUROLOGIC DETERIORATION;OP OSTEOBLASTS;OUTCOME MEASURES","6;5;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",8,0.28,18.09,10.75,2.75,1,0,1.75,10.5,0,1,10.75,0,1,6.5,0,0,0,3.5,6,1,0,0,83.5,83.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7,351,10.87,2,0.4,83.2,0,0,0,0,3,0,0,2,0,3,2,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","5;3;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;INFECTIOUS DISEASES;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;HEMATOLOGY;HEPATITIS;HEPATITIS - B;LIVER DISEASE;RARE DISEASES;AGING;ARTHRITIS;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;LYMPHOMA;ORPHAN DRUG;RHEUMATOID ARTHRITIS","5;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM","1;1","6.1 PHARMACEUTICALS","5","LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA","2;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","4",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2014,55,10.8909090909091,2,0.5,0.272727272727273,0.236363636363636,0.254545454545455,0.345454545454545,2,18,17,7,8,0.33,0.31,0.13,0.15,19.89,0.52633008109975,0.145454545454545,0.945454545454545,3.94059405940594,0.508510069030936,0.38,0.272727272727273,0.251748251748252,"ANGELO CAMPANOZZI;IRENE RUTIGLIANO;ANGELO ZULLO;VINCENZO DE FRANCESCO;CESARE HASSAN;MASSIMO PETTOELLO‐MANTOVANI;ALFREDO DI LEO;LORENZO RIDOLA;DARIO GALANTE;LUCA MACARINI;MARIO D’ALTILIA;ANTONIO FACCIORUSSO;MICHELE SACCO;PAOLO TONTI;ANTONIO PENNELLA;ELENA RANIERI;NICOLA D’ALTILIA;M. BARONE;G NARDELLA;DINO PEDROTTI","6;6;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","DARIO GALANTE;ELENA RANIERI;DINO PEDROTTI;MICHELE FALCONE;GIUSEPPE STEFANO NETTI;ANGELO ZULLO;VINCENZO DE FRANCESCO;MARGHERITA GIGANTE;ANTONIO FACCIORUSSO;M. BARONE;CESARE HASSAN;ANGELO CAMPANOZZI;IRENE RUTIGLIANO;LORENZO RIDOLA;MASSIMO PETTOELLO‐MANTOVANI;GIANPAOLO GRILLI;G NARDELLA;NATALE DANIELE BRUNETTI;MATTEO DI BIASE;ALFREDO DI LEO","1.42;1.17;1.17;1;1;0.95;0.95;0.83;0.75;0.75;0.7;0.62;0.62;0.53;0.52;0.47;0.46;0.45;0.45;0.42","VINCENZO DE FRANCESCO;DARIO GALANTE;LUCA MACARINI;ANTONIO FACCIORUSSO;PAOLO TONTI;ELENA RANIERI;M. BARONE;G NARDELLA;RAFFAELE ANTONETTI;NATALE DANIELE BRUNETTI;ANTONIO LONGO;FLORIANA GIORGIO;CIRO MUNDI;ROSARIO MAGALDI;MATTEO DI BIASE;S. ROMITO;GIANPAOLO GRILLI;MATTEO RINALDI;VALENTINA DEL PRETE;FRANCESCA MALLAMACI","6;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","DARIO GALANTE;ELENA RANIERI;MICHELE FALCONE;GIUSEPPE STEFANO NETTI;VINCENZO DE FRANCESCO;ANTONIO FACCIORUSSO;M. BARONE;GIANPAOLO GRILLI;G NARDELLA;NATALE DANIELE BRUNETTI;MATTEO DI BIASE;FLORIANA GIORGIO;STERPETA DIELLA;MADDALENA GIGANTE;ANTONIO LONGO;LUCA MACARINI;MATTEO RINALDI;PAOLO TONTI;MAURIZIO POSTORINO;ROBERTO LEONE","1.42;1.17;1;1;0.95;0.75;0.75;0.47;0.46;0.45;0.45;0.39;0.33;0.33;0.33;0.32;0.29;0.28;0.28;0.25","ROSARIO MAGALDI;VINCENZO DE FRANCESCO;DANIELE FARINA;ELENA GALLO;FABIO MOSCA;FABRIZIO FERRARI;FEDERICA VAGNARELLI;HUBERT MESSNER;ILARIA STOLFI;LIDIA DECEMBRINO;LINA BOLLANI;LINDA BORDIGNON;LIVIA RENZULLO;LORENZA PUGNI;LUIGI MEMO;MARIO GIOVANNI ROMEO;MATTEO RINALDI;MAURO STRONATI;MICHAEL MOSTERT;MICHAEL P. MEYER","190;178;176;176;176;176;176;176;176;176;176;176;176;176;176;176;176;176;176;176","ROSARIO MAGALDI;VINCENZO DE FRANCESCO;MATTEO RINALDI;CIRO MUNDI;DAVIDE BOLIGNANO;LORENZO GHIADONI;PATRIZIA PIZZINI;RAVI THADHANI;ANTONIO FACCIORUSSO;M. BARONE;MATTEO ANTONINO;NICOLA CRUCINIO;VALENTINA DEL PRETE;VIVIANA NEVE;ROBERTO LEONE;GIANPAOLO GRILLI;ANDREA IGOREN GUARICCI;CHIARA MARTINI;DEODATA MONTRONE;DOMENICO COCCO","190;177;176;127;118;118;118;118;101;101;94;94;94;94;74;69;41;41;41;41","VINCENZO DE FRANCESCO;DARIO GALANTE;ANTONIO FACCIORUSSO;ELENA RANIERI;M. BARONE;GIANPAOLO GRILLI;RAFFAELE ANTONETTI;ROSARIO MAGALDI;S. ROMITO;CIRO MUNDI;GIANFRANCO COSTANTINO;MATTEO ANTONINO;MATTEO RINALDI;MAURIZIO POSTORINO;NATALE DANIELE BRUNETTI;NICOLA CRUCINIO;ROBERTO LEONE;SILVANA CAPALBO;VALENTINA DEL PRETE;VIVIANA NEVE","6;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;HISTORY;PHILOSOPHY;ECONOMICS;ENGINEERING;MATERIALS SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","51;19;6;4;3;3;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;GASTROENTEROLOGY;PEDIATRICS;SURGERY;BIOCHEMISTRY;GENETICS;IMMUNOLOGY;ONCOLOGY;PATHOLOGY;RADIOLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;ENDOCRINOLOGY;ANESTHESIA;CANCER RESEARCH;ENVIRONMENTAL HEALTH;PSYCHIATRY;UROLOGY;ARCHAEOLOGY;DERMATOLOGY;FAMILY MEDICINE;OBSTETRICS;OPTICS;PALEONTOLOGY;PHARMACOLOGY;VIROLOGY","39;12;10;10;8;8;8;8;8;8;5;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2","DISEASE;HELICOBACTER PYLORI;ANTIBIOTICS;CANCER;COHORT;GENE;IN VITRO;PREGNANCY;ANTIGEN;ARTERY;CLINICAL TRIAL;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;HEART FAILURE;HEPATOCELLULAR CARCINOMA;KIDNEY DISEASE;MYOCARDIAL INFARCTION;REGIMEN;VITAMIN D AND NEUROLOGY;ABLATION;ADVERSE EFFECT;ANGIOGRAPHY;ANTIBODY;ASTHMA;CALCIUM;CLINICAL PRACTICE;DIABETES MELLITUS;ELECTROENCEPHALOGRAPHY;ENDOSCOPY;INCIDENCE (GEOMETRY);INTERIM;LUNG;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;PHARMACOTHERAPY;POPULATION;PROPOFOL;RENAL FUNCTION;RETROSPECTIVE COHORT STUDY;SEVOFLURANE;STAGE (STRATIGRAPHY);THYROID;TRANSPLANTATION;URINARY SYSTEM;VOMITING","7;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HELICOBACTER PYLORI INFECTION;CYTOTOXIC T CELL;AMOXICILLIN;CD8;CORONARY ANGIOGRAPHY;METRONIDAZOLE;BREAST CANCER;CLARITHROMYCIN;COLORECTAL CANCER;GESTATIONAL AGE;INTERIM ANALYSIS;LOW BIRTH WEIGHT;PARATHYROID HORMONE;RABEPRAZOLE;RADIOFREQUENCY ABLATION;ADENOCARCINOMA;ADMITTANCE;ADRENOCORTICAL ADENOMA;AGAROSE GEL ELECTROPHORESIS;AIRWAY OBSTRUCTION;ALLELE;ALZHEIMER'S DISEASE;ANTIBIOTIC RESISTANCE;ANTIEPILEPTIC DRUG;ARGININE;ATELECTASIS;AUTOIMMUNE DISEASE;AUTOIMMUNITY;AXILLARY VEIN;BIRTH WEIGHT;BISPECTRAL INDEX;BREATH TEST;BRONCHOSPASM;BUNDLE BRANCH BLOCK;CARCINOGENESIS;CARDIAC MAGNETIC RESONANCE;CARDIOMYOPATHY;CARNEY COMPLEX;CELL CYCLE;CERVICAL CANCER;CHOLECYSTITIS;CHRONIC HEPATITIS;CISPLATIN;CLINICAL DISEASE;CLINICAL ENDPOINT;COELIAC DISEASE;COGNITIVE IMPAIRMENT;COMPUTED TOMOGRAPHIC ANGIOGRAPHY;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CONSTRUCT VALIDITY;CORONARY ATHEROSCLEROSIS;CYCLOPHOSPHAMIDE;DIASTOLE;DISEASE MONITORING;DNA SEQUENCING;DOXORUBICIN;EJECTION FRACTION;END STAGE RENAL DISEASE;ENTEROPATHY;EX VIVO;EXHALED BREATH CONDENSATE;EXPANDED DISABILITY STATUS SCALE;FETUS;FINGOLIMOD;FLUCONAZOLE;FLUORESCENCE MICROSCOPE;GESTATION;GI BLEEDING;GONORRHEA;HELICOBACTER INFECTIONS;HYPERINTENSITY;HYPOGLYCEMIA;IMMUNOFLUORESCENCE;INSULIN RESISTANCE;INTIMA-MEDIA THICKNESS;KIDNEY TRANSPLANTATION;LAMOTRIGINE;LEFT BUNDLE BRANCH BLOCK;LEFT CORONARY ARTERY;LEFT PULMONARY ARTERY;LENALIDOMIDE;LEVETIRACETAM;LEVOBUPIVACAINE;LEVOFLOXACIN;LIVER CANCER;LOG-RANK TEST;MINIMAL RESIDUAL DISEASE;MINOCYCLINE;MITOTANE;MUTANT;NATALIZUMAB;NEISSERIACEAE;NEURODEGENERATION;PACLITAXEL;PEPTIC;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PLACEBO;PORTAL HYPERTENSION;PRIMARY AND SECONDARY ANTIBODIES;PROPYLTHIOURACIL;PROTEINURIA;PYROSEQUENCING;RELAPSING REMITTING;REMIFENTANIL;RIGHT BUNDLE BRANCH BLOCK;SEROLOGY;STAT3;STUPOR;SUBGROUP ANALYSIS;THYROID DISEASE;TRANSARTERIAL EMBOLIZATION;UNIVARIATE ANALYSIS;UPPER ENDOSCOPY;UPPER GASTROINTESTINAL BLEEDING;URINALYSIS;VITAMIN D DEFICIENCY;WHITE MATTER","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CTL*;TINIDAZOLE;UREA BREATH TEST;ADOPTIVE CELL TRANSFER;ALPHA (FINANCE);ANTIGEN-PRESENTING CELL;ASYMMETRIC DIMETHYLARGININE;CAPECITABINE;DIASTOLIC HEART FAILURE;DOPPLER ECHOCARDIOGRAPHY;DOPPLER IMAGING;ESOPHAGEAL VARICES;FIBROBLAST GROWTH FACTOR 23;GASTROESOPHAGEAL JUNCTION;GLUCOSE HOMEOSTASIS;HAPLOINSUFFICIENCY;HOLOPROSENCEPHALY;HPV INFECTION;HYPOVITAMINOSIS;INTERNAL CAPSULE;INTRAVENTRICULAR HEMORRHAGE;KRAS;LAMIVUDINE;METASTATIC BREAST CANCER;NAB-PACLITAXEL;ONCOGENE;RIGHT CORONARY ARTERY;SECONDARY HYPERPARATHYROIDISM;SEROPREVALENCE;STAT;TRIPLE NEGATIVE;TRIPLE-NEGATIVE BREAST CANCER;TUMOR SUPPRESSOR GENE;VINORELBINE","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;T-LYMPHOCYTES, CYTOTOXIC;HELICOBACTER INFECTIONS;ITALY;ANTI-BACTERIAL AGENTS;RENAL INSUFFICIENCY, CHRONIC;HELICOBACTER PYLORI;AGED, 80 AND OVER;ANTIBODIES, MONOCLONAL, HUMANIZED;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;MAGNETIC RESONANCE IMAGING;NEOPLASM RECURRENCE, LOCAL;BONE DENSITY CONSERVATION AGENTS","31;24;21;18;16;14;14;10;8;8;7;7;6;5;5;5;5;5;5;4","HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;VITAMIN D AND HEALTH OUTCOMES;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;HEPATOCELLULAR CARCINOMA;;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;CARDIOTOXICITY OF CANCER TREATMENTS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;COMPLICATIONS OF GALLSTONE DISEASE;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE","6;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","VITAMIN D;CELIAC DISEASE;CTL*;REGIMEN;ANTIGEN PRESENTATION;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL PRACTICE;COMPUTED TOMOGRAPHY ANGIOGRAPHY;HELICOBACTER PYLORI;INTERIM;INTERIM ANALYSIS;METASTATIC BREAST CANCER;PEDIATRIC INTUBATION;PHARMACOTHERAPY;PRETERM INFANTS;RABEPRAZOLE;RADIOFREQUENCY ABLATION;T CELL IMMUNITY;T CELL THERAPY","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HELICOBACTER PYLORI;HEPATOCELLULAR CARCINOMA;ACUTE CHOLECYSTITIS;BREAST CANCER;CARCINOMA PATIENTS;CELIAC DISEASE;CLINICAL PRACTICE;INTERIM ANALYSIS;LATE PRETERM;MAGNETIC RESONANCE;MULTICENTER PHASE;MULTIPLE SCLEROSIS;PATIENTS TREATED;PEDIATRIC POPULATION;PYLORI ERADICATION;RADIOFREQUENCY ABLATION;SCLEROSIS PATIENTS;SOUTHERN ITALY;ACUTE METABOLIC;ACUTE MYELOID;ADVANCED BREAST;ADVERSE REACTIONS;AIRWAY STENTING;ALLOGENEIC STEM;ALPHA RHYTHMS;ALZHEIMERS DISEASE;AMNESIC MILD;ANGIOGRAPHY MPMCTA;ANTIEPILEPTIC DRUGS;ANTIGEN-SPECIFIC CD","5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","DAY CONCOMITANT;HCC PATIENTS;PATIENTS FREE;LATE PRETERM;MG OMEPRAZOLE;RENAL EVENTS;BILATERAL PUTAMINAL;PATIENTS TREATED;AD SUBJECTS;ADJUSTED ANALYSES;ALPHA SOURCES;BRANCH BLOCK;BUNDLE BRANCH;CKD PROGRESSION;CLINICAL ACTIVITY;CLINICAL PRACTICE;DISEASE ACTIVITY;FGF- LEVEL;GESTATIONAL AGE;LATE PRETERMS;METABOLIC ACIDOSIS;MG CLARITHROMYCIN;MG TINIDAZOLE;NORMAL SALINE;OCCIPITAL ALPHA;OCCIPITAL LOBE;OCCIPITAL SOURCES;POSTOPERATIVE PAIN;SEQUENTIAL THERAPY;SF LEVELS","6;6;6;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",12,0.22,3.45,3,1,1,0,0,1,1,1,3,0,0,1.75,0,1,0,1,2.25,0,0,0,41,41,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,2.5,183.25,5.8,1,0.25,15.75,0,0,0,0,1,0,0,3,0,2,2,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Belgium;United Kingdom;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS","4;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PEDIATRIC;AGING;CANCER;CHILDHOOD LEUKEMIA;GENETICS;HEMATOLOGY;HYPERTENSION;NUTRITION;ORPHAN DRUG;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;PREVENTION;RARE DISEASES;TRANSPLANTATION","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL","1;1;1","6.1 PHARMACEUTICALS","1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2015,34,13.2941176470588,1.41176470588235,0.708333333333333,0.176470588235294,0.147058823529412,0.205882352941176,0.61764705882353,1,12,5,5,5,0.35,0.15,0.15,0.15,21.47,0.576110026733594,0.264705882352941,1,4.36363636363637,0.430501561109637,0.166666666666667,0.24,0.233766233766234,"MARIA IOLE NATALICCHIO;RAFFAELE ANTONETTI;LORETO GESUALDO;ARIANNA NERI;CECILIA FAZIO;GIOVANNI TRIPEPI;ALFREDO DI LEO;ANNA DI TARANTO;SILVANA CAPALBO;AMALIA AZZARITI;CARMINE ZOCCALI;GIANFRANCO COSTANTINO;PAOLA STEFANELLI;ROCCO TOTARO;GABRIELLA GUIDA;MICHELE GUIDA;SABINO STRIPPOLI;PANTALEO BUFO;ANNA ALBANO;IOLE NATALICCHIO","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PALMA MANDUZIO;CARMINE ZOCCALI;LUCA DE NICOLA;GIANFRANCO COSTANTINO;ROCCO TOTARO;P. BELLANTONIO;RAFFAELE ANTONETTI;MARIA IOLE NATALICCHIO;ANNA DI TARANTO;GIOVANNI TRIPEPI;MATTEO DI BIASE;ARIANNA NERI;CECILIA FAZIO;PAOLA STEFANELLI;VINCENZO DE FRANCESCO;AMALIA AZZARITI;GABRIELLA GUIDA;MICHELE GUIDA;SABINO STRIPPOLI;ANNA ALBANO","1;0.67;0.5;0.43;0.43;0.33;0.32;0.28;0.28;0.24;0.2;0.19;0.19;0.19;0.18;0.17;0.17;0.17;0.17;0.17","MARIA IOLE NATALICCHIO;RAFFAELE ANTONETTI;LORETO GESUALDO;GIOVANNI TRIPEPI;ANNA DI TARANTO;SILVANA CAPALBO;CARMINE ZOCCALI;GIANFRANCO COSTANTINO;ROCCO TOTARO;IOLE NATALICCHIO;CIRO MUNDI;VINCENZO DE FRANCESCO;MATTEO DI BIASE;MARIO FANELLI;ROMANO BUCCI;TIZIANA ROLLO;PALMA MANDUZIO;ANDREA CUCULO;ROSELLA DE NITTIS;GRAZIA IARIA","3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","PALMA MANDUZIO;CARMINE ZOCCALI;GIANFRANCO COSTANTINO;ROCCO TOTARO;RAFFAELE ANTONETTI;MARIA IOLE NATALICCHIO;ANNA DI TARANTO;GIOVANNI TRIPEPI;MATTEO DI BIASE;VINCENZO DE FRANCESCO;IOLE NATALICCHIO;TIZIANA ROLLO;ROSELLA DE NITTIS;FRANCESCA MALLAMACI;DARIO GALANTE;PAOLA SANCHES CELLA;GIANPAOLO GRILLI;LORETO GESUALDO;CIRO MUNDI;ROMANO BUCCI","1;0.67;0.43;0.43;0.32;0.28;0.28;0.24;0.2;0.18;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.15;0.15;0.14","ANTONIO BOLDRINI;ANTONIO DEL VECCHIO;CAMILLA GIZZI;CARLO DANI;DANIELE TREVISANUTO;DIEGO GAZZOLO;F. SCOPESI;FABIO MOSCA;FABRIZIO SANDRI;GIANLUCA LISTA;GIOVANNI VENTO;HUBERT MESSNER;LUCA BONI;MASSIMO AGOSTI;MASSIMO BELLETTATO;PAOLO BIBAN;ROSARIO MAGALDI;CARMINE ZOCCALI;LUCA DE NICOLA;LORETO GESUALDO","130;130;130;130;130;130;130;130;130;130;130;130;130;130;130;130;130;98;98;84","ROSARIO MAGALDI;CARMINE ZOCCALI;CIRO MUNDI;FABIO BARTOLI;MARCELLO NOBILI;LUIGI MARIA SPECCHIO;LORETO GESUALDO;VINCENZO DE FRANCESCO;ANNAMARIA BELLESIA;ANDREA CUCULO;MARIA MATTEO;SALVATORE DE ROSA;ROMANO BUCCI;AURORA FUIANI;GIANFRANCO COSTANTINO;MARIA IOLE NATALICCHIO;LUIGI DI MARTINO;MATTEO DI BIASE;GRAZIA IARIA;MARIO FANELLI","130;98;61;57;57;51;50;47;38;37;37;34;33;27;27;22;21;21;18;16","RAFFAELE ANTONETTI;MARIA IOLE NATALICCHIO;ANNA DI TARANTO;CARMINE ZOCCALI;CIRO MUNDI;GIOVANNI TRIPEPI;SILVANA CAPALBO;VINCENZO DE FRANCESCO;ANDREA CUCULO;ANNAMARIA BELLESIA;AURORA FUIANI;CLELIA PRATTICHIZZO;FABIO BARTOLI;GIANFRANCO COSTANTINO;GIANPAOLO GRILLI;GIUSEPPE STEFANO NETTI;GRAZIA IARIA;LORETO GESUALDO;LUIGI DI MARTINO;LUIGI MARIA SPECCHIO","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY","33;16;6;4;1;1;1;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;ONCOLOGY;BIOCHEMISTRY;SURGERY;CANCER RESEARCH;CARDIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PATHOLOGY;PEDIATRICS;PSYCHIATRY;OPTICS;INTENSIVE CARE MEDICINE;MICROBIOLOGY;RADIOLOGY;EMERGENCY MEDICINE;GYNECOLOGY;IMMUNOLOGY;NURSING;PALEONTOLOGY;VIROLOGY","29;8;8;6;6;5;5;5;5;5;5;5;4;3;3;3;2;2;2;2;2;2","GENE;CANCER;DISEASE;ADVERSE EFFECT;EPIDEMIOLOGY;INCIDENCE (GEOMETRY);POPULATION;ANTIBIOTICS;CHEMOTHERAPY;CLINICAL TRIAL;COHORT;MYOCARDIAL INFARCTION;PREGNANCY;PROSPECTIVE COHORT STUDY;BACTERIA;ENZYME;HORMONE;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;MYELOID LEUKEMIA;RANDOMIZED CONTROLLED TRIAL;REGIMEN","9;7;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;FINGOLIMOD;GENOTYPE;MUTATION;NATALIZUMAB;NEISSERIA MENINGITIDIS;RELAPSING REMITTING;UNIVARIATE ANALYSIS;ADENOCARCINOMA;ALZHEIMER'S DISEASE;AMENORRHEA;AMOXICILLIN;ANDROGEN;ANTIBIOTIC RESISTANCE;AORTIC VALVE REPLACEMENT;AORTIC VALVE STENOSIS;APERT SYNDROME;BECK DEPRESSION INVENTORY;BLEOMYCIN;CASE FATALITY RATE;CAUSE OF DEATH;CD8;CELL CYCLE;CERVICAL CANCER;CHONDROGENESIS;CHRONIC HEPATITIS;CLARITHROMYCIN;COGNITIVE IMPAIRMENT;CONTINUOUS POSITIVE AIRWAY PRESSURE;CONVENTIONAL PCI;CORONARY ARTERY CALCIUM;CRANIOFACIAL ABNORMALITY;CRANIOFACIAL SURGERY;CYTARABINE;CYTOKERATIN;DACARBAZINE;DEEP VEIN;DEFERASIROX;DESORPTION;DIASTOLE;DISEASE SURVEILLANCE;EMBRYONIC STEM CELL;EPIDEMIOLOGICAL SURVEILLANCE;EPIDERMAL GROWTH FACTOR RECEPTOR;ESCHERICHIA COLI;FIBRONECTIN;GENE EXPRESSION;GESTATIONAL AGE;GONADOTROPIN;HELICOBACTER PYLORI INFECTION;HEME;HODGKIN'S LYMPHOMA;HYPERURICEMIA;IMATINIB;INFERTILITY;INTRAEPITHELIAL LYMPHOCYTE;LIFETIME RISK;MAPK/ERK PATHWAY;MESSENGER RNA;METASTATIC MELANOMA;METHYLATION;METRONIDAZOLE;MISCARRIAGE;MULTIPLE DRUG RESISTANCE;NEISSERIACEAE;OVERWEIGHT;OVULATION;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;POLYSOMNOGRAPHY;POSTMARKETING SURVEILLANCE;PREGNANCY RATE;PROSTATE CANCER;PROTEINURIA;PSORIATIC ARTHRITIS;REGENERATIVE MEDICINE;REPRODUCTIVE MEDICINE;RITUXIMAB;SECONDARY SEX CHARACTERISTIC;SEXUAL INTERCOURSE;SPERM MOTILITY;TACROLIMUS;TEMOZOLOMIDE;THYROID CARCINOMA;THYROIDITIS;TISSUE TRANSGLUTAMINASE;TRACHEOESOPHAGEAL FISTULA;VINBLASTINE","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KRAS;MENINGOCOCCAL DISEASE;ADENOCARCINOMA OF THE LUNG;AGATSTON SCORE;ANDROGEN RECEPTOR;BRONCHOPULMONARY DYSPLASIA;CARDIAC SKELETON;CD3;CENTRAL SLEEP APNEA;DNA METHYLATION;DOPPLER IMAGING;HEME OXYGENASE;HPV INFECTION;INDUCED PLURIPOTENT STEM CELL;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;MEDULLARY CARCINOMA;MELANOCORTIN 1 RECEPTOR;MEMBRANOUS NEPHROPATHY;METHYLTRANSFERASE;MOLECULAR MEDICINE;MULTILOCUS SEQUENCE TYPING;NILOTINIB;SEMEN ANALYSIS;UREA BREATH TEST;V600E;VEMURAFENIB;VINCRISTINE","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;ITALY;MALE;MENINGOCOCCAL INFECTIONS;MIDDLE AGED;AGED;ADULT;HODGKIN DISEASE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARDIOVASCULAR DISEASES;INCIDENCE;RENAL INSUFFICIENCY, CHRONIC;ADOLESCENT;AORTIC VALVE INSUFFICIENCY;AORTIC VALVE STENOSIS;CARDIAC CATHETERIZATION;CELIAC DISEASE;EPILEPSY","18;16;15;14;14;8;8;7;6;6;5;5;5;5;4;4;4;4;4;4","ACUTE MYELOID LEUKEMIA;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND PATHOGENESIS OF BACTERIAL MENINGITIS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN LUNG CANCER RESEARCH;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;EFFICACY AND RESISTANCE IN CML TREATMENT;ELECTROSPUN NANOFIBERS IN BIOMEDICAL APPLICATIONS;EPILEPSY AND SEIZURES;ESOPHAGEAL INTERVENTION TECHNIQUES;GENETICS AND DEVELOPMENT OF CRANIOFACIAL ABNORMALITIES;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS B INFECTION AND TREATMENT;LYMPHOID NEOPLASMS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF VALVULAR HEART DISEASE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;MELANOMA;NATALIZUMAB;REGIMEN;RELAPSING REMITTING;TREATMENT;TREATMENT OUTCOMES;UNIVARIATE ANALYSIS;ABVD;ACUTE MYELOID LEUKEMIA;AGATSTON SCORE;ANDROGEN INSENSITIVITY SYNDROME;ANTIMICROBIAL SUSCEPTIBILITY TESTING;APERT SYNDROME;AZACITIDINE;BIOLOGIC SCAFFOLDS;BRAF GENE;BRAF MUTATIONS;BRONCHOPULMONARY DYSPLASIA;CARDIAC SKELETON","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","INVASIVE MENINGOCOCCAL;METASTATIC MELANOMA;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;PROSPECTIVE STUDY;ACUTE MYELOID;ADENOCARCINOMA HARBORING;ADULT RENAL;ADVANCED VASCULAR;ALZHEIMERS DISEASE;AMOXICILLIN DUAL;ANDROGEN INSENSITIVITY;ANTI-TNF-Α THERAPY;AORTIC VALVE;ARTHRITIS PSA;BID FRONTLINE;BIOACTIVE NANOFIBER;BIOLOGICAL MARKERS;BIORESORBABLE VASCULAR;BIPARTITION SURGERY;BRAF INHIBITORS;BRAF MUTATION;CARDIOVASCULAR ASSESSMENT;CARDIOVASCULAR COMORBIDITIES;CELIAC DISEASE;CELL CARCINOMA;CENTRAL SLEEP;CHEMO-MODULATING TEMOZOLOMIDE;CHRONIC HEART;CHRONIC HEPATITIS","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PATIENTS FREE;DISEASE ACTIVITY;MULTIPLE SCLEROSIS;AD PATIENTS;AGATSTON SCORE;CELL LINES;CUMULATIVE PROPORTION;ECHOCARDIOGRAPHIC ASSESSMENT;MCR STATUS;MCR VARIANTS;AORTIC ANNULUS;CK EXPRESSION;EEG MARKER;HOSPITAL ADMISSIONS;MAGNETIC RESONANCE;MEDIAN PFS;METHYLATION STATUS;MGMT METHYLATION;ODDS RATIO;PTS TREATED;REFRACTORY EPILEPSY;RELAPSING-REMITTING MULTIPLE;RESONANCE IMAGING;SIGNIFICANT DIFFERENCE;AD INDIVIDUALS;AD SUBGROUP;ANNULUS SIZE;APE XRCC;ATTEMPTING PREGNANCY;BER PATHWAY","7;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2",13,0.38,9.5,7,4,1,1,1,0,0,1,7,0,0,5.5,1,0,2.25,2,5,0,0,0,106,106,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,4.71,4764.71,19.44,2,0.29,122.71,0,0,1,0,2,0,0,4,0,5,2,0,0,0,0,0,0,5,2,0,6,0,0,1,0,0,0,0,0,0,"Australia;Italy;Japan;Netherlands","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","7;3;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;AGING;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BREAST CANCER;LUNG;PATIENT SAFETY;CARDIOVASCULAR;COMPLEMENTARY AND INTEGRATIVE HEALTH;ESTROGEN;HEART DISEASE;HEMATOLOGY;INFANT MORTALITY;LYMPHOMA;NEONATAL RESPIRATORY DISTRESS;ORPHAN DRUG;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD","7;6;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;RESPIRATORY;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH","3;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES","4;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2016,52,13.1730769230769,2.11538461538462,0.472727272727273,0.346153846153846,0.230769230769231,0.173076923076923,0.384615384615385,1,27,12,7,3,0.52,0.23,0.13,0.06,20.25,0.623402816484685,0.192307692307692,0.865384615384615,4.02643171806167,0.410036290125887,0.296774193548387,0.3,0.306122448979592,"NATALE DANIELE BRUNETTI;MATTEO DI BIASE;CARMINE ZOCCALI;LUCA MACARINI;RICCARDO IEVA;ANGELO ZULLO;RAFFAELE ANTONETTI;GIROLAMO SPAGNOLETTI;GIOVANNI TRIPEPI;CESARE HASSAN;FRANCESCA MALLAMACI;LUIGI DI MARTINO;FRANCESCO SANTORO;VINCENZO DE FRANCESCO;ROSARIO MAGALDI;PIER LUIGI PELLEGRINO;GIUSEPPINA SPINOSA;MASSIMO GRIMALDI;GRAZIAPIA CASAVECCHIA;ANDREA CUCULO","9;9;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2","MATTEO DI BIASE;NATALE DANIELE BRUNETTI;RIZZI GAETANO;CARMINE ZOCCALI;GIROLAMO SPAGNOLETTI;RICCARDO IEVA;ANGELO ZULLO;C. SEPEDE;LUCIA MORACA;LUCA MACARINI;PIER LUIGI PELLEGRINO;ANTONIO J. D’ANTUONO;MICHELE CORREALE;MARCO PAGLIALONGA;ANTONIO LUCE;PATRIZIA EMILIANI;CESARE HASSAN;VINCENZO DE FRANCESCO;FRANCESCO SANTORO;DIEGO BRANCACCIO","1.31;1.17;1;0.75;0.6;0.54;0.52;0.5;0.5;0.48;0.48;0.4;0.4;0.4;0.4;0.4;0.38;0.38;0.34;0.33","MATTEO DI BIASE;CARMINE ZOCCALI;LUCA MACARINI;RICCARDO IEVA;RAFFAELE ANTONETTI;GIROLAMO SPAGNOLETTI;GIOVANNI TRIPEPI;FRANCESCA MALLAMACI;LUIGI DI MARTINO;VINCENZO DE FRANCESCO;ROSARIO MAGALDI;PIER LUIGI PELLEGRINO;GIUSEPPINA SPINOSA;GRAZIAPIA CASAVECCHIA;ANDREA CUCULO;MATTEO RINALDI;VINCENZO DE FRANCESCO;MATTEO GRAVINA;ANTONIO J. D’ANTUONO;CLAUDIA TORINO","9;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MATTEO DI BIASE;RIZZI GAETANO;CARMINE ZOCCALI;GIROLAMO SPAGNOLETTI;RICCARDO IEVA;C. SEPEDE;LUCIA MORACA;LUCA MACARINI;PIER LUIGI PELLEGRINO;ANTONIO J. D’ANTUONO;MICHELE CORREALE;MARCO PAGLIALONGA;ANTONIO LUCE;PATRIZIA EMILIANI;VINCENZO DE FRANCESCO;LUIGI DI MARTINO;ROSARIO MAGALDI;MATTEO RINALDI;VINCENZO DE FRANCESCO;RAFFAELE ANTONETTI","1.31;1;0.75;0.6;0.54;0.5;0.5;0.48;0.48;0.4;0.4;0.4;0.4;0.4;0.38;0.31;0.3;0.29;0.29;0.28","GIOVANNI TRIPEPI;CARMINE ZOCCALI;CLAUDIA TORINO;DAVIDE BOLIGNANO;FRANCESCA MALLAMACI;A ZUCCALÀ;ADAMASCO CUPISTI;ANNA MARIA MALAGONI;ANTONIO BARILLÀ;CHIARA SUMMARIA;DANIELE CIURLINO;ENRICO POZZATO;FABIO MANFREDINI;FABRIZIO FABRIZI;FILIPPO AUCELLA;FRANCESCO RAPISARDA;GAETANO LUCISANO;GIORGIO FUÍANO;GRAZIELLA BONANNO;GRAZIELLA D’ARRIGO","354;346;342;342;342;330;330;330;330;330;330;330;330;330;330;330;330;330;330;330","FRANCESCA MALLAMACI;FABRIZIO FABRIZI;PIERGIORGIO MESSA;ANTONIO FACCIORUSSO;RICCARDO IEVA;PIER LUIGI PELLEGRINO;ROSARIO MAGALDI;VINCENZO DE FRANCESCO;MICHELA CAMPO;MATTEO RINALDI;LUIGI DI MARTINO;GIUSEPPINA SPINOSA;RAFFAELE ANTONETTI;MARIA IOLE NATALICCHIO;GIOVANNI TRIPEPI;A. CHIALÀ;APULIAN CHILDHOOD-ONSET DIABETES REGISTRY WORKGROUP;FLORENZO IANNONE;GIOVANNI LAPADULA;GIUSEPPE LOPALCO","342;330;330;123;63;58;57;52;43;39;37;36;29;27;24;23;23;23;23;23","VINCENZO DE FRANCESCO;RAFFAELE ANTONETTI;CARMINE ZOCCALI;FRANCESCA MALLAMACI;ROSARIO MAGALDI;RICCARDO IEVA;ANTONIO RUGGIERO;G MAFFEI;GIOVANNI TRIPEPI;GIUSEPPINA SPINOSA;LUCA MACARINI;MARIA IOLE NATALICCHIO;MATTEO GRAVINA;MATTEO RINALDI;MICHELE CORREALE;PIER LUIGI PELLEGRINO;SILVANA CAPALBO;A. CHIALÀ;ALESSANDRA LALLA;ANDREA CUCULO","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PHILOSOPHY;ECONOMICS;GEOGRAPHY;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","51;10;7;6;3;3;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;RADIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;ONCOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;PHYSICAL THERAPY;ANESTHESIA;BIOCHEMISTRY;EPISTEMOLOGY;OBSTETRICS;OPTICS;QUANTUM MECHANICS;EMERGENCY MEDICINE;FAMILY MEDICINE;MECHANICAL ENGINEERING;OPERATING SYSTEM;PALEONTOLOGY;PEDIATRICS;VIROLOGY","39;13;11;10;8;7;7;6;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2","CANCER;ADVERSE EFFECT;DISEASE;DIABETES MELLITUS;HEART FAILURE;MYOCARDIAL INFARCTION;ATRIAL FIBRILLATION;INCIDENCE (GEOMETRY);KIDNEY DISEASE;MYELOID LEUKEMIA;NEUROLOGY;PREGNANCY;PROSPECTIVE COHORT STUDY;RECEPTOR;STOMACH;ABLATION;ANALGESIC;ANGIOGRAPHY;ANGIOPLASTY;CATHETER;CLINICAL TRIAL;CONCOMITANT;CONFIDENCE INTERVAL;DISCONTINUATION;DUODENUM;GENE;LYMPHOMA;NEUROSURGERY;PROCESS (COMPUTING);QUALITY (PHILOSOPHY);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;RESUSCITATION;RETROSPECTIVE COHORT STUDY;TUMOR NECROSIS FACTOR ALPHA;VIRUS;VITAMIN D AND NEUROLOGY","9;8;7;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONARY ANGIOGRAPHY;BREAST CANCER;CANCER PAIN;CARDIOMYOPATHY;CARDIOPULMONARY RESUSCITATION;CATHETER ABLATION;EJECTION FRACTION;FETUS;IMATINIB;METASTASIS;OPIOID;PSORIATIC ARTHRITIS;ADALIMUMAB;ALLELE;ANGIOMA;ANTRUM;BIRTH WEIGHT;BRACHYTHERAPY;BURKITT'S LYMPHOMA;CARCINOGENESIS;CARDIAC MAGNETIC RESONANCE;CAUDA EQUINA;CAUSE OF DEATH;CEPHALOSPORIN;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;CHROMOSOMAL TRANSLOCATION;CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION;CLINICAL ENDPOINT;COGNITIVE IMPAIRMENT;COLORECTAL CANCER;CONTINUOUS POSITIVE AIRWAY PRESSURE;CONVENTIONAL PCI;DEPRESSIVE SYMPTOMS;DIGITALIS;DISEASE REGISTRY;ETANERCEPT;EXHALED BREATH CONDENSATE;GASTRIC EMPTYING;GENOTYPE;GESTATIONAL AGE;HAZARD RATIO;HEALTH PROFESSIONALS;HELICOBACTER INFECTIONS;HEPATITIS B VIRUS;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;INFLAMMATORY BOWEL DISEASE;INFLIXIMAB;INTERLEUKIN;INTRACLASS CORRELATION;LOW BIRTH WEIGHT;MANTLE CELL LYMPHOMA;MEAN AIRWAY PRESSURE;MYELOID SARCOMA;NEONATAL SEPSIS;PARKINSON'S DISEASE;PERCUTANEOUS CORONARY INTERVENTION;PERIPHERAL BLOOD MONONUCLEAR CELL;PERIPHERAL NEUROPATHY;PHASES OF CLINICAL RESEARCH;PROINFLAMMATORY CYTOKINE;PSORIASIS AREA AND SEVERITY INDEX;QUALITY ASSURANCE;QUARTILE;RESTENOSIS;SUPRAVENTRICULAR TACHYCARDIA;TOLERABILITY;TYPE 1 DIABETES;TYROSINE-KINASE INHIBITOR;VALVE REPLACEMENT;VIRAL LOAD;VITAMIN D DEFICIENCY;WARFARIN;WEIGHT LOSS","3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NILOTINIB;ANTIRETROVIRAL THERAPY;ARTERY DISSECTION;ATRIAL TACHYCARDIA;BASIC LIFE SUPPORT;CARDIAC ABLATION;CEFIXIME;CHORIOAMNIONITIS;CORONARY STENT;CRYOGLOBULINEMIA;DASATINIB;DNA MISMATCH REPAIR;ENTHESITIS;GASTROPARESIS;GENOTYPING;GERIATRIC DEPRESSION SCALE;HBSAG;HLA-B;KRAS;KRUKENBERG TUMOR;LEFT ATRIAL APPENDAGE OCCLUSION;LEVODOPA;LYMPHOVASCULAR INVASION;MACE;MECONIUM;METASTATIC BREAST CANCER;METHYLENETETRAHYDROFOLATE REDUCTASE;MINI–MENTAL STATE EXAMINATION;NEONATAL RESPIRATORY DISTRESS SYNDROME;OXYCODONE;PHILADELPHIA CHROMOSOME;PLACENTA;PREMATURE RUPTURE OF MEMBRANES;PRETERM DELIVERY;PRIMARY ANGIOPLASTY;RUPTURE OF MEMBRANES;SENTINEL LYMPH NODE;SENTINEL NODE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ITALY;ADULT;TREATMENT OUTCOME;ATRIAL FIBRILLATION;RENAL INSUFFICIENCY, CHRONIC;THALASSEMIA;ADOLESCENT;AGED, 80 AND OVER;HEART ATRIA;RETROSPECTIVE STUDIES;PYRIMIDINES;TAKOTSUBO CARDIOMYOPATHY;VASODILATOR AGENTS;ARTHRITIS, PSORIATIC","33;23;22;19;16;15;15;11;9;8;7;7;6;6;6;6;5;5;5;4","ATRIAL FIBRILLATION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;EFFICACY AND RESISTANCE IN CML TREATMENT;ACUTE MYELOID LEUKEMIA;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EPIDEMIOLOGY AND CAUSES OF PRETERM BIRTH;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;ETHICAL CONSIDERATIONS IN MEDICAL RESEARCH PARTICIPATION;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;TREATMENT;BREAST CANCER;CANCER PAIN;CATHETER ABLATION;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CONCOMITANT;DISCONTINUATION;HEMODIALYSIS;HUMAN MILK COMPOSITION;PAIN MANAGEMENT;RADIOFREQUENCY ABLATION;TAKOTSUBO SYNDROME;TRANSCATHETER AORTIC-VALVE REPLACEMENT;3D PRINTED;ABACAVIR;ANGIOMA;ANTIMICROBIAL RESISTANCE GENES;APPENDAGE","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","ATRIAL FIBRILLATION;BREAST CANCER;CANCER PAIN;CANCER PATIENTS;CHRONIC KIDNEY;CLINICAL OUTCOMES;KIDNEY DISEASE;LEFT ATRIAL;LOCALLY ADVANCED;MULTICENTER STUDY;PSORIATIC ARTHRITIS;SINGLE-ARM STUDY;TAKOTSUBO CARDIOMYOPATHY;ACADEMIC SINGLE-ARM;ADMISSION LEVELS;ADULT PATIENTS;ADVANCED CERVICAL;ADVANCED RECTAL;ADVERSE EVENTS;ALL-COMER REGISTRY;ALLOGENEIC STEM;AMPLIFICATION RETROSPECTIVE;ANTI-TUMOR NECROSIS;AORTIC VALVE;APPENDAGE CLOSURE;ARTERY DISSECTION;ARTHRITIS TAKING;ASSOCIATION THERAPY;ASSURANCE PROGRAM;ASYSTEMATIC REVIEW","2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;PORTAL HYPERTENSION;MALE BREAST;MELD SCORE;ADVERSE EVENTS;BOVINE CAPRINE;CANCER PAIN;MEDIAN AGE;RECRUITMENT MANEUVER;SURFACTANT ADMINISTRATION;TRIPLE THERAPY;WHEY PROTEIN;DAY TRIPLE;DOUBLE-DOSE THERAPY;DRUG DISCONTINUATION;GRADE TOXICITIES;HR CI;LD RATE;LIVER DISEASE;LOWER LEVELS;LYMPH NODE;MAGNETIC RESONANCE;OVINE MILK;PATIENTS LD;PROTEIN FRACTION;PROTEIN FRACTIONS;RESONANCE IMAGING;AXILLARY LYMPH;BP PALINDROME;BRAIN CAVERNOMATOSIS","8;8;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2",19,0.37,7.12,4.5,2,1.75,1,8.75,0,0,1,6,1,0,4,0,0,1,2,3.25,7,0,0,47.5,47.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,3.57,156.71,9.86,2,0.29,30.86,0,0,2,0,0,0,1,4,0,7,0,0,0,0,0,0,0,6,1,0,7,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;36 CREATIVE ARTS AND WRITING;3603 MUSIC;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4204 MIDWIFERY","6;3;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PEDIATRIC;RARE DISEASES;CANCER;CARDIOVASCULAR;HEMATOLOGY;INFANT MORTALITY;LUNG;PATIENT SAFETY;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;DIGESTIVE DISEASES;HEART DISEASE;LIVER DISEASE;MENTAL HEALTH","7;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.4 SURGERY;6.7 PHYSICAL","3;1;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2017,68,14.1323529411765,2.13235294117647,0.468965517241379,0.279411764705882,0.264705882352941,0.235294117647059,0.63235294117647,1,33,13,10,3,0.49,0.19,0.15,0.04,16.25,0.551314166577093,0.308823529411765,0.911764705882353,3.6530612244898,0.370656408439356,0.296703296703297,0.228956228956229,0.32034632034632,"GIROLAMO SPAGNOLETTI;MARCO PAGLIALONGA;ROBERTO LORENZETTI;VINCENZO MONDA;GIOVANNI MESSINA;ANTONIETTA MESSINA;MATTEO DI BIASE;S. ROMITO;CLAUDIA CARDONE;ANTONIO TURSI;NICOLA DELLA VALLE;MONICA SALERNO;FRANCESCO PAOLO CANTATORE;FRANCESCO SESSA;POTITO D’AGROSA;TERESA TROIANI;ANTONIO J. D’ANTUONO;CARLO AVOLIO;LEONARDO ALLEGRETTA;GABRIELLA MARSALA","5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","ANGELO ZULLO;GIROLAMO SPAGNOLETTI;MARCO PAGLIALONGA;POTITO D’AGROSA;ANTONIO J. D’ANTUONO;FRANCESCO COLUCCI;MATTEO DI BIASE;NATALE DANIELE BRUNETTI;DOMENICO LOIZZI;FRANCESCO SOLLITTO;DOMENICO STAFFIERE;PATRIZIA EMILIANI;ANNALUCIA CARBONE;MASSIMO CONESE;FRANCESCO PAOLO CANTATORE;ANNA NUNZIA POLITO;ANTONELLO BELLOMO;ROBERTO LORENZETTI;FRANCESCO SANTORO;RICCARDO POLIMENO","1.2;1;1;0.6;0.6;0.6;0.58;0.49;0.42;0.42;0.4;0.4;0.39;0.39;0.39;0.37;0.36;0.35;0.34;0.33","GIROLAMO SPAGNOLETTI;MARCO PAGLIALONGA;S. ROMITO;NICOLA DELLA VALLE;FRANCESCO PAOLO CANTATORE;CARLO AVOLIO;GABRIELLA MARSALA;MICHELE CORREALE;CARMINE ZOCCALI;ANGELO ZULLO;FRANCESCO COLUCCI;DOMENICO LOIZZI;FRANCESCO SOLLITTO;ROSARIO MAGALDI;NICOLAS M. VAN MIEGHEM;FRANCESCA SANGUEDOLCE;MARIA PIA FOSCHINO BARBARO;MASSIMO CONESE;MASSIMO PETTOELLO‐MANTOVANI;VITO PROCACCI","5;5;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ANGELO ZULLO;GIROLAMO SPAGNOLETTI;MARCO PAGLIALONGA;FRANCESCO COLUCCI;DOMENICO LOIZZI;FRANCESCO SOLLITTO;DOMENICO STAFFIERE;PATRIZIA EMILIANI;MASSIMO CONESE;FRANCESCO PAOLO CANTATORE;ANNA NUNZIA POLITO;S. GORGOGLIONE;G MAFFEI;CARLO AVOLIO;ROSATEA QUERCIA;GIULIA PACELLA;MICHELE CORREALE;TOMMASO MARTINO;MICHELE CASSANO;CARMINE ZOCCALI","1.2;1;1;0.6;0.42;0.42;0.4;0.4;0.39;0.39;0.37;0.33;0.33;0.32;0.31;0.31;0.3;0.29;0.29;0.27","GIUSEPPE LUCISANO;ALDO P. MAGGIONI;ANTONIO NICOLUCCI;CRISTIANA SCARANNA;FABRIZIO CAPPELLINI;FRANCESCO GIORGINO;GABRIELE RICCARDI;GIORGIO SESTI;LUCIA RICCI‐VITIANI;MARIA MASULLI;MASSIMO BOEMI;MICHELE SACCO;OLGA VACCARO;PAOLO MOCARELLI;STEFANO SIGNORINI;A. CORSI;A. DI BENEDETTO;A. RANCHELLI;A.C. BABINI;AGOSTINO CONSOLI","553;512;512;512;512;512;512;512;512;512;512;512;512;512;512;256;256;256;256;256","OLGA LA MACCHIA;MICHELE CORREALE;CARMINE ZOCCALI;MASSIMO CONESE;GABRIELLA MARSALA;GIOVANNI TRIPEPI;M. DI BISCEGLIE;ALBERTO SCIUSCO;GILDA CINNELLA;M. DAMBROSIO;NICOLA DELLA VALLE;PASQUALE RAIMONDO;GIANFRANCO COSTANTINO;RICCARDO IEVA;BEN REN;CARL SCHULTZ;LENNART VAN GILS;LUIGI DI MARTINO;MARCEL L. GELEIJNSE;NICOLAS M. VAN MIEGHEM","256;103;64;64;60;48;43;42;42;42;42;42;41;34;31;31;31;31;31;31","GIROLAMO SPAGNOLETTI;MARCO PAGLIALONGA;S. ROMITO;GABRIELLA MARSALA;CARMINE ZOCCALI;NICOLA DELLA VALLE;FRANCESCO COLUCCI;MICHELE CORREALE;ROSARIO MAGALDI;ANNA NUNZIA POLITO;CARLO AVOLIO;FRANCESCA SANGUEDOLCE;FRANCESCO PAOLO CANTATORE;GIANFRANCO COSTANTINO;LUIGI DI MARTINO;M. DI BISCEGLIE;MASSIMO CONESE;MICHELE CASSANO;PAOLA RITA DI CORATO;PATRIZIA EMILIANI","5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;ECONOMICS;PSYCHOLOGY;BUSINESS;ENGINEERING;MATERIALS SCIENCE;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;GEOLOGY;HISTORY;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","66;15;5;4;3;3;3;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PATHOLOGY;PSYCHIATRY;EMERGENCY MEDICINE;GENETICS;ANESTHESIA;INTENSIVE CARE MEDICINE;PHYSICAL THERAPY;PEDIATRICS;RADIOLOGY;DERMATOLOGY;IMMUNOLOGY;BIOCHEMISTRY;MACROECONOMICS;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;NURSING;UROLOGY","46;16;10;9;8;8;8;8;7;7;6;6;6;5;5;4;4;3;3;3;3;3;3","CANCER;ADVERSE EFFECT;DISEASE;POPULATION;MYOCARDIAL INFARCTION;RESUSCITATION;CLINICAL TRIAL;CONFIDENCE INTERVAL;GENE;RECEPTOR;ASTHMA;CHEMOTHERAPY;COMBINATION THERAPY;DEPRESSION (ECONOMICS);EXACERBATION;HEART FAILURE;LUNG;PREGNANCY;QUALITY OF LIFE (HEALTHCARE);AORTIC VALVE;BIOPSY;BLOOD PRESSURE;COHORT;CONCORDANCE;CORONARY ARTERY DISEASE;DEFORMITY;DISCONTINUATION;EMERGENCY DEPARTMENT;EVEROLIMUS;HEMODYNAMICS;INCIDENCE (GEOMETRY);INTERQUARTILE RANGE;LUNG CANCER;MULTIPLE SCLEROSIS;NECROTIZING ENTEROCOLITIS;NOSE;NOTIONAL AMOUNT;OTORHINOLARYNGOLOGY;PATHOGENESIS;PULMONARY HYPERTENSION;PUNCHING;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;RETRAINING;RHEUMATOID ARTHRITIS;SEPSIS;STIMULATION;STROKE (ENGINE);TRANSPLANTATION;TUBERCULOSIS;TUMOR NECROSIS FACTOR ALPHA","12;10;10;8;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INFLIXIMAB;ADALIMUMAB;CARDIOPULMONARY RESUSCITATION;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;INFLAMMATORY BOWEL DISEASE;ULCERATIVE COLITIS;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;ETANERCEPT;NASAL SEPTUM;NOSE DISEASES;PERFORATION;PROGRESSIVE DISEASE;PROSTATE;PSORIATIC ARTHRITIS;RHINOLOGY;SEPTOPLASTY;TOLERABILITY","6;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","BASIC LIFE SUPPORT;AROMATASE;CALPROTECTIN;COLECTOMY;GOLIMUMAB;REGORAFENIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ABATACEPT;ALTERNATIVE SPLICING;ANEMIA OF CHRONIC DISEASE;BOSENTAN;CANNABINOID RECEPTOR;CATHEPSIN K;CEFIXIME;COPY-NUMBER VARIATION;DEVELOPMENTAL DYSLEXIA;DISEASE MANAGEMENT;DNA METHYLATION;FUNCTIONAL RESIDUAL CAPACITY;GLIMEPIRIDE;HAMILTON RATING SCALE FOR DEPRESSION;IRINOTECAN;KRAS;LACTOBACILLUS RHAMNOSUS;METASTATIC BREAST CANCER;MISSENSE MUTATION;NIVOLUMAB;NUCLEOTIDE EXCISION REPAIR;OSTEOPENIA;OXYCODONE;PAIN LADDER;PIOGLITAZONE;PITTSBURGH SLEEP QUALITY INDEX;PLASMA CELL NEOPLASM;PRIMARY MOTOR CORTEX;PROSTATE CARCINOMA;PROSTATECTOMY;RNA SPLICING;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN;TNF INHIBITOR;UREA BREATH TEST;USTEKINUMAB;WERNICKE'S ENCEPHALOPATHY","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;ITALY;COLITIS, ULCERATIVE;BREAST NEOPLASMS;AGED, 80 AND OVER;ANTI-BACTERIAL AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;HEART VENTRICLES;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;ANDROSTADIENES;ANTIBODIES, MONOCLONAL;BONE NEOPLASMS","40;27;24;21;18;15;14;10;9;8;6;6;6;6;6;6;6;5;5;5","MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MANAGEMENT OF VALVULAR HEART DISEASE;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;NASAL SURGERY TECHNIQUES AND OUTCOMES;RHEUMATOID ARTHRITIS;ANESTHESIA AND SEDATION MANAGEMENT;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;ASTHMA;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CARDIAC REHABILITATION AND CARDIOVASCULAR HEALTH INTERVENTIONS;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT","4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","TREATMENT;CLINICAL ENDPOINT;COMBINATION THERAPY;DEPRESSION (ECONOMICS);DRUG-INDUCED COLITIS;ULCERATIVE COLITIS;ADVANCED LIFE SUPPORT;BREAST CANCER;CONCORDANCE;CPR QUALITY;DISCONTINUATION;ECHOCARDIOGRAPHY;EVEROLIMUS;EXEMESTANE;GOLIMUMAB;INTERQUARTILE RANGE;METASTATIC COLORECTAL CANCER;MICROSCOPIC COLITIS;NECROTIZING ENTEROCOLITIS;NONINVASIVE VENTILATION","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CARDIOPULMONARY RESUSCITATION;CLINICAL OUTCOME;METASTATIC COLORECTAL;ULCERATIVE COLITIS;ADVANCED BREAST;AORTIC VALVE;ARTERIAL HYPERTENSION;BASIC LIFE;BOWEL DISEASES;CARDIOVASCULAR EVENTS;CHEMOREFRACTORY METASTATIC;COLORECTAL CANCER;EMERGENCY DEPARTMENT;EXPERTS OPINION;INFLAMMATORY BOWEL;ITALIAN SOCIETY;LIFE SUPPORT;MULTICENTER STUDY;NASAL SEPTAL;NONINVASIVE VENTILATION;OBSERVATIONAL STUDY;PARAVALVULAR LEAKAGE;PATIENTS PTS;PERFORATIONS SIR;PRACTICAL SKILLS;PRIMARY INFLAMMATORY;PSORIATIC ARTHRITIS;PULMONARY ARTERIAL;RHINOLOGY EXPERTS","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GASTRIC ACIDITY;LAM AVULSION;MONTHS CI;ACIDITY EXPOSURE;ADVERSE EVENTS;COMBINATION THERAPY;FRAME ECCENTRICITY;STENT FRAME;UPFRONT COMBINATION;VISCERAL FAT;ADVISORY BOARD;BRISTOL-MYERS SQUIB;CLINICAL RESPONSE;EPITHELIOID HEMANGIOENDOTHELIOMA;HR CI;ICU ADMISSION;METASTATIC SETTING;PATIENTS TREATED;PLASMA SAMPLES;SAFETY PROFILE;ZSI DEVICE;ADVISORY BOARDS;BIRTH WEIGHT;BREAST CANCER;CLINICAL OUTCOMES;COMPUTED TOMOGRAPHY;DOUBLE ORAL;ECHOCARDIOGRAPHIC PARAMETERS;HC CELLS;IPAH PATIENTS","22;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4",24,0.35,7.7,8,1.75,2.5,0,6.75,1,0,1,9,0,0,7.25,5,8,1,3,6.25,3.25,0,0,54,54,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,3.75,787.25,4.26,1,0.25,85.75,0,0,0,0,1,0,0,3,0,1,3,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Denmark;Japan;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;3;1;1;1;1","CLINICAL RESEARCH;ASSISTIVE TECHNOLOGY;BIOENGINEERING;COMPARATIVE EFFECTIVENESS RESEARCH;PATIENT SAFETY;ACUTE RESPIRATORY DISTRESS SYNDROME;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DEPRESSION;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG;MAJOR DEPRESSIVE DISORDER;MENTAL HEALTH;RARE DISEASES;SERIOUS MENTAL ILLNESS","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;MENTAL HEALTH;RESPIRATORY","1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2018,71,15.1408450704225,1.87323943661972,0.533834586466165,0.225352112676056,0.169014084507042,0.0985915492957746,0.563380281690141,1,22,20,11,14,0.31,0.28,0.15,0.2,12.51,0.409956011909213,0.225352112676056,0.943661971830986,3.54929577464789,0.466282670741536,0.32421875,0.370909090909091,0.311688311688312,"GABRIELLA MARSALA;FRANCESCO LAVANO;BEATRICE GALLAI;MATTEO DI BIASE;ANNA NUNZIA POLITO;ROSA MAROTTA;MONICA SALERNO;MICHELE SORRENTINO;FRANCESCO CERRONI;ELISABETTA PICCIOCCHI;PAOLO MURABITO;CARMINE ZOCCALI;GABRIELE TRIPI;DIEGO GERACI;SERENA MARIANNA LAVANO;MARIO GIUSEPPE CHISARI;FRANCESCO SESSA;NICOLA CASCAVILLA;CARLO AVOLIO;FRANCESCA MALLAMACI","8;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4","CARMINE ZOCCALI;FRANCESCA MALLAMACI;GAETANO RIZZI;DARIO GALANTE;MATTEO DI BIASE;GIOVANNI CONSANI;NATALE DANIELE BRUNETTI;GABRIELLA MARSALA;LUCA MACARINI;ANDREA SANTAMATO;CARLO AVOLIO;ELENA CARAPELLE;GRAZIA CASAVECCHIA;ANNA NUNZIA POLITO;GIOVANNI MESSINA;MICHELE CORREALE;FRANCESCA DE MARINIS;CESARE HASSAN;RAFFAELE MANTA;BRUNO ANNIBALE","1.29;1.24;1;0.78;0.64;0.5;0.46;0.41;0.41;0.4;0.37;0.37;0.36;0.36;0.34;0.3;0.29;0.29;0.29;0.29","GABRIELLA MARSALA;MATTEO DI BIASE;ANNA NUNZIA POLITO;CARMINE ZOCCALI;CARLO AVOLIO;FRANCESCA MALLAMACI;NATALE DANIELE BRUNETTI;ELENA CARAPELLE;MICHELE CORREALE;MARIA IOLE NATALICCHIO;TOMMASO MARTINO;ANDREA SANTAMATO;BARBARA INFANTE;G. D’ORSI;DARIO GALANTE;ALESSANDRA LALLA;TERESA SANTANTONIO;LIVIO TULLO;GRAZIA CASAVECCHIA;GIOVANNA D’ANDREA","8;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","CARMINE ZOCCALI;FRANCESCA MALLAMACI;GAETANO RIZZI;DARIO GALANTE;MATTEO DI BIASE;NATALE DANIELE BRUNETTI;GABRIELLA MARSALA;ANDREA SANTAMATO;CARLO AVOLIO;ELENA CARAPELLE;GRAZIA CASAVECCHIA;ANNA NUNZIA POLITO;MICHELE CORREALE;GIANPAOLO GRILLI;ANNA RAGO;MARIA IOLE NATALICCHIO;F. PERFETTO;TOMMASO MARTINO;G. D’ORSI;ALESSANDRA LALLA","1.29;1.24;1;0.78;0.64;0.46;0.41;0.4;0.37;0.37;0.36;0.36;0.3;0.29;0.28;0.28;0.27;0.24;0.24;0.24","GIOVANNI MESSINA;FRANCESCO SESSA;GABRIELLA MARSALA;MONICA SALERNO;ANNA VALENZANO;ANTONIETTA MESSINA;VINCENZO MONDA;CARMINE ZOCCALI;ALESSANDRO CONTE;ELISABETTA CASELLI;FILIPPO BERLOCO;GABRIELE PELISSERO;GIOVANNI VILLONE;LORENZO TOGNON;LUCA ARNOLDO;MADDALENA COCCAGNA;NELSO TRUA;PAOLA ANTONIOLI;ROSANNA TARRICONE;SANTE MAZZACANE","92;85;85;85;81;81;81;76;73;73;73;73;73;73;73;73;73;73;73;73","GABRIELLA MARSALA;GIOVANNI VILLONE;TERESA SANTANTONIO;FRANCESCA MALLAMACI;G MAFFEI;PIO LIBERATORE;GIANFRANCO COSTANTINO;MARIA IOLE NATALICCHIO;ANTONIO RUGGIERO;CARLO DI STASO;GRAZIA CASAVECCHIA;GUGLIELMO MAULUCCI;CARMINE ZOCCALI;ROMANO BUCCI;OLGA LAMACCHIA;SILVANA CAPALBO;BARBARA INFANTE;GIOVANNA D’ANDREA;ALESSANDRA LALLA;CARLO AVOLIO","81;73;53;51;49;49;46;44;40;40;40;40;36;34;33;33;32;32;31;31","ANNA NUNZIA POLITO;FRANCESCA MALLAMACI;ALESSANDRA LALLA;ANDREA SANTAMATO;CARLO AVOLIO;ELENA CARAPELLE;G. D’ORSI;GABRIELLA MARSALA;MARIA IOLE NATALICCHIO;MARIA TERESA DI CLAUDIO;TERESA SANTANTONIO;TOMMASO MARTINO;BARBARA INFANTE;GIOVANNA D’ANDREA;CARMINE ZOCCALI;DARIO GALANTE;LIVIO TULLO;MICHELE CORREALE;SILVANA CAPALBO;ANDREA CUCULO","6;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;1","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;ENGINEERING;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","67;9;9;8;4;4;4;2;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;INTENSIVE CARE MEDICINE;PATHOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;ANESTHESIA;ONCOLOGY;RADIOLOGY;PEDIATRICS;PHYSICAL THERAPY;BIOCHEMISTRY;ENDOCRINOLOGY;FAMILY MEDICINE;GASTROENTEROLOGY;GENETICS;NEUROSCIENCE;PHYSICAL MEDICINE AND REHABILITATION;CANCER RESEARCH;IMMUNOLOGY;NUCLEAR MEDICINE;NURSING;OPTICS;PSYCHOTHERAPIST","48;18;17;10;10;9;9;7;7;7;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3","DISEASE;ADVERSE EFFECT;POPULATION;RANDOMIZED CONTROLLED TRIAL;HEART FAILURE;ALTERNATIVE MEDICINE;BLOOD PRESSURE;CANCER;DISCONTINUATION;MAGNETIC RESONANCE IMAGING;ATRIAL FIBRILLATION;COHORT;EPILEPSY;GENE;KIDNEY DISEASE;LYMPHOMA;NEPHROLOGY;QUALITY OF LIFE (HEALTHCARE);ARTHRITIS;ATHLETES;CAPSULE ENDOSCOPY;CARCINOMA;CHEMOTHERAPY;CONCORDANCE;CONFIDENCE INTERVAL;DIABETES MELLITUS;ELECTROENCEPHALOGRAPHY;ENDOSCOPY;HEALTH CARE;HEART DISEASE;HEMATOLOGY;HEPATITIS C;INCIDENCE (GEOMETRY);LESION;LIVER DISEASE;MIGRAINE;MULTIVARIATE ANALYSIS;MYOTONIC DYSTROPHY;PROSPECTIVE COHORT STUDY;PULMONARY ARTERY;PULMONARY HYPERTENSION;RADIATION THERAPY;RANGE OF MOTION;RENAL CELL CARCINOMA;RETROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS;RHEUMATOLOGY;SECOND OPINION;THALASSEMIA;TRANSPLANTATION","11;6;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;ADALIMUMAB;CARDIOMYOPATHY;COLORECTAL CANCER;DISEASE BURDEN;EJECTION FRACTION;FLUID-ATTENUATED INVERSION RECOVERY;HYPERINTENSITY;INFLIXIMAB;OSTEOARTHRITIS;PLACEBO;ACUTE DECOMPENSATED HEART FAILURE;ALBUMINURIA;AMBULATORY BLOOD PRESSURE;ANGIOTENSIN-CONVERTING ENZYME;ATRIAL FLUTTER;AUTOANTIBODY;BASAL (MEDICINE);BICUSPID AORTIC VALVE;BIRTH WEIGHT;BISPECTRAL INDEX;BRACHIAL ARTERY;BRIEF PAIN INVENTORY;CAPSULITIS;CARDIAC FUNCTION CURVE;CARDIORENAL SYNDROME;CATALASE;CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION;CLONOGENIC ASSAY;COELIAC DISEASE;CONTINUOUS POSITIVE AIRWAY PRESSURE;DACARBAZINE;DESFLURANE;DIFFUSION MRI;DILATED CARDIOMYOPATHY;DYSLIPIDEMIA;EMERGENCE DELIRIUM;ENDOCRINE SYSTEM;EPIDERMAL GROWTH FACTOR RECEPTOR;ETANERCEPT;EX VIVO;EXON;EXPANDED DISABILITY STATUS SCALE;EZETIMIBE;FOOTBALL PLAYERS;FRAMINGHAM RISK SCORE;GESTATIONAL AGE;GLOTTIS;HAZARD RATIO;HEART RATE;HEART TRANSPLANTATION;HEPATITIS C VIRUS;HODGKIN LYMPHOMA;ICTAL;IMATINIB;IMMUNOTHERAPY;IMPLANTABLE LOOP RECORDER;INFLAMMATORY BOWEL DISEASE;ISOCENTER;LARYNGOSCOPY;LIPOPROTEIN;MANUAL THERAPY;MEAN AIRWAY PRESSURE;METASTASIS;METHYLATION;MITOCHONDRIAL DNA;MOTOR CORTEX;MRI SCAN;MULTICENTER STUDY;MUTATION;NATALIZUMAB;NEUTROPENIA;NON-RAPID EYE MOVEMENT SLEEP;PAPILLARY FIBROELASTOMA;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PILONIDAL DISEASE;PNEUMOMEDIASTINUM;POLYSOMNOGRAPHY;PRIMARY HEADACHE;PROTOCOL (SCIENCE);PSORIASIS AREA AND SEVERITY INDEX;PSORIATIC ARTHRITIS;RADIOFREQUENCY ABLATION;RADIOSENSITIVITY;REMIFENTANIL;RENAL TRANSPLANT;RHEUMATOID FACTOR;RITUXIMAB;SALVAGE THERAPY;SHOULDER IMPINGEMENT SYNDROME;STEADY-STATE FREE PRECESSION IMAGING;SUBCUTANEOUS EMPHYSEMA;SYRINGOMYELIA;TEMOZOLOMIDE;TENDINITIS;TRACHEAL INTUBATION;TRANSCRANIAL MAGNETIC STIMULATION;TYPE 2 DIABETES;TYROSINE KINASE;TYROSINE-KINASE INHIBITOR;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS;VENTRICULAR PACING","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABATACEPT;ACE INHIBITOR;APOLIPOPROTEIN A1;AUTONOMIC NERVOUS SYSTEM;BRENTUXIMAB VEDOTIN;CALPROTECTIN;COLECTOMY;CROSSOVER STUDY;ENDOCRINE DISEASE;GEFITINIB;HEART RATE VARIABILITY;KRAS;LARYNGOSCOPES;LDL RECEPTOR;METHYLTRANSFERASE;NILOTINIB;NIVOLUMAB;OXALIPLATIN;PARASOMNIA;PRIMARY MOTOR CORTEX;RIOCIGUAT;USTEKINUMAB","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;MIDDLE AGED;ITALY;AGED;ADULT;HEART FAILURE;AGED, 80 AND OVER;HYPERTENSION;CARDIOVASCULAR DISEASES;PROSPECTIVE STUDIES;TREATMENT OUTCOME;BRAIN NEOPLASMS;CARCINOMA, RENAL CELL;KIDNEY NEOPLASMS;RENAL INSUFFICIENCY, CHRONIC;YOUNG ADULT;ADOLESCENT","40;31;29;23;21;20;18;17;13;11;10;9;9;9;8;7;7;7;7;6","BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CHOLESTEROL-LOWERING TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DEVELOPMENTAL PERSPECTIVE ON MOTOR SKILL COMPETENCE;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;ADVANCEMENTS IN LUNG CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANESTHESIA AND SEDATION MANAGEMENT;ATRIAL FIBRILLATION;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;BATTERY RECYCLING AND RARE EARTH RECOVERY;BIOLOGICAL EFFECTS OF ELECTROMAGNETIC FIELDS;CANCER IMMUNOTHERAPY;CANCER OF UNKNOWN PRIMARY SITE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","DISCONTINUATION;CLINICAL ENDPOINT;ECHOCARDIOGRAPHY;NEPHROLOGY;TREATMENT;ADAMTS13;CAPSULE ENDOSCOPY;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;CHOLESTEROL-LOWERING;CONCORDANCE;DOUBLE-BALLOON ENTEROSCOPY;FLUID-ATTENUATED INVERSION RECOVERY;HEMATOLOGY;HEPATITIS C;HYPERTENSION;LIVER DISEASE;PAIN MODULATION;SECOND OPINION;ABATACEPT","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","RANDOMIZED CONTROLLED;ADAMTS ACTIVITY;BLOOD PRESSURE;BOWEL VIDEO;CAPSULE ENDOSCOPY;CARDIAC COMPLICATIONS;CARDIOVASCULAR IMAGING;CELL CARCINOMA;DISEASE BURDEN;DYSTROPHY TYPE;ENDOSCOPY VCE;EVALUATING RECORDINGS;II STUDY;KIDNEY DISEASE;LIVER DISEASE;LONG-TERM FOLLOW-UP;LONGITUDINAL STUDY;METASTATIC RENAL;MYOTONIC DYSTROPHY;OBSERVATIONAL STUDY;PHASE II;PLASMIC SCORE;PULMONARY HYPERTENSION;RENAL CELL;SOUTHERN ITALY;THALASSEMIA MAJOR;THROMBOTIC MICROANGIOPATHIES;TRAINED NURSES;TRANSPLANT PATIENTS;VIDEO CAPSULE","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LEFT VENTRICULAR;PLASMIC SCORE;VOLUME OVERLOAD;BARI ITALY;BRAIN MRI;TYPE DIABETES;CYCLIN-DEPENDENT KINASE;OVARIAN CANCER;PACING THRESHOLD;THROMBOTIC MICROANGIOPATHIES;ADVERSE EVENTS;ALTERATED SIGNAL;GROWTH FACTOR;LUNG CONGESTION;ODDS RATIO;SODIUM INTAKE;ACE INHIBITOR;ADAMTS ACTIVITY;BRAF VE;CONSECUTIVE PATIENTS;DIFFUSION-WEIGHTED-IMAGING DWI;EJECTION FRACTION;FLAIR SEQUENCES;FLUID OVERLOAD;FLUID-ATTENUATED-INVERSION-RECOVERY FLAIR;FOGGIA ITALY;ITALY NEPHROLOGY;PACING FAILURE;PREOPERATIVE TREATMENT;RA PATIENTS","10;9;9;7;7;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",27,0.38,7,10.5,1,0,2,1,0,0,1,11,0,0,11,0,0,1,5,9,2.25,0,0,59.5,59.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,4,2375,6.74,3,0.5,116.83,0,0,0,0,3,0,1,2,0,4,2,0,0,0,0,0,0,6,0,0,6,0,0,0,0,0,0,0,0,0,"Italy;Spain;United States","5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","5;4;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;CARDIOVASCULAR;DIGESTIVE DISEASES;HEART DISEASE;HEPATITIS;INFECTIOUS DISEASES;LIVER DISEASE;CHRONIC LIVER DISEASE AND CIRRHOSIS;EMERGING INFECTIOUS DISEASES;GENETICS;HEART DISEASE - CORONARY HEART DISEASE;HEPATITIS - B;HEPATITIS - C;LUNG;RARE DISEASES","6;5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","INFECTION;CARDIOVASCULAR","2;1","6.1 PHARMACEUTICALS;6.4 SURGERY","4;1","COLON AND RECTAL CANCER","1","5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE","8","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;49 MATHEMATICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;37 EARTH SCIENCES;3705 GEOLOGY;40 ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;4904 PURE MATHEMATICS","6;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PREVENTION","1;1;1","GENERIC HEALTH RELEVANCE;INFECTION","1;1",NA,NA,"CLINICAL","1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","1;1",NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2019,41,15.9512195121951,2.46341463414634,0.405940594059406,0.219512195121951,0.219512195121951,0.121951219512195,0.560975609756098,0,16,10,1,3,0.39,0.24,0.02,0.07,22.22,0.913748209655862,0.268292682926829,0.951219512195122,3.68896321070234,0.43841813238191,0.228571428571429,0.261904761904762,0.19047619047619,"FRANCESCA MALLAMACI;SILVANA CAPALBO;ANTONIO FACCIORUSSO;CARMINE ZOCCALI;NATALE DANIELE BRUNETTI;MATTEO ANTONINO;RITA RIZZI;GIOVANNI REDDICONTO;ROBERT EKART;GIOVANNI TRIPEPI;NICOLA DI RENZO;GIUSEPPE TARANTINI;G. PALAZZO;FRANCESCO PRECENZANO;GRAZIA MARIA GIOVANNA PASTORINO;NICOLA CASCAVILLA;ANTONIETTA FALCONE;PANTELIS SARAFIDIS;MARCO CAROTENUTO;MICHELE CORREALE","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTONIO FACCIORUSSO;MATTEO ANTONINO;SILVANA CAPALBO;NATALE DANIELE BRUNETTI;FRANCESCA MALLAMACI;NICOLA MUSCATIELLO;VINCENZO ROSARIO BUCCINO;IOANNIS ALEXANDROS CHARITOS;CARMINE ZOCCALI;MATTEO DI BIASE;E ORSITTO;LUIGÌ SANTACROCE;RODOLFO SACCO;LUCREZIA BOTTALICO;SKËNDER TOPI;GIOVANNI TRIPEPI;MARIA GRAZIA FRANZESE;ANTONIO TURCO;L. CIUFFREDA;GAETANO PALUMBO","0.62;0.62;0.45;0.43;0.38;0.37;0.37;0.35;0.28;0.27;0.25;0.25;0.25;0.25;0.25;0.22;0.2;0.2;0.2;0.2","FRANCESCA MALLAMACI;SILVANA CAPALBO;ANTONIO FACCIORUSSO;CARMINE ZOCCALI;NATALE DANIELE BRUNETTI;MATTEO ANTONINO;GIOVANNI TRIPEPI;MICHELE CORREALE;IOANNIS ALEXANDROS CHARITOS;ANNA NUNZIA POLITO;NICOLA MUSCATIELLO;VINCENZO ROSARIO BUCCINO;GIUSEPPE CARRIERI;MARIA GRAZIA FRANZESE;SANTE DI GIOIA;GRAZIELLA CARIDI;ROMANO BUCCI;MARIA NOBILI;OSCAR SELVAGGIO;MICHELA RAUSEO","4;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ANTONIO FACCIORUSSO;MATTEO ANTONINO;SILVANA CAPALBO;NATALE DANIELE BRUNETTI;FRANCESCA MALLAMACI;NICOLA MUSCATIELLO;VINCENZO ROSARIO BUCCINO;IOANNIS ALEXANDROS CHARITOS;CARMINE ZOCCALI;RODOLFO SACCO;GIOVANNI TRIPEPI;MARIA GRAZIA FRANZESE;ANTONIO TURCO;L. CIUFFREDA;GAETANO PALUMBO;VINCENZA FERNANDA FESCE;MICHELE CORREALE;RICCARDO IEVA;VALENTINA DEL PRETE;ROSA SANTACROCE","0.62;0.62;0.45;0.43;0.38;0.37;0.37;0.35;0.28;0.25;0.22;0.2;0.2;0.2;0.2;0.2;0.19;0.17;0.17;0.17","DETAJIN JUNHASAVASDIKUL;DOMENICO LUCA GRIECO;EDDY FAN;IBRAHIM SOLIMAN;JEAN-CHRISTOPHE M. RICHARD;LAURENT BROCHARD;LORENZO DEL SORBO;LÜ CHEN;MICHAEL C. SKLAR;MICHELA RAUSEO;NIALL D. FERGUSON;NUTTAPOL RITTAYAMAI;FRANCESCA MALLAMACI;CHARLES J. FERRO;PANTELIS SARAFIDIS;ROBERT EKART;CARMINE ZOCCALI;GÉRARD M. LONDON;ALBERTO ORTÍZ;ANDRZEJ WIĘCEK","235;235;235;235;235;235;235;235;235;235;235;235;221;194;194;194;191;176;164;164","MICHELA RAUSEO;FRANCESCA MALLAMACI;CARMINE ZOCCALI;ANTONIO FACCIORUSSO;MATTEO ANTONINO;GILDA CINNELLA;ANNA NUNZIA POLITO;ALESSANDRO PADOVANI;ANTONELLA ALBERICI;BARBARA BORRONI;CHIARA ZECCA;ERIOLA BAGOJ;GIANCARLO LOGROSCINO;GIULIANO BINETTI;LUISA BENUSSI;MARCO PICCININNI;PETRONILLA BATTISTA;ROBERTA BARONE;ROBERTA GHIDONI;ROSA CAPOZZO","235;221;191;51;51;46;44;35;35;35;35;35;35;35;35;35;35;35;35;35","FRANCESCA MALLAMACI;ANTONIO FACCIORUSSO;CARMINE ZOCCALI;MATTEO ANTONINO;ANNA NUNZIA POLITO;GIOVANNI TRIPEPI;IOANNIS ALEXANDROS CHARITOS;NICOLA MUSCATIELLO;VINCENZO ROSARIO BUCCINO;ALESSANDRA CATUCCI;ALESSANDRO PADOVANI;ANGELA MAFRICA;ANNA MARINACCIO;ANNAMARIA D’APRILE;ANTONELLA ALBERICI;ANTONELLA CONTALDO;ANTONIO TURCO;BARBARA BORRONI;CARLO AVOLIO;CARLO DI BONAVENTURA","4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;PSYCHOLOGY;MATHEMATICS;ART;GEOLOGY;HISTORY;MATERIALS SCIENCE;PHILOSOPHY","40;10;5;3;3;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;ONCOLOGY;PEDIATRICS;GENETICS;PSYCHIATRY;RADIOLOGY;ANESTHESIA;IMMUNOLOGY;MECHANICAL ENGINEERING;PATHOLOGY;ASTROBIOLOGY;AUDIOLOGY;BIOINFORMATICS;ENDOCRINOLOGY;GENERAL SURGERY;GEOMETRY;MICROBIOLOGY;NURSING;OPTICS;PHARMACOLOGY;QUANTUM MECHANICS","37;12;8;7;7;6;6;6;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","DISEASE;POPULATION;COHORT;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;BLOOD PRESSURE;CHEMOTHERAPY;GENE;LUNG;MULTIPLE MYELOMA;CANCER;KIDNEY DISEASE;MECHANICAL VENTILATION;PREGNANCY;RETROSPECTIVE COHORT STUDY;ANTIBIOTICS;ASYMPTOMATIC;BIOPSY;CIRRHOSIS;COMPLICATION;CYST;DEXAMETHASONE;DISCONTINUATION;ENDOSCOPIC ULTRASOUND;FIBRINOGEN;HEPATOLOGY;INCIDENCE (GEOMETRY);INFLAMMATION;INTERQUARTILE RANGE;MAGNETIC RESONANCE IMAGING;RECEPTOR;REFRACTORY (PLANETARY SCIENCE);REGIMEN;VENTILATION (ARCHITECTURE)","6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BORTEZOMIB;EJECTION FRACTION;ANTIBIOTIC PROPHYLAXIS;CLINICAL ENDPOINT;FINE-NEEDLE ASPIRATION;GESTATIONAL AGE;LENALIDOMIDE;MULTICENTER STUDY;POSITIVE END-EXPIRATORY PRESSURE;SALVAGE THERAPY;ADRENOCORTICOTROPIC HORMONE;AGONIST;ANTICONVULSANT;ARTIFICIAL URINARY SPHINCTER;BRAGG PEAK;BREAST CANCER;C-REACTIVE PROTEIN;CANNABIDIOL;CANNABINOID;CARDIAC MAGNETIC RESONANCE;CARDIAC MAGNETIC RESONANCE IMAGING;CARDIOPROTECTION;CHARGED PARTICLE;CIPROFLOXACIN;COLORECTAL CANCER;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CONGENITAL MALFORMATIONS;CRACKLES;CYCLOPHOSPHAMIDE;DEMENTIA;EPITOPE;FACTOR XIII;FLUOROURACIL;FRAGILE X;FRAMINGHAM RISK SCORE;GENETIC DISORDER;GENOME;GENOTYPE;HEART RATE;HEPATITIS C VIRUS;HEPATORENAL SYNDROME;ICTAL;INFLAMMATORY BOWEL DISEASE;INGUINAL HERNIA;ION BEAM;IRRITABILITY;LEFT VENTRICULAR HYPERTROPHY;LIVER FIBROSIS;LUNG ULTRASOUND;LUNG VOLUMES;MEDICAL GENETICS;MUCOSITIS;NASAL CANNULA;NEUTROPENIA;PARTICLE BEAM;PARTICLE THERAPY;PATENT FORAMEN OVALE;PEDIATRIC GASTROENTEROLOGY;PERAMPANEL;PERIPHERAL EDEMA;PHENOTYPE;POLYMERASE CHAIN REACTION;POLYSOMNOGRAPHY;PROGRESSIVE MYOCLONUS EPILEPSY;PROSTATE;PROTEASOME INHIBITOR;PSORIATIC ARTHRITIS;PULMONARY COMPLIANCE;PULMONARY EDEMA;RITUXIMAB;SPLENECTOMY;SPONTANEOUS BACTERIAL PERITONITIS;SPUTUM;STRESS INCONTINENCE;THALIDOMIDE;TIDAL VOLUME;TRANEXAMIC ACID;TYPE 2 DIABETES MELLITUS;VALSARTAN;VIRAL LOAD","3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACCESSORY SPLEEN;ANTIRETROVIRAL THERAPY;APREMILAST;BENDAMUSTINE;CAPECITABINE;CARFILZOMIB;COPY-NUMBER VARIATION;FACTOR XIII DEFICIENCY;FMR1;FRONTOTEMPORAL DEMENTIA;GLUCAGON-LIKE PEPTIDE 1 RECEPTOR;GP41;INFLAMMATORY BOWEL DISEASES;NORFLOXACIN;PHARMACOGENETICS;POMALIDOMIDE;PRESYNCOPE;PROSTATECTOMY;REVERSE TRANSCRIPTASE;RIBAVIRIN;SACUBITRIL;STROKE VOLUME;TETRAHYDROCANNABINOL;THYMIDYLATE SYNTHASE;TRANSIENT ELASTOGRAPHY;TRASTUZUMAB;VEDOLIZUMAB","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ITALY;BACTERIAL INFECTIONS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;AGED;DEOXYCYTIDINE;FLUOROURACIL;RENAL INSUFFICIENCY, CHRONIC;TREATMENT OUTCOME;LIVER CIRRHOSIS;PERITONITIS;ANEMIA;ATRIAL FIBRILLATION;BREAST NEOPLASMS;CAPECITABINE","25;15;15;13;11;10;9;8;7;7;6;6;6;6;5;5;4;4;4;4","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFICACY AND RESISTANCE IN CML TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;HEPATITIS C INFECTION AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;HISTORY OF MEDICINE AND MEDICAL PRACTICES;INTUSSUSCEPTION AND MECKEL'S DIVERTICULUM","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ECHOCARDIOGRAPHY;INTERNATIONAL MYELOMA WORKING GROUP;CLINICAL ENDPOINT;DISCONTINUATION;ENDOSCOPIC ULTRASOUND;INTERQUARTILE RANGE;LEFT VENTRICULAR FUNCTION;POSITIVE END-EXPIRATORY PRESSURE;REFRACTORY (PLANETARY SCIENCE);REGIMEN;SALVAGE THERAPY;TREATMENT;ACCESSORY SPLEEN;ACUTE PANCREATITIS;ACUTE RESPIRATORY DISTRESS SYNDROME;ANGIOGRAPHY;ANTIEPILEPTIC DRUGS;ANTIRETROVIRAL THERAPY;APREMILAST;ARTIFICIAL URINARY SPHINCTER","3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CHRONIC KIDNEY;KIDNEY DISEASE;MULTIPLE MYELOMA;CENTER EXPERIENCE;CLINICAL PRACTICE;CONTROLLED TRIAL;EMATOLOGICA PUGLIESE;ENDOSCOPIC ULTRASOUND;FINE-NEEDLE ASPIRATION;INFLAMMATORY BOWEL;ITALIAN SOCIETY;MAGNETIC RESONANCE;PALLIATIVE CARE;PANCREATIC CYSTS;RANDOMIZED CONTROLLED;RETE EMATOLOGICA;SINGLE CENTER;ULTRASOUND FINE-NEEDLE;ACCESSORY SPLEEN;ACTH LEVELS;ACUTE KIDNEY;ACUTE PANCREATITIS;ACUTE RESPIRATORY;AGASGA POPULATION;AGE INFANTS;AJCC PROGNOSTIC;ALCMAEONÂS SCHOOL;ANGIOGENIC FACTORS;ANTIRETROVIRAL REGIMENS;APPLICATIONS CHARGED","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","PROGNOSTIC STAGE;MONTHS RANGE;CLINICAL PRACTICE;RISK FACTORS;ANATOMIC STAGE;DETECTION RATE;IGD MM;INFLAMMATORY STATUS;ADVERSE EVENTS;HEART FAILURE;LT MGDL;PATIENTS TREATED;PLASMA LEVELS;POM LODEX;ACTIVATED INFLAMMATORY;BONE MARROW;BORTEZOMIBBASED REGIMENS;CARDIAC SURGERY;CARDIOONCOLOGY UNIT;CARDIOVASCULAR EVENTS;CLINICAL TRIAL;CLINICAL TRIALS;COMPLETE RESPONSE;CONSECUTIVE PATIENTS;EXTRA OSSEOUS;INDEPENDENT RISK;LEFT VENTRICULAR;MARROW PLASMA;MEDIAN OS;MEDIAN PFS","9;8;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",20,0.49,6.61,7.25,2.25,1,0,3.5,0,0,0,7.25,0,0,7.25,0,6.25,2.5,10,5.75,2,0,0,72.5,72.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,2.42,547.92,14.63,5,0.42,45.83,0,0,0,0,4,0,1,7,0,8,4,0,0,0,0,0,0,12,0,0,12,0,0,0,0,0,0,0,0,0,"Italy;Belgium;United States","6;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4206 PUBLIC HEALTH;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3210 NUTRITION AND DIETETICS;39 EDUCATION;3904 SPECIALIST STUDIES IN EDUCATION;4203 HEALTH SERVICES AND SYSTEMS;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","11;7;3;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;CANCER;DIGESTIVE DISEASES;PREVENTION;BIOMEDICAL IMAGING;BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;NUTRITION;AGING;BIOENGINEERING;CHILDHOOD LEUKEMIA;CHRONIC LIVER DISEASE AND CIRRHOSIS;COLO-RECTAL CANCER;COMPLEMENTARY AND INTEGRATIVE HEALTH;DEPRESSION","12;9;4;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION;MENTAL HEALTH;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;STROKE","1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","7;2;1;1","COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;PANCREATIC CANCER","1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2020,88,14.4090909090909,2.21590909090909,0.451282051282051,0.375,0.227272727272727,0.193181818181818,0.613636363636364,0,27,29,6,10,0.31,0.33,0.07,0.11,18.7,0.742286090898503,0.215909090909091,0.954545454545455,4.32596685082873,0.442788261298767,0.364393939393939,0.266233766233766,0.359649122807017,"NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MICHELE CORREALE;MAURIZIO ZIZZO;LUIGÌ SANTACROCE;STEFANO ASCANI;MAGDA ZANELLI;IOANNIS ALEXANDROS CHARITOS;FRANCESCA SANGUEDOLCE;MARCO SPERANDEO;CARLA MARIA IRENE QUARATO;VALERIO ANNESSI;MATTEO DI BIASE;GIOVANNI TRIPEPI;ANTONIO FACCIORUSSO;LUCIA TRICARICO;CARMINE ZOCCALI;TERESA SANTANTONIO;MARIAPIA VENUTI;G. NOIA","11;7;7;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;3","LUIGÌ SANTACROCE;IOANNIS ALEXANDROS CHARITOS;NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MICHELE CORREALE;MAURIZIO ZIZZO;STEFANO ASCANI;MAGDA ZANELLI;CARLA MARIA IRENE QUARATO;LEONARDO PENNISI;ANNA LEPORE;MARCO SPERANDEO;FRANCESCA SANGUEDOLCE;VALERIO ANNESSI;MARIAPIA VENUTI;CARMINE ZOCCALI;G MAFFEI;FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI","1.14;1.14;1.12;0.83;0.79;0.7;0.7;0.7;0.66;0.65;0.65;0.64;0.6;0.6;0.54;0.53;0.51;0.5;0.5;0.5","NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MICHELE CORREALE;IOANNIS ALEXANDROS CHARITOS;FRANCESCA SANGUEDOLCE;CARLA MARIA IRENE QUARATO;MATTEO DI BIASE;GIOVANNI TRIPEPI;ANTONIO FACCIORUSSO;CARMINE ZOCCALI;TERESA SANTANTONIO;MARIAPIA VENUTI;G. NOIA;MARIA PIA FOSCHINO BARBARO;LEONARDO PENNISI;FRANCESCA MALLAMACI;RODOLFO SACCO;GIUSEPPE MACCAGNANO;SERGIO LO CAPUTO;ANNA LEPORE","11;7;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","IOANNIS ALEXANDROS CHARITOS;NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MICHELE CORREALE;CARLA MARIA IRENE QUARATO;LEONARDO PENNISI;ANNA LEPORE;FRANCESCA SANGUEDOLCE;MARIAPIA VENUTI;CARMINE ZOCCALI;G MAFFEI;FEDELE LEMBO;AURELIO PORTINCASA;DOMENICO PARISI;LIBERATO ROBERTO CECCHINO;PIO LIBERATORE;ANTONIO FACCIORUSSO;GIOVANNI TRIPEPI;MATTEO DI BIASE;MICHELE CORREALE","1.14;1.12;0.83;0.79;0.66;0.65;0.65;0.6;0.54;0.53;0.51;0.5;0.5;0.5;0.5;0.5;0.5;0.49;0.48;0.34","ATTILIO GUARINI;NICOLA DI RENZO;ADRIANO VENDITTI;AGOSTINO TAFURI;ALESSANDRA ROMANO;ALESSANDRO BUSCA;ALESSANDRO CORSO;ALESSANDRO MOROTTI;ALFREDO MOLTENI;ANNA CANDONI;ANNA MARIA SCATTOLIN;ANNARITA CONCONI;ANNAROSA CUCCARO;ANTONIO CUNEO;ANTONIO PINTO;ATTILIO OLIVIERI;ATTO BILLIO;AUGUSTO B. FEDERICI;BRUNANGELO FALINI;CARLO GAMBACORTI‐PASSERINI","529;529;510;510;510;510;510;510;510;510;510;510;510;510;510;510;510;510;510;510","CELESTINO FERRANDINA;CINZIA ROTONDO;MICHELE CORREALE;IOANNIS ALEXANDROS CHARITOS;VINCENZO DI NOIA;G MAFFEI;MARIA PIA FOSCHINO BARBARO;ARMANDO DE CARLO;FRANCESCA MALLAMACI;GIUSEPPINA MEROLLA;CARMINE ZOCCALI;A P TRAVASSOS DA ROSA;LUCIA DE FEO;MICHELE CENTRA;MICHELINA SARNO;TERESA SANTANTONIO;TOMMASO GRANATO;DONATO LACEDONIA;GIOVANNI TRIPEPI;FRANCESCA SANGUEDOLCE","510;235;144;79;76;53;51;49;47;44;40;36;36;36;36;36;36;35;34;32","MICHELE CORREALE;DONATO LACEDONIA;IOANNIS ALEXANDROS CHARITOS;FRANCESCA SANGUEDOLCE;CARLA MARIA IRENE QUARATO;MARIAPIA VENUTI;ANTONIO FACCIORUSSO;CARMINE ZOCCALI;FRANCESCA MALLAMACI;G. NOIA;GIOVANNI TRIPEPI;GIUSEPPE MACCAGNANO;MARIA PIA FOSCHINO BARBARO;PIER LUIGI PELLEGRINO;TERESA SANTANTONIO;ANNA LEPORE;LEONARDO PENNISI;ALESSANDRA LALLA;ANNARITA SABETTA;ANNARITA VALENZANO","9;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;ENGINEERING;HISTORY;BUSINESS;CHEMISTRY;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;ART;GEOLOGY","86;12;7;4;4;4;4;4;3;3;2;2;2;2;2;1;1","INTERNAL MEDICINE;CARDIOLOGY;PATHOLOGY;INTENSIVE CARE MEDICINE;SURGERY;RADIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PSYCHIATRY;GASTROENTEROLOGY;VIROLOGY;MEDICAL EMERGENCY;NURSING;PEDIATRICS;ANESTHESIA;DERMATOLOGY;GENETICS;MATHEMATICS EDUCATION;NUCLEAR MEDICINE;OPTICS;SOCIAL SCIENCE","71;18;18;16;16;11;10;9;8;7;6;6;5;5;5;4;4;4;4;4;4;4","DISEASE;CANCER;ADVERSE EFFECT;BLOOD PRESSURE;HEART FAILURE;POPULATION;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;OUTBREAK;ANTIBODY;KIDNEY DISEASE;LUNG;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;ASYMPTOMATIC;BIOPSY;DISCONTINUATION;INTERQUARTILE RANGE;PULMONARY ARTERY;PULMONARY HYPERTENSION;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY","18;10;8;8;8;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;COLORECTAL CANCER;EJECTION FRACTION;HAZARD RATIO;HEART RATE;HEPATITIS C VIRUS;SEROLOGY;TOLERABILITY;VASCULAR RESISTANCE;ACUTE CORONARY SYNDROME;BREAST CANCER;CELL CYCLE;CONVENTIONAL PCI;CORONARY ANGIOGRAPHY;EZETIMIBE;FINE-NEEDLE ASPIRATION;INTERVENTRICULAR SEPTUM;MULTICENTER STUDY;OVERWEIGHT;PARKINSON'S DISEASE;PERCUTANEOUS CORONARY INTERVENTION;WARFARIN","8;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);BRADYCARDIA;CAPECITABINE;CARDIAC RESYNCHRONIZATION THERAPY;CYCLIN D1;LEVODOPA;SEROPREVALENCE;TICAGRELOR;AA AMYLOIDOSIS;AL AMYLOIDOSIS;AMYLOID FIBRIL;APOLIPOPROTEIN A1;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;AXIN2;BASDAI;BATTERY CAPACITY;BIORESORBABLE SCAFFOLD;BIVALIRUDIN;BOSENTAN;CARFILZOMIB;CATENIN;CERTOLIZUMAB PEGOL;COLONOSCOPY;CORONARY ANGIOGRAM;CYP2C19;DABIGATRAN;DYSKINESIA;GENE EXPRESSION PROFILING;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HES1;HYPOPNEA;LAFORA DISEASE;MATRIX GLA PROTEIN;METASTATIC BREAST CANCER;NEONATAL RESPIRATORY DISTRESS SYNDROME;OMALIZUMAB;OREXIN;PEMBROLIZUMAB;PLACENTA;POISON CONTROL CENTER;PRASUGREL;RIBAVIRIN;RIVAROXABAN;SACUBITRIL;SACUBITRIL, VALSARTAN;STROKE VOLUME;SYNOVIAL FLUID;TARGET LESION;TIMI;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;UNDERWEIGHT","8;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;ITALY;AGED;SQUAMOUS CELL CARCINOMA OF HEAD AND NECK;TREATMENT OUTCOME;CARDIOVASCULAR DISEASES;COVID-19;HIV INFECTIONS;KIDNEY NEOPLASMS;LUNG;ANTIBODIES, MONOCLONAL, HUMANIZED;BREAST NEOPLASMS;CYSTS;DRUG THERAPY, COMBINATION;KIDNEY FAILURE, CHRONIC","49;37;20;18;14;13;11;10;10;9;7;7;7;7;6;5;5;5;5;5","DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATITIS C INFECTION AND TREATMENT;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ASTHMA;CHOLESTEROL-LOWERING TREATMENT;CORONAVIRUS DISEASE 2019 RESEARCH;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;HEPATOCELLULAR CARCINOMA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;PULMONARY CALCIFICATION AND NODULAR TUMORS IN THE LUNG;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANESTHESIA AND SEDATION MANAGEMENT;ATRIAL FIBRILLATION;BODY CONTOURING TECHNIQUES AND PROCEDURES;CANCER IMMUNOTHERAPY;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS","4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","TREATMENT;PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;CORONAVIRUS;DISCONTINUATION;INTERQUARTILE RANGE;PULMONARY HYPERTENSION;LUNG ULTRASOUND;RIGHT HEART ASSESSMENT;TOLERABILITY;BREAST CANCER;CARBIDOPA;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;CARDIAC ULTRASOUND;CHOLESTEROL-LOWERING;CORONA VIRUS;ECHOCARDIOGRAPHY;ERYTHEMA","7;5;4;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2","HEART FAILURE;ADVANCED BREAST;ADVANCED HEART;ADVANCED PARKINSONS;ARTERIAL HYPERTENSION;BREAST CANCER;CARDIAC RESYNCHRONIZATION;CELL CARCINOMA;CHRONIC HEART;DEVICE LONGEVITY;DISEASE PATIENTS;EXTERNAL VALIDATION;FINE-NEEDLE ASPIRATION;GENETIC STUDY;HEPATOCELLULAR CARCINOMA;II TRIAL;INTESTINAL GEL;INVESTIGATION EFFICACY;LCIG ADVANCED;LEVODOPA-CARBIDOPA INTESTINAL;LIVER DISEASE;MULTI-SITE PACING;OPTIMAL CARDIAC;PACING STRATEGIES;PARKINSONS DISEASE;PHASE II;PITER COHORT;PROPENSITY SCORE;PULMONARY ARTERIAL;PULMONARY HYPERTENSION","5;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICAL ONCOLOGY;ONCOLOGY UNIT;MD DIVISION;REGGIO EMILIA;DERMATOLOGY UNIVERSITY;FOGGIA FOGGIA;UNIT OSPEDALE;BREAST UNIT;ONCOLOGY BREAST;UNIT AZIENDA;PUBMED SCOPUS;AZIENDA OSPEDALIERA;HR CI;MD MEDICAL;CROSSREF PUBMED;BARI BARI;BARI ITALYSEARCH;BIOMEDICAL SCIENCE;DI FOGGIA;FOGGIA ITALY;FOGGIA ITALYSEARCH;HUMAN ONCOLOGY;RIUNITI DI;AZIENDA UNITÀ;BRINDISI ITALYSEARCH;CASA SOLLIEVO;DELLA SOFFERENZA;DI REGGIO;FAZZI LECCE;FULL-TEXT VERSION","36;20;18;18;16;16;16;14;14;14;13;12;12;12;11;10;10;10;10;10;10;10;10;8;8;8;8;8;8;8",36,0.41,5.06,6.25,1,2,0,2,0,0,1,7.25,1,0,5.5,0,0,3,6.25,5,3.5,0,0,47,47,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,3.8,209.4,8.85,3,0.3,46.2,0,0,1,0,1,0,1,7,0,4,6,0,0,0,0,0,0,10,0,0,10,0,0,0,0,0,0,0,0,0,"United States;Italy","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","10;6;3;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;HEMATOLOGY;RARE DISEASES;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;INFECTIOUS DISEASES;MENTAL HEALTH;PATIENT SAFETY;PREVENTION;SERIOUS MENTAL ILLNESS;CHRONIC LIVER DISEASE AND CIRRHOSIS;DEPRESSION;HEPATITIS;HEPATITIS - B;LIVER DISEASE;LYMPHOMA;MAJOR DEPRESSIVE DISORDER;ORPHAN DRUG","8;5;5;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;MENTAL HEALTH;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;INJURIES AND ACCIDENTS","3;2;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","3;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;BLADDER CANCER;BLOOD CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER","3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2021,128,14.8828125,2.921875,0.342245989304813,0.390625,0.296875,0.28125,0.6953125,2,42,24,26,8,0.33,0.19,0.2,0.06,8.71,0.564885577504726,0.203125,0.9140625,4.54079254079254,0.478153092748016,0.446671438797423,0.442282176028306,0.449174311926606,"NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MARIA PIA FOSCHINO BARBARO;GIULIA SCIOSCIA;TERESA SANTANTONIO;SERGIO LO CAPUTO;PIETRO MAZZEO;MICHELE CORREALE;MICHELE CORREALE;LUCIA TRICARICO;CARLA MARIA IRENE QUARATO;FRANCESCA SANGUEDOLCE;MICHELE MAGNESA;MASSIMO IACOVIELLO;PASQUALE TONDO;MAURIZIO ZIZZO;CARLO AVOLIO;RODOLFO SACCO;AURELIO PORTINCASA;FRANCESCO LUZZA","19;17;16;16;10;9;8;8;7;7;7;6;6;6;6;5;5;5;5;5","NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MARIA PIA FOSCHINO BARBARO;GIULIA SCIOSCIA;AURELIO PORTINCASA;UMBERTO VINCENZI;AURORA FUIANI;TERESA SANTANTONIO;FEDELE LEMBO;DOMENICO PARISI;LIBERATO ROBERTO CECCHINO;SERGIO LO CAPUTO;MASSIMO IACOVIELLO;MICHELE CORREALE;ROSA PRATO;FRANCESCO SOLLITTO;LUCIA TRICARICO;FRANCESCA SANGUEDOLCE;CARLA MARIA IRENE QUARATO;A MALLARDI","1.88;1.8;1.74;1.74;1.17;1;1;0.94;0.92;0.92;0.92;0.81;0.77;0.75;0.73;0.68;0.67;0.65;0.64;0.63","NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MARIA PIA FOSCHINO BARBARO;GIULIA SCIOSCIA;TERESA SANTANTONIO;SERGIO LO CAPUTO;MICHELE CORREALE;MICHELE CORREALE;LUCIA TRICARICO;CARLA MARIA IRENE QUARATO;FRANCESCA SANGUEDOLCE;MICHELE MAGNESA;MASSIMO IACOVIELLO;PASQUALE TONDO;CARLO AVOLIO;RODOLFO SACCO;AURELIO PORTINCASA;G. D’ORSI;A MALLARDI;FRANCESCO SOLLITTO","19;17;16;16;10;9;8;7;7;7;6;6;6;6;5;5;5;5;5;5","NATALE DANIELE BRUNETTI;DONATO LACEDONIA;MARIA PIA FOSCHINO BARBARO;GIULIA SCIOSCIA;AURELIO PORTINCASA;UMBERTO VINCENZI;AURORA FUIANI;TERESA SANTANTONIO;FEDELE LEMBO;DOMENICO PARISI;LIBERATO ROBERTO CECCHINO;SERGIO LO CAPUTO;MASSIMO IACOVIELLO;MICHELE CORREALE;ROSA PRATO;FRANCESCO SOLLITTO;LUCIA TRICARICO;FRANCESCA SANGUEDOLCE;CARLA MARIA IRENE QUARATO;A MALLARDI","1.88;1.8;1.74;1.74;1.17;1;1;0.94;0.92;0.92;0.92;0.81;0.77;0.75;0.73;0.68;0.67;0.65;0.64;0.63","DONATO LACEDONIA;TERESA SANTANTONIO;GIULIA SCIOSCIA;MARIA PIA FOSCHINO BARBARO;SERGIO LO CAPUTO;NATALE DANIELE BRUNETTI;MICHELE CORREALE;VITANGELO DATTOLI;G. D’ORSI;PASQUALE TONDO;LEONARDO BAIOCCHI;CARLA MARIA IRENE QUARATO;ROSA PRATO;CARLO AVOLIO;PIERA SOCCIO;FRANCESCA FORTUNATO;GIUSEPPE CARRIERI;RODOLFO SACCO;GUIDO GIORDANO;PIETRO MAZZEO","159;157;150;150;150;120;84;75;74;70;68;67;67;61;59;57;57;57;53;52","DONATO LACEDONIA;GIULIA SCIOSCIA;MARIA PIA FOSCHINO BARBARO;MICHELE CORREALE;VITANGELO DATTOLI;G. D’ORSI;TERESA SANTANTONIO;PASQUALE TONDO;SERGIO LO CAPUTO;CARLO AVOLIO;RODOLFO SACCO;GUIDO GIORDANO;CARLA MARIA IRENE QUARATO;LUIGI CORMIO;MARIA TERESA DI CLAUDIO;ROSELLA DE NITTIS;PIERA SOCCIO;PIER LUIGI PELLEGRINO;FEDERICA MACI;VINCENZO DI NOIA","154;145;127;84;75;74;74;70;67;61;57;53;52;45;41;41;40;36;35;34","DONATO LACEDONIA;MICHELE CORREALE;GIULIA SCIOSCIA;MARIA PIA FOSCHINO BARBARO;PASQUALE TONDO;TERESA SANTANTONIO;NATALE DANIELE BRUNETTI;RODOLFO SACCO;AURELIO PORTINCASA;CARLA MARIA IRENE QUARATO;CARLO AVOLIO;FRANCESCA SANGUEDOLCE;G. D’ORSI;SERGIO LO CAPUTO;DOMENICO PARISI;FEDELE LEMBO;FEDERICA MACI;GUIDO GIORDANO;LIBERATO ROBERTO CECCHINO;G MAFFEI","15;15;14;14;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;SOCIOLOGY;ECONOMICS;COMPUTER SCIENCE;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;GEOLOGY;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY","126;20;15;8;7;6;3;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;PATHOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;IMMUNOLOGY;PEDIATRICS;GASTROENTEROLOGY;ANESTHESIA;BIOCHEMISTRY;PSYCHIATRY;INTENSIVE CARE MEDICINE;ONCOLOGY;OPTICS;EMERGENCY MEDICINE;GENETICS;VIROLOGY;DERMATOLOGY;NURSING","104;29;29;28;15;15;14;14;13;12;11;11;10;9;9;7;7;7;6;6","DISEASE;HEART FAILURE;BLOOD PRESSURE;LUNG;POPULATION;COHORT;GENE;RETROSPECTIVE COHORT STUDY;CANCER;INCIDENCE (GEOMETRY);PNEUMONIA;ADVERSE EFFECT;ASYMPTOMATIC;CLINICAL TRIAL;ULTRASOUND;ANTIBIOTICS;ASTHMA;ATRIAL FIBRILLATION;EPILEPSY;OUTBREAK;VIRUS","27;14;13;13;13;11;10;10;9;8;7;6;6;6;6;5;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);EJECTION FRACTION;VALSARTAN;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;IDIOPATHIC PULMONARY FIBROSIS;ANTIBIOTIC RESISTANCE;CROHN'S DISEASE;HAZARD RATIO;INFLIXIMAB;SPIROMETRY;VIRAL LOAD;ADENOCARCINOMA;AGE OF ONSET;BLADDER CANCER;BREAST CANCER;CARCINOMA IN SITU;CARDIOGENIC SHOCK;CARDIOMYOPATHY;EOSINOPHIL;HEART RATE;INFLAMMATORY BOWEL DISEASE;LUNG FUNCTION;LUNG ULTRASOUND;MUTATION;NATRIURETIC PEPTIDE;PHENOTYPE;PSEUDOMONAS AERUGINOSA;PULMONARY FIBROSIS;SEROLOGY;SPASTIC;TYPE 2 DIABETES MELLITUS;ULCERATIVE COLITIS","21;12;9;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);SACUBITRIL;SACUBITRIL, VALSARTAN;CARDIAC RESYNCHRONIZATION THERAPY;DIFFUSING CAPACITY;MEPOLIZUMAB;NINTEDANIB;PIRFENIDONE;SEROPREVALENCE;TAKOTSUBO SYNDROME;ACINETOBACTER BAUMANNII;ADENOSQUAMOUS CARCINOMA;ANTIBIOTIC STEWARDSHIP;ANTIMICROBIAL STEWARDSHIP;APNEA–HYPOPNEA INDEX;ARTERY DISSECTION;AXIAL SPONDYLOARTHRITIS;BETA-CATENIN;BRADYCARDIA;BREAST CARCINOMA;CALPROTECTIN;CEFTAZIDIME;COLECTOMY;DASATINIB;DIABETIC MACULAR EDEMA;DIFFUSE ALVEOLAR DAMAGE;DNA METHYLATION;EXHALED NITRIC OXIDE;FOURNIER GANGRENE;GOLIMUMAB;HIGH TIBIAL OSTEOTOMY;HYPOPNEA;INFLAMMATORY BREAST CANCER;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;IVABRADINE;KLEBSIELLA PNEUMONIAE;LAFORA DISEASE;LAMIVUDINE;LOSS FUNCTION;MACE;MEDIASTINAL EMPHYSEMA;MEROPENEM;MICROVESICLES;MONOCLONAL;NEUROENDOCRINE DIFFERENTIATION;NILOTINIB;OBETICHOLIC ACID;OXALIPLATIN;PEMBROLIZUMAB;PROLYMPHOCYTIC LEUKEMIA;RESPIRATORY DISTURBANCE INDEX;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIFABUTIN;SLEEP STUDY;TRANSITIONAL CELL CARCINOMA;TRANSPULMONARY PRESSURE;URINE CYTOLOGY;USTEKINUMAB;VEDOLIZUMAB;WOMAC","21;9;9;4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;COVID-19;MALE;FEMALE;AGED;MIDDLE AGED;ITALY;RETROSPECTIVE STUDIES;HEART FAILURE;TREATMENT OUTCOME;ADULT;SARS-COV-2;IDIOPATHIC PULMONARY FIBROSIS;VALSARTAN;BIPHENYL COMPOUNDS;CARCINOMA, TRANSITIONAL CELL;PROSPECTIVE STUDIES;URINARY BLADDER NEOPLASMS;AMINOBUTYRATES","64;63;29;28;25;23;21;20;16;15;12;11;11;8;8;7;7;7;7;6","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;CORONAVIRUS DISEASE 2019 RESEARCH;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EPILEPSY AND SEIZURES;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PANCREATIC CANCER RESEARCH AND TREATMENT;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GLOBAL BURDEN OF ANTIMICROBIAL RESISTANCE;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE","5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","TREATMENT;PANDEMIC;SACUBITRIL;SACUBITRIL, VALSARTAN;CARDIAC RESYNCHRONIZATION THERAPY;LEFT VENTRICULAR FUNCTION;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;CARDIAC ULTRASOUND;DISCONTINUATION;ETIOLOGY;IDIOPATHIC PULMONARY FIBROSIS;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;LUNG ULTRASOUND;CALCIFICATION;ECHOCARDIOGRAPHY;INTERQUARTILE RANGE;POINT-OF-CARE ULTRASONOGRAPHY;PRESENTATION (OBSTETRICS);REFRACTORY (PLANETARY SCIENCE)","10;9;9;9;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3","HEART FAILURE;CHRONIC HEART;COHORT STUDY;COVID- PANDEMIC;EJECTION FRACTION;IDIOPATHIC PULMONARY;PULMONARY FIBROSIS;ENDOTHELIAL FUNCTION;LEFT VENTRICULAR;MULTIPLE SCLEROSIS;NEEDLE BIOPSY;OBSERVATIONAL STUDY;PRIMARY PREVENTION;PULMONARY HYPERTENSION;REDUCED EJECTION;TRANSTHORACIC ULTRASOUND;VERTEBRAL FRACTURES;VIKI STUDY;BLOOD DONORS;BOTULINUM TOXIN;BRCA- PATHOGENIC;BREAST CARCINOMA;CARDIOVASCULAR EVENTS;CEREBROVASCULAR EVENTS;CLINICAL IMPLICATIONS;CLINICAL PRACTICE;COVID- PATIENTS;CROHNS DISEASE;CT SCAN;DEFORMATION IMAGING","10;7;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","DOSE INTENSITY;HR CI;ADVERSE EVENTS;CT SCAN;EJECTION FRACTION;COVID- PANDEMIC;HEART FAILURE;IPF PATIENTS;PDAC PATIENTS;FAMILY HISTORY;HR CRI;PATIENTS TREATED;BLOOD DONORS;CHEST CT;CLINICAL PRACTICE;CONSECUTIVE PATIENTS;INTERSTITIAL PNEUMONIA;NYHA CLASS;TTS PATIENTS;ABSTRACT AIMS;COVID- INFECTION;DISEASE PROGRESSION;HEART RATE;LEFT VENTRICULAR;LONG-TERM FOLLOW-UP;MEDIAN AGE;PATHOGENIC VARIANTS;PATIENTS UNDERWENT;DEEP LEARNING;DIAGNOSTIC ACCURACY","15;14;13;11;11;10;10;10;10;9;9;9;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;7;6;6",47,0.37,4.64,4.5,0,1,0,1,0,0,0,5.5,0,0,4.25,0,1,1,3,4,4,0,0,35,35,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,3.27,1929.73,6.71,8,0.73,72.27,0,0,0,3,1,0,0,7,0,5,6,0,0,0,0,0,0,10,0,1,11,0,0,0,0,0,0,0,0,0,"Italy;Canada;Denmark;Japan;Netherlands;Saudi Arabia;Sweden;Switzerland;United States","6;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","11;8;1;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;PATIENT SAFETY;HEART DISEASE;INFECTIOUS DISEASES;PREVENTION;RARE DISEASES;IMMUNIZATION;VACCINE RELATED;ACUTE RESPIRATORY DISTRESS SYNDROME;ASTHMA;ATHEROSCLEROSIS;BIOTECHNOLOGY;BRAIN DISORDERS;CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;CONTRACEPTION/REPRODUCTION;DIGESTIVE DISEASES","11;4;4;4;4;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;RESPIRATORY","4;2","6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","6;2;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER","1;1;1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"TAYLOR & FRANCIS GROUP","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;1","BIOMEDICAL IMAGING;CANCER;DIGESTIVE DISEASES;LIVER DISEASE","1;1;1;1","ORAL AND GASTROINTESTINAL","1",NA,NA,"CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","1","LIVER CANCER","1",NA,NA
"AOU_RIUNITIFOGGIA",2022,121,22.4462809917355,2.72727272727273,0.366666666666667,0.256198347107438,0.231404958677686,0.15702479338843,0.752066115702479,2,32,23,26,10,0.26,0.19,0.21,0.08,4.74,0.531410713173531,0.264462809917355,0.909090909090909,4.13821138211383,0.498454653195815,0.384259259259259,0.497474747474747,0.451923076923077,"NATALE DANIELE BRUNETTI;MASSIMO IACOVIELLO;MICHELE CORREALE;MARIA PIA FOSCHINO BARBARO;MICHELE CORREALE;DONATO LACEDONIA;GIULIA SCIOSCIA;PIETRO MAZZEO;PASQUALE TONDO;NICOLA DI RENZO;RICCARDO IEVA;VITO TERLIZZI;GRAZIA CASAVECCHIA;NICOLA CASCAVILLA;MARCO CONFALONIERI;R BARONE;LORELLA MELILLO;LUCIA TRICARICO;PELLEGRINO MUSTO;A MALLARDI","20;15;12;11;11;9;8;7;7;6;6;6;6;5;5;5;5;5;5;5","MICHELE CORREALE;NATALE DANIELE BRUNETTI;MASSIMO IACOVIELLO;MARIA PIA FOSCHINO BARBARO;ANDREA SANTAMATO;DONATO LACEDONIA;GIULIA SCIOSCIA;PASQUALE TONDO;ANTONIO COLAMARIA;FRANCESCO CARBONE;CARLO AVOLIO;VITO TERLIZZI;RICCARDO IEVA;GRAZIA CASAVECCHIA;MICHELE CORREALE;R BARONE;NICOLA PIO FOCHI;EMANUELE D’AMICO;FRANCESCO SANTORO;MATTEO DI BIASE","1.93;1.6;1.3;1.18;1.06;1;0.99;0.9;0.68;0.68;0.65;0.64;0.6;0.6;0.56;0.56;0.54;0.5;0.47;0.44","NATALE DANIELE BRUNETTI;MASSIMO IACOVIELLO;MICHELE CORREALE;MARIA PIA FOSCHINO BARBARO;MICHELE CORREALE;DONATO LACEDONIA;GIULIA SCIOSCIA;PIETRO MAZZEO;PASQUALE TONDO;RICCARDO IEVA;VITO TERLIZZI;GRAZIA CASAVECCHIA;R BARONE;LORELLA MELILLO;LUCIA TRICARICO;A MALLARDI;FRANCESCO SANTORO;MATTEO DI BIASE;MARTINO FORTUNATO;CARLO AVOLIO","20;15;12;11;11;9;8;7;7;6;6;6;5;5;5;5;5;5;4;4","MICHELE CORREALE;NATALE DANIELE BRUNETTI;MASSIMO IACOVIELLO;MARIA PIA FOSCHINO BARBARO;ANDREA SANTAMATO;DONATO LACEDONIA;GIULIA SCIOSCIA;PASQUALE TONDO;ANTONIO COLAMARIA;FRANCESCO CARBONE;CARLO AVOLIO;VITO TERLIZZI;RICCARDO IEVA;GRAZIA CASAVECCHIA;MICHELE CORREALE;R BARONE;NICOLA PIO FOCHI;EMANUELE D’AMICO;FRANCESCO SANTORO;MATTEO DI BIASE","1.93;1.6;1.3;1.18;1.06;1;0.99;0.9;0.68;0.68;0.65;0.64;0.6;0.6;0.56;0.56;0.54;0.5;0.47;0.44","MICHELE CORREALE;NATALE DANIELE BRUNETTI;MARCO CONFALONIERI;DONATO LACEDONIA;TERESA SANTANTONIO;DANIELA FRANCISCI;MARIA PIA FOSCHINO BARBARO;RODOLFO SACCO;MARCO FALCONE;G MAFFEI;VALENTINA MERCURIO;ALBERTO BERARDI;ALEKSANDRA ZWIJACZ;ALESSANDRA FOGLIANESE;ANAÏS TORREGROSSA;ANNE-LOUISE KOLLEGGER;ARILD RØNNESTAD;BARTŁOMIEJ GROCHOWSKI;CARMELO GERACI;CLAUS KLINGENBERG","67;60;55;49;49;48;48;48;45;43;39;38;38;38;38;38;38;38;38;38","MICHELE CORREALE;TERESA SANTANTONIO;RODOLFO SACCO;G MAFFEI;DOMENICO MARTINELLI;ROSA PRATO;GIAN MARIA BUSETTO;ROSELLA DE NITTIS;FRANCESCA FORTUNATO;GABRIELLA DI MATTEO;GIUSEPPINA IANNELLI;LEONARDO ASCATIGNO;MARICA MILAZZO;UMBERTO FARINA;NICOLA DELLA VALLE;PIER LUIGI PELLEGRINO;DONATO LACEDONIA;GIULIA SCIOSCIA;ANNA CARRETTA;ANNA NUNZIA POLITO","67;49;45;43;38;38;37;32;30;29;29;29;29;29;25;25;22;22;21;18","MICHELE CORREALE;NATALE DANIELE BRUNETTI;MASSIMO IACOVIELLO;DONATO LACEDONIA;GIULIA SCIOSCIA;MARIA PIA FOSCHINO BARBARO;RICCARDO IEVA;VITO TERLIZZI;GRAZIA CASAVECCHIA;R BARONE;RODOLFO SACCO;CARLO AVOLIO;FRANCESCO SANTORO;GIOVANNI GOFFREDO;GIUSEPPE MACCAGNANO;LORELLA MELILLO;MARCO MELE;PIETRO MAZZEO;TERESA SANTANTONIO;ANTONIO COLAMARIA","22;10;10;8;8;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;BUSINESS;GEOGRAPHY;HISTORY;GEOLOGY;MATERIALS SCIENCE","117;25;14;9;7;6;5;4;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;INTENSIVE CARE MEDICINE;GENETICS;PSYCHIATRY;RADIOLOGY;GASTROENTEROLOGY;ONCOLOGY;OPTICS;VIROLOGY;BIOCHEMISTRY;PALEONTOLOGY;PHYSICAL THERAPY;ANESTHESIA;ASTROBIOLOGY;DERMATOLOGY;LAW;MICROBIOLOGY","91;33;27;18;17;16;16;14;12;12;12;9;9;7;7;6;6;6;5;5;5;5;5","DISEASE;HEART FAILURE;POPULATION;ADVERSE EFFECT;BLOOD PRESSURE;COHORT;GENE;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;CANCER;CHEMOTHERAPY;MULTIPLE MYELOMA;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;VACCINATION;VENTRICLE;ANTIBIOTICS;ANTIBODY;ASYMPTOMATIC;ATRIAL FIBRILLATION;CLINICAL TRIAL;REFRACTORY (PLANETARY SCIENCE)","22;16;15;13;11;10;10;10;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);EJECTION FRACTION;VALSARTAN;LENALIDOMIDE;CLINICAL ENDPOINT;HAZARD RATIO;SALVAGE THERAPY;2019-20 CORONAVIRUS OUTBREAK;ADALIMUMAB;EXPANDED DISABILITY STATUS SCALE;GENE EXPRESSION;INFLAMMATORY BOWEL DISEASE;NEUTROPENIA;PHENOTYPE;TOLERABILITY;UNIVARIATE ANALYSIS;VASCULAR RESISTANCE;ACUTE CORONARY SYNDROME;ADENOCARCINOMA;AGONIST;ANGIOTENSIN-CONVERTING ENZYME;ANTIBIOTIC RESISTANCE;BONE MINERAL;BORTEZOMIB;CARCINOGENESIS;CATHETER ABLATION;COLORECTAL CANCER;DIASTOLE;ETANERCEPT;FEMORAL NECK;FLUCONAZOLE;HEART RATE;HYPOXIA (ENVIRONMENTAL);INFERTILITY;MICRORNA;NEPRILYSIN;PERIPHERAL BLOOD MONONUCLEAR CELL;PSORIATIC ARTHRITIS;REGULATION OF GENE EXPRESSION;RELATIVE RISK;RENIN–ANGIOTENSIN SYSTEM;RITUXIMAB;TELEMEDICINE;THORACENTESIS;ULCERATIVE COLITIS;VENTRICULAR REMODELING","16;12;7;6;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);SACUBITRIL;SACUBITRIL, VALSARTAN;DARATUMUMAB;SPECKLE TRACKING ECHOCARDIOGRAPHY;CARFILZOMIB;CILIOPATHY;ENALAPRIL;FEBRILE NEUTROPENIA;OBETICHOLIC ACID;ABATACEPT;ADULT STEM CELL;ALPHA (FINANCE);ANGIOTENSIN RECEPTOR;ATRIAL TACHYCARDIA;AZOOSPERMIA;BARDET–BIEDL SYNDROME;BASDAI;BRADYCARDIA;BRENTUXIMAB VEDOTIN;BROTH MICRODILUTION;CALPROTECTIN;CARDIAC INDEX;CARDIAC RESYNCHRONIZATION THERAPY;CAREGIVER BURDEN;CEFTAZIDIME;CONCUSSION;CRITICAL LIMB ISCHEMIA;CTGF;DASATINIB;DNA METHYLATION;DOPPLER IMAGING;DYSKINESIA;FAMILY PLANNING;GENETIC HETEROGENEITY;GENOTYPE-PHENOTYPE DISTINCTION;GOLIMUMAB;GROUND-GLASS OPACITY;HBSAG;HYPERINSULINEMIA;INFLAMMATORY BOWEL DISEASES;KLEBSIELLA PNEUMONIAE;LEISHMANIA INFANTUM;LEVODOPA;MALE INFERTILITY;MODIFIED RANKIN SCALE;MONOCLONAL;NILOTINIB;NIVOLUMAB;OCRELIZUMAB;PANCREATIC DUCTAL ADENOCARCINOMA;PEMBROLIZUMAB;POSACONAZOLE;PRENATAL DIAGNOSIS;QUANTITATIVE COMPUTED TOMOGRAPHY;SEMEN ANALYSIS;SPITZ NEVUS;SULFASALAZINE;TERIFLUNOMIDE;TNF INHIBITOR;TROPONIN COMPLEX;UNDERWEIGHT;USTEKINUMAB;VARICOCELE","16;7;5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;COVID-19;FEMALE;MALE;RETROSPECTIVE STUDIES;SARS-COV-2;HEART FAILURE;TETRAZOLES;MIDDLE AGED;ANGIOTENSIN RECEPTOR ANTAGONISTS;TREATMENT OUTCOME;ACUTE KIDNEY INJURY;ADULT;AGED;ANTI-BACTERIAL AGENTS;ITALY;PROSPECTIVE STUDIES;STROKE;FEVER","66;54;22;14;13;12;12;11;10;9;8;8;7;7;7;7;7;7;7;5","RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF HEART FAILURE;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;EPILEPSY AND SEIZURES;GLOBAL BURDEN OF ANTIMICROBIAL RESISTANCE;IMMUNOGENICITY OF BIOSIMILAR THERAPEUTICS IN DRUG DEVELOPMENT;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS","7;6;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","LEFT VENTRICULAR FUNCTION;SACUBITRIL;CARDIAC IMAGING;CLINICAL ENDPOINT;PANDEMIC;TREATMENT;CARDIOVASCULAR RISK ASSESSMENT;ECHOCARDIOGRAPHY;REFRACTORY (PLANETARY SCIENCE);SACUBITRIL, VALSARTAN;VACCINES;2019-20 CORONAVIRUS OUTBREAK;REGIMEN;RIGHT HEART ASSESSMENT;SALVAGE THERAPY;DARATUMUMAB;DISCONTINUATION;ETIOLOGY;INTERQUARTILE RANGE;SPECKLE TRACKING ECHOCARDIOGRAPHY","8;7;6;6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3","HEART FAILURE;EMATOLOGICA PUGLIESE;MULTIPLE MYELOMA;RETE EMATOLOGICA;ARTERIAL HYPERTENSION;CHRONIC HEART;CLINICAL EXPERIENCE;OBSERVATIONAL STUDY;PULMONARY ARTERIAL;RETROSPECTIVE CLINICAL;SALVAGE THERAPY;CLINICAL TRIALS;CORONARY ANGIOGRAPHY;COVID- PANDEMIC;EJECTION FRACTION;INITIAL FOLLOW-UP;ITALIAN MULTICENTER;MULTICENTER RETROSPECTIVE;REAL LIFE;REDUCED EJECTION;RENAL RESISTANCE;RESISTANCE INDEX;RHEUMATOID ARTHRITIS;ADALIMUMAB BIOSIMILARS;ADVERSE EVENTS;ARTHRITIS PATIENTS;BILIARY CHOLANGITIS;BLOOD MONONUCLEAR;CATHETER ABLATION;CIRRHOTIC PATIENTS","10;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","PATIENTS TREATED;ADVERSE EVENTS;HR CI;MEDIAN FOLLOW-UP;RA PATIENTS;CORONARY ANGIOGRAPHY;HEART FAILURE;MEDIAN AGE;EJECTION FRACTION;PATIENTS UNDERGOING;SARS-COV- INFECTION;ENROLLED PATIENTS;LEFT ATRIAL;LONGITUDINAL STRAIN;RELATIONSHIP RECIPROCITY;CONFIDENCE INTERVAL;INHIBITOR THERAPY;INTENSIVE CARE;LDL LEVELS;OBSERVATIONAL STUDY;PAH PATIENTS;PATIENTS UNDERWENT;ACUTE CORONARY;ADA BIOSIMILARS;ATRIAL STRAIN;CONTINUOUS HYPOXIA;CORONAVIRUS DISEASE;COX REGRESSION;DISTAL FEMUR;ICU ADMISSION","17;16;16;16;14;13;13;12;11;11;11;9;9;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6",47,0.39,7.1,5.5,1,1.75,0,4.25,0,0,1,6.5,1,0,5.75,0,0,1,4.5,4,3,0,0,17,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,2.29,3757,4.64,2,0.29,164.86,1,0,1,0,3,0,0,2,0,5,2,0,0,0,0,0,0,6,0,1,7,0,0,0,0,0,0,0,0,0,"Italy;United States;Germany","2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","7;5;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;CANCER;CARDIOVASCULAR;HEART DISEASE;LUNG;PREVENTION;RARE DISEASES;AGING;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BRAIN DISORDERS;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIABETES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;HEPATITIS;HEPATITIS - B","7;6;5;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;INFECTION;RESPIRATORY;STROKE","3;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","3;2;1","LIVER CANCER;PROSTATE CANCER","1;1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2023,94,22.4042553191489,2.24468085106383,0.445497630331754,0.202127659574468,0.202127659574468,0.0531914893617021,0.765957446808511,0,30,19,21,5,0.32,0.2,0.22,0.05,4.16,0.949005155762124,0.25531914893617,0.957446808510638,3.94615384615385,0.422842178929112,0.366310160427807,0.513911620294599,0.431818181818182,"NATALE DANIELE BRUNETTI;MASSIMO IACOVIELLO;MICHELE CORREALE;PELLEGRINO MUSTO;NICOLA DI RENZO;GUIDO GIORDANO;LORELLA MELILLO;ANTONIO COLAMARIA;GIOVANNI GOFFREDO;GIUSEPPE TARANTINI;RICCARDO IEVA;ALESSANDRO MAGGI;VITO TERLIZZI;VINCENZO PAVONE;DOMENICO PASTORE;AUGUSTO LEONE;MICHELE CORREALE;MONICA BOCCHIA;GIUSEPPINA SPINOSA;ANNA CANDONI","13;11;7;7;6;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3","MASSIMO IACOVIELLO;NATALE DANIELE BRUNETTI;EDOARDO GRONDA;GIOVANNI GOFFREDO;MICHELE CORREALE;VITO TERLIZZI;ANTONIO COLAMARIA;RICCARDO IEVA;R BARONE;AUGUSTO LEONE;GUIDO GIORDANO;MICHELE CORREALE;MANUELA BENVENUTO;ANDREA SANTAMATO;STEFANIA SPINA;SALVATORE FACCIORUSSO;MATTEO DI BIASE;P. L. PELLEGRINO;FRANCESCO CARBONE;ERICA PIRONTI","1.48;1.22;0.75;0.59;0.57;0.44;0.44;0.4;0.37;0.36;0.35;0.35;0.33;0.31;0.31;0.31;0.31;0.27;0.27;0.27","NATALE DANIELE BRUNETTI;MASSIMO IACOVIELLO;MICHELE CORREALE;GUIDO GIORDANO;LORELLA MELILLO;ANTONIO COLAMARIA;GIOVANNI GOFFREDO;RICCARDO IEVA;VITO TERLIZZI;MICHELE CORREALE;GIUSEPPINA SPINOSA;ERICA PIRONTI;EDOARDO GRONDA;NICOLA DELLA VALLE;DONATO LACEDONIA;DANIELA MIANI;GIULIA SCIOSCIA;R BARONE;ALESSANDRA VILLANI;ELENA PERUZZI","13;11;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3","MASSIMO IACOVIELLO;NATALE DANIELE BRUNETTI;EDOARDO GRONDA;GIOVANNI GOFFREDO;MICHELE CORREALE;VITO TERLIZZI;ANTONIO COLAMARIA;RICCARDO IEVA;R BARONE;GUIDO GIORDANO;MICHELE CORREALE;MANUELA BENVENUTO;ANDREA SANTAMATO;STEFANIA SPINA;MATTEO DI BIASE;P. L. PELLEGRINO;ERICA PIRONTI;DONATO LACEDONIA;GIULIA SCIOSCIA;GIORGIA MORIONDO","1.48;1.22;0.75;0.59;0.57;0.44;0.44;0.4;0.37;0.35;0.35;0.33;0.31;0.31;0.31;0.27;0.27;0.26;0.26;0.26","NICOLA COPPOLA;TERESA SANTANTONIO;GUIDO GIORDANO;MATTEO LANDRISCINA;ALBERTO ENRICO MARAOLO;ALESSANDRA MULARONI;ALESSIO FARCOMENI;ALICE ANNALISA MEDAGLIA;ANDREA MARINO;ANNA CARRETTA;ANTONINA FRANCO;ANTONIO ALBANESE;ANTONIO CASCIO;BRUNO CACOPARDO;CALOGERO RICCARDO BUSCEMI;CARMELO IACOBELLO;CHRISTIAN SGROI;CLAUDIA GIOÈ;DONATELLA PALAZZO;FILIPPO PIERALLI","63;63;61;56;53;53;53;53;53;53;53;53;53;53;53;53;53;53;53;53","TERESA SANTANTONIO;GUIDO GIORDANO;ANNA CARRETTA;MARIA LUCA D’ERRICO;MATTEO LANDRISCINA;MARCO MELE;MICHELE CORREALE;ANTONIO COLAMARIA;FRANCESCA MALLAMACI;NATALE DANIELE BRUNETTI;MATTEO ANTONIO SACCO;DONATO LACEDONIA;GIULIA SCIOSCIA;P. L. PELLEGRINO;FRANCESCO SANTORO;G MAFFEI;GABRIELLA MARSALA;ANTONIO COLECCHIA;ANTONIO MASTROIANNI;MARIA PIA FOSCHINO BARBARO","63;54;53;53;50;35;31;20;18;17;16;14;14;14;13;11;11;10;10;10","MICHELE CORREALE;NATALE DANIELE BRUNETTI;LORELLA MELILLO;ANTONIO COLAMARIA;P. L. PELLEGRINO;ERICA PIRONTI;GAETANO PALUMBO;GRAZIA CASAVECCHIA;NICOLA DELLA VALLE;GIUSEPPINA SPINOSA;GUIDO GIORDANO;MARCO MELE;ANDREA SANTAMATO;DONATO LACEDONIA;FRANCESCA SANGUEDOLCE;FRANCESCO SANTORO;G MAFFEI;GIULIA SCIOSCIA;LUCIA TAURINO;RODOLFO SACCO","11;8;6;5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;MATHEMATICS","92;18;9;7;6;4;3;1;1","INTERNAL MEDICINE;CARDIOLOGY;PEDIATRICS;SURGERY;ONCOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;IMMUNOLOGY;PSYCHIATRY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;RADIOLOGY;EMERGENCY MEDICINE;ENDOCRINOLOGY;ANESTHESIA;CANCER RESEARCH;NEUROSCIENCE;OPTICS","80;21;19;19;14;13;11;10;9;9;8;8;8;7;6;6;5;5;5;5","HEART FAILURE;DISEASE;GENE;CANCER;BLOOD PRESSURE;CHEMOTHERAPY;PROSPECTIVE COHORT STUDY;COHORT;POPULATION;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;DIABETES MELLITUS;ATRIAL FIBRILLATION;EPILEPSY;RANDOMIZED CONTROLLED TRIAL;RENAL FUNCTION;ADVERSE EFFECT;COHORT STUDY;CREATININE;INCIDENCE (GEOMETRY);KIDNEY DISEASE;LEUKEMIA;MULTIPLE MYELOMA;MYELOID LEUKEMIA;REFRACTORY (PLANETARY SCIENCE)","16;15;12;11;10;9;9;8;8;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4","EJECTION FRACTION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);VALSARTAN;COLORECTAL CANCER;BORTEZOMIB;CARDIAC FUNCTION CURVE;CLINICAL ENDPOINT;GENE EXPRESSION;HEART RATE;LENALIDOMIDE;MICRORNA;PANCREATIC CANCER;TYPE 2 DIABETES;ULCERATIVE COLITIS;2019-20 CORONAVIRUS OUTBREAK;ALBUMINURIA;ALLELE;CARDIAC OUTPUT;CROHN'S DISEASE;GEMCITABINE;IMATINIB;IMMUNOTHERAPY;INFLAMMATORY BOWEL DISEASE;METASTASIS;MINIMAL RESIDUAL DISEASE;MOTOR CORTEX;NATRIURETIC PEPTIDE;NEONATAL SEPSIS;PHENOTYPE;PROGRESSION-FREE SURVIVAL;STATUS EPILEPTICUS;VASCULAR RESISTANCE;VENTRICULAR REMODELING;WARFARIN","14;6;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);SACUBITRIL;SACUBITRIL, VALSARTAN;CARDIAC RESYNCHRONIZATION THERAPY;DARATUMUMAB;CARDIAC INDEX;CARFILZOMIB;DAPAGLIFLOZIN;DNA METHYLATION;MICROVESICLES;SPECKLE TRACKING ECHOCARDIOGRAPHY;VEDOLIZUMAB;VITAMIN K ANTAGONIST;ACE INHIBITOR;ACINETOBACTER BAUMANNII;ALLERGEN IMMUNOTHERAPY;ANAPLASTIC LYMPHOMA KINASE;BENDAMUSTINE;BILIARY TRACT CANCER;BRAIN METASTASIS;BREAKPOINT;CD163;CD33;CENTRAL SULCUS;CLASSICAL HODGKIN LYMPHOMA;COLECTOMY;COLONOSCOPY;DASATINIB;DISEASE MANAGEMENT;DORSOLATERAL PREFRONTAL CORTEX;ENHANCER;EXOME SEQUENCING;HBSAG;HYDROSALPINX;IBRUTINIB;IMATINIB MESYLATE;IRINOTECAN;KLEBSIELLA PNEUMONIAE;MICROSATELLITE;MIGRAINE WITH AURA;MISSENSE MUTATION;MOLECULAR EPIDEMIOLOGY;NILOTINIB;NIVOLUMAB;OBINUTUZUMAB;OMALIZUMAB;PACHYGYRIA;PHOSPHATE BINDER;POMALIDOMIDE;PROBAND;REGULATORY SEQUENCE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIGHT CORONARY ARTERY;RIVAROXABAN;SANGER SEQUENCING;SEROPREVALENCE","6;5;5;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;ITALY;RETROSPECTIVE STUDIES;MALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;EPILEPSY;HEART FAILURE;PROSPECTIVE STUDIES;COVID-19;PANCREATIC NEOPLASMS;TREATMENT OUTCOME;AGED;ANTI-BACTERIAL AGENTS;ANTICONVULSANTS;CHILD;COLITIS, ULCERATIVE;ELECTROCARDIOGRAPHY;MULTIPLE SCLEROSIS","48;45;13;12;11;9;7;7;7;7;6;6;5;4;4;4;4;4;4;4","MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;DIAGNOSIS AND TREATMENT OF HEART FAILURE;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;PANCREATIC CANCER RESEARCH AND TREATMENT;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS;EPILEPSY AND SEIZURES;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;IMPACT OF COVID-19 INFECTION ON PREGNANCY OUTCOMES;MORTALITY AND SEQUELAE OF PRETERM BIRTH;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE","6;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1","LEFT VENTRICULAR FUNCTION;SACUBITRIL;SACUBITRIL, VALSARTAN;SGLT2 INHIBITORS;TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY;CLINICAL ENDPOINT;ECHOCARDIOGRAPHY;PANDEMIC;REFRACTORY (PLANETARY SCIENCE);CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;CONCOMITANT;DARATUMUMAB;DISCONTINUATION;HEMATOLOGY;INSULIN THERAPY;LEFT VENTRICULAR DYSFUNCTION;ULCERATIVE COLITIS;ALBUMINURIA","6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2","HEART FAILURE;CHRONIC HEART;LEFT ATRIAL;MYELOID LEUKEMIA;ACUTE MYELOID;EJECTION FRACTION;ITALIAN MULTICENTER;ITALIAN SOCIETY;MULTICENTER STUDY;MULTIPLE MYELOMA;OBSERVATIONAL STUDY;PATIENTS AFFECTED;REALIT STUDY;REDUCED EJECTION;THERAPEUTIC CHARACTERISTICS;ULCERATIVE COLITIS;ATRIAL STRAIN;AZACITIDINE POST-REMISSION;CARDIAC SURGERY;CARDIO RENO;CARDIOVASCULAR IMAGING;CML CAMPUS;COLITIS VERSUS;CONTROLLED PILOT;COVID- PANDEMIC;CROHNS DISEASE;DEVELOPMENTAL DELAY;DIRECT ORAL;DISEASE RESULTS;ECHOCARDIOGRAPHIC LABORATORIES","12;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HEART FAILURE;CARDIAC SURGERY;EJECTION FRACTION;SGLTI THERAPY;LEFT VENTRICULAR;ADVERSE EVENTS;MONTHS CI;BONE FRAGILITY;HR CI;PATIENTS TREATED;NYHA CLASS;STATISTICALLY SIGNIFICANT;AGED MONTHS;CD CD;CLINICAL CHARACTERISTICS;DIABETES MELLITUS;LONGITUDINAL STRAIN;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;PSORIATIC ARTHRITIS;REDUCED EJECTION;RENAL FUNCTION;CLINICAL PRACTICE;CLINICAL TRIALS;CML RELATED;FRAGILITY FRACTURE;FUNCTION ASSESSED;HEART RATE;INTERNATIONAL GUIDELINES;LA STRAIN","20;13;13;12;11;10;10;9;9;9;8;8;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6",33,0.35,7,6,0,1,0,1.75,0,0,0,6,0,0,4.5,1,0,1,5,3.5,2,0,0,12,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,3.33,488.67,2.54,1,0.33,72.67,0,0,0,0,1,0,0,2,0,3,0,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PREVENTION;AGING;AUTISM;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;HYPERTENSION;INFECTIOUS DISEASES;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MENTAL HEALTH;NEUROSCIENCES;PEDIATRIC;PROSTATE CANCER;REHABILITATION","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;MENTAL HEALTH;NEUROLOGICAL","1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.4 SURGERY","1;1;1;1;1","PROSTATE CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIFOGGIA",2024,69,25.7391304347826,2.14492753623188,0.466216216216216,0.217391304347826,0.188405797101449,0.202898550724638,0.681159420289855,0,25,15,8,4,0.36,0.22,0.12,0.06,0.99,1.03118402775799,0.289855072463768,0.942028985507246,3.45841392649903,0.486305306919969,0.439393939393939,0.435483870967742,0.472148541114058,"MICHELE CORREALE;GIULIA SCIOSCIA;DONATO LACEDONIA;MASSIMO IACOVIELLO;LUCIA TRICARICO;MARIA PIA FOSCHINO BARBARO;ANDREA SANTAMATO;ALBERTO PALAZZUOLI;PASQUALE TONDO;NATALE DANIELE BRUNETTI;B. COCO;MAURO VIGANÒ;LUCHINO CHESSA;GAETANO BERTINO;ALESSANDRO PICELLI;MARCO BATTAGLIA;VALENTINA MERCURIO;ALESSIO BARICICH;PIERA SOCCIO;GRAZIA ANNA NIRO","10;8;7;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","MICHELE CORREALE;GIULIA SCIOSCIA;DONATO LACEDONIA;ANDREA SANTAMATO;PASQUALE TONDO;MARIA PIA FOSCHINO BARBARO;LUCIA TRICARICO;NATALE DANIELE BRUNETTI;ALBERTO PALAZZUOLI;MASSIMO IACOVIELLO;STEFANIA SPINA;ALESSANDRO PICELLI;MARCO BATTAGLIA;ALESSIO BARICICH;ESTER MARIA LUCIA BEVERE;PIERA SOCCIO;G MAFFEI;ENRICA MANCA;P. DÉMOLY;DAVIDE CAIMMI","0.82;0.7;0.68;0.55;0.54;0.5;0.48;0.44;0.39;0.38;0.37;0.35;0.35;0.35;0.34;0.34;0.34;0.33;0.33;0.33","MICHELE CORREALE;GIULIA SCIOSCIA;DONATO LACEDONIA;MASSIMO IACOVIELLO;LUCIA TRICARICO;MARIA PIA FOSCHINO BARBARO;ANDREA SANTAMATO;PASQUALE TONDO;G MAFFEI;MICHELE GRANATIERO;FRANCESCO SANTORO;STEFANIA SPINA;TERESA SANTANTONIO;MICHELE CORREALE;ANTONIO VITULLO;NICOLA DELLA VALLE;GUIDO GIORDANO;ROSELLA DE NITTIS;LUIGI CORMIO;RODOLFO SACCO","10;8;7;7;6;5;5;5;4;3;3;3;3;3;3;2;2;2;2;2","MICHELE CORREALE;GIULIA SCIOSCIA;DONATO LACEDONIA;ANDREA SANTAMATO;PASQUALE TONDO;MARIA PIA FOSCHINO BARBARO;LUCIA TRICARICO;MASSIMO IACOVIELLO;STEFANIA SPINA;G MAFFEI;SALVATORE FACCIORUSSO;PIERLUIGI ZAZA;RAFFAELLA LAMPARELLI;ROSA SAVINO;GABRIELE VILLANI;ROSELLA DE NITTIS;FABIO ARENA;MARIA NOBILI;LUIGI SANTORO;RAFFAELLA COCOMAZZI","0.82;0.7;0.68;0.55;0.54;0.5;0.48;0.38;0.37;0.34;0.28;0.25;0.25;0.25;0.25;0.23;0.23;0.2;0.2;0.2","FRANCESCO SANTORO;AMEDEO PIAZZA;AMIN KASSAM;ANTONIO COLAMARIA;CARLO CAVALIERE;DONATO LACEDONIA;FELICE ESPOSITO;FRANCESCO CORRIVETTI;GIORGIO İACONETTA;GIOVANNI CIRROTTOLA;GIULIA SCIOSCIA;LUIGI MARIA CAVALLO;MATTEO DE NOTARIS;PASQUALE TONDO;SERGIO CORVINO;TOMA SPIRIEV;ALESSANDRO VICENTINI;AMATO SANTORO;ANDREA ROSSI;ANGELO AURICCHIO","11;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;9;9;9;9","ANTONIO COLAMARIA;FRANCESCO SANTORO;GIOVANNI CIRROTTOLA;GIULIA SCIOSCIA;DONATO LACEDONIA;MICHELE CORREALE;CARLA MARIA IRENE QUARATO;MARIA PIA FOSCHINO BARBARO;ANDREA SANTAMATO;NICOLA DELLA VALLE;ANNA CARRETTA;GIAN MARIA BUSETTO;GUIDO GIORDANO;PIERLUIGI BRUGNARO;TERESA SANTANTONIO;FABIO ARENA;G MAFFEI;LUCIA TRICARICO;MASSIMO IACOVIELLO;ROSELLA DE NITTIS","10;10;10;10;9;9;7;7;4;4;3;3;3;3;3;2;2;2;2;2","MICHELE CORREALE;GIULIA SCIOSCIA;ANDREA SANTAMATO;DONATO LACEDONIA;G MAFFEI;MASSIMO IACOVIELLO;LUCIA TRICARICO;STEFANIA SPINA;ANTONIO COLAMARIA;CARLA MARIA IRENE QUARATO;FABIO ARENA;FRANCESCO SANTORO;GIAN MARIA BUSETTO;GUIDO GIORDANO;MARCO MELE;MARIA PIA FOSCHINO BARBARO;NICOLA DELLA VALLE;ROSELLA DE NITTIS;SALVATORE FACCIORUSSO;TERESA SANTANTONIO","13;7;5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;ECONOMICS;HISTORY;POLITICAL SCIENCE;SOCIOLOGY","67;17;6;6;5;5;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;INTENSIVE CARE MEDICINE;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;PATHOLOGY;PEDIATRICS;ANESTHESIA;IMMUNOLOGY;PHYSICAL THERAPY;ENVIRONMENTAL HEALTH;PHYSICAL MEDICINE AND REHABILITATION;ENDOCRINOLOGY;ONCOLOGY;OPTICS;RADIOLOGY;VIROLOGY;BIOINFORMATICS;EMERGENCY MEDICINE;MICROBIOLOGY;NEUROSCIENCE;NURSING;OPERATING SYSTEM;PHARMACOLOGY","52;15;13;10;9;8;7;7;7;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3","DISEASE;HEART FAILURE;GENE;COHORT;CONFIDENCE INTERVAL;OBSERVATIONAL STUDY;SPASTICITY;BLOOD PRESSURE;BOTULINUM TOXIN;CANCER;INCIDENCE (GEOMETRY);POPULATION;PROSPECTIVE COHORT STUDY;PULMONARY HYPERTENSION;RECEPTOR;ADVERSE EFFECT;ANTIBODY;ASTHMA;CHEMOTHERAPY;CLINICAL TRIAL;COHORT STUDY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LUNG;OBSTRUCTIVE SLEEP APNEA;ODDS RATIO;PREGNANCY","12;9;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","EJECTION FRACTION;AGONIST;CONTINUOUS POSITIVE AIRWAY PRESSURE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);ADALIMUMAB;BIRTH WEIGHT;BOTULINUM NEUROTOXIN;BRONCHOALVEOLAR LAVAGE;DNA SEQUENCING;GEMCITABINE;GESTATIONAL AGE;HAZARD RATIO;IDIOPATHIC PULMONARY FIBROSIS;IMMUNOTHERAPY;INTERSTITIAL LUNG DISEASE;LOW BIRTH WEIGHT;PATHOPHYSIOLOGY OF HYPERTENSION;PROSTATE;PROSTATE CANCER;ULCERATIVE COLITIS","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);OBETICHOLIC ACID;LOWER URINARY TRACT SYMPTOMS;NIVOLUMAB;USTEKINUMAB;ANTI-NUCLEAR ANTIBODY;ANTIRETROVIRAL THERAPY;APNEA–HYPOPNEA INDEX;BASOPHIL;BIOMARKER DISCOVERY;BRONCHOPULMONARY DYSPLASIA;CEFTAZIDIME;CHRONOTROPIC;COGNITIVE RESERVE;CONNECTIVE TISSUE DISEASE;CYSTIC HYGROMA;DABIGATRAN;DAPAGLIFLOZIN;DARATUMUMAB;DIRECT BILIRUBIN;DNA METHYLATION;EGG ALLERGY;ELIMINATION DIET;EXHALED NITRIC OXIDE;EXOME SEQUENCING;GERD;HBSAG;HEPATITIS DELTA;HYDROPS FETALIS;HYPOPNEA;IMIPENEM;INTERLEUKIN 23;KIDNEY DEVELOPMENT;MEGAKARYOCYTE;MILK ALLERGY;ORAL FOOD CHALLENGE;ORAL IMMUNOTHERAPY;POMALIDOMIDE;PREMATURE BIRTH;PRENATAL DIAGNOSIS;RECEPTOR ANTAGONIST;RESPIRATORY ALLERGY;RIVAROXABAN;SACUBITRIL;SACUBITRIL, VALSARTAN;VANCOMYCIN;VEDOLIZUMAB","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;TREATMENT OUTCOME;ITALY;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;HEART FAILURE;BOTULINUM TOXINS, TYPE A;FOLLOW-UP STUDIES;HYPERTENSION, PULMONARY;MUSCLE SPASTICITY;PROGNOSIS;COHORT STUDIES;ECHOCARDIOGRAPHY","37;32;24;24;20;15;15;10;8;7;7;5;5;4;4;4;4;4;3;3","BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;ASTHMA;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND TREATMENT OF HEART FAILURE;CHOLANGIOCARCINOMA;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEPATITIS C INFECTION AND TREATMENT;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;CONE-BEAM COMPUTED TOMOGRAPHY IN DENTISTRY;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","TREATMENT;SPASTICITY;ENDOTHELIAL DYSFUNCTION;LEFT VENTRICULAR FUNCTION;OBETICHOLIC ACID;PRIMARY SCLEROSING CHOLANGITIS;PULMONARY HYPERTENSION;ASTHMA;BILIARY TRACT CANCER;BOTULINUM NEUROTOXIN;DISCONTINUATION;DURVALUMAB;ECHOCARDIOGRAPHY;HIV INFECTION;HYPERTENSION;NEUROTOXIN;NONINVASIVE VENTILATION;PATHOGENESIS;PATHOPHYSIOLOGY OF HYPERTENSION;POSITIVE END-EXPIRATORY PRESSURE","7;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HEART FAILURE;ARTERIAL HYPERTENSION;BILIARY CHOLANGITIS;BOTULINUM TOXIN;NERVE BLOCKS;PRIMARY BILIARY;PULMONARY ARTERIAL;REAL-LIFE STUDY;ADVANCED BILIARY;BILIARY TRACT;CHRONIC HEART;CLINICAL REMISSION;COVID- PATIENTS;DIAGNOSTIC NERVE;EJECTION FRACTION;ENDOTHELIAL FUNCTION;MULTICENTER REAL-WORLD;OBETICHOLIC ACID;PRETERM INFANTS;PROSTATE VOLUME;REAL-WORLD EXPERIENCE;REDUCED EJECTION;SEVERE ASTHMA;SURFACTANT ADMINISTRATION;TRACT CANCER;ULCERATIVE COLITIS;URINARY INCONTINENCE;USTEKINUMAB SAFETY;ACID DRIVES;ACID-TREATED PATIENTS","8;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","CLINICAL REMISSION;HEART FAILURE;SIGNIFICANT DIFFERENCES;DIAGNOSTIC NERVE;EJECTION FRACTION;FAILURE HF;COVID- PATIENTS;NERVE BLOCKS;ANTIBIOTIC EXPOSURE;BOTULINUM NEUROTOXIN-A;CLINICAL PRACTICE;HR CI;EARLY-ONSET SEPSIS;ENROLLED PATIENTS;OXIDATIVE STRESS;PV ML;ARTERIAL HYPERTENSION;CARDIAC REMODELING;CN LT;CULTURE-NEGATIVE EARLY-ONSET;EXTENDED OPEN-DOOR;GAUGE NEEDLES;GOAL-SETTING PROCESS;HF PATIENTS;INTERSTITIAL LUNG;MLM EE;NERVE BLOCK;NYHA CLASS;OPTIPHARMHF REGISTRY;PATIENTS UNDERWENT","12;11;9;8;8;8;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
